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Summary 
One of the fundamental aspects of innate immunity is the ability of immune cells, 
particularly antigen-presenting cells (APCs) such as macrophages and dendritic 
cells(DCs), to detect and respond to potential microbial pathogens or even 
endogeneous molecules that have become altered and pose a threat to the system.  
These cells employ an array of pattern recognition receptors (PRRs) that can recognize 
these pathogens or altered endogeneous molecules either directly by binding to 
pathogen associated molecular patterns (PAMPs) found on the microbial cell surfaces 
or indirectly via opsonins such as complement components and immunoglobulins 
which have deposited on the surfaces of cellular or molecular targets. In this study, we 
focused on two major PRRs found on APCs, the opsonic complement receptor 3 (CR3) 
and non-opsonic scavenger receptor class A (SR-A). We will attempt to investigate 
certain aspects of their ligand binding properties and delineate downstream signaling 
pathways upon ligand engagement.  
 
SR-A is a non-opsonic PRR important for the clearance of infectious and endogenous 
molecular and cellular debris. Although ligand binding properties of SR-A have been 
extensively studied in relation to modified low density lipoproteins (LDL), the 
mechanisms governing its broad ligand specificity and interaction with other ligands, 
particularly PAMPs, is not completely elucidated.  In addition, its signaling properties 
remain poorly understood. In this study, we express SR-A isoform 1 (SR-AI) on 
human embryonic kidney (HEK) 293T cells, which lack most PRRs including SR-A, 
and report that E. coli DH5stimulation of these transfected cells mediated NF-B 
activation and chemokine production i.e. interleukin 8 (IL-8) and monocyte 
chemoattractant protein 1 (MCP-1). Opsonization with complement C3 is required for 
 viii
E. coli DH5to stimulate SR-AI signaling as it was abolished by heat inactivation of 
sera, C3 depletion of the sera or anti-C3 antibodies. Selected point mutations in the 
scavenger receptor cysteine rich (SRCR) but not the collageneous domain abolish SR-
AI signaling response to the opsonized E. coli DH5. Purified SR-AI binds to iC3b but 
not to C3 or C3b which suggests SR-AI as a complement receptor for opsonic iC3b. In 
contrast to DH5, SR-AI cannot mediate NF-B activation in response to the SR-A 
ligands LPS and fucoidan.  We have also established that the cytoplasmic tail of SR-AI 
is not required for DH5-induced NF-B activation, suggesting the possibility of one 
or more co-receptors involved in SR-AI signaling. The identity of the co-receptor is 
presently unknown but does not include Toll-like receptors (TLRs).  The co-receptor 
appears to co-localize with SR-AI on lipid rafts of HEK293T cells and its signaling 
involves phosphatidylinositol-3-kinase (PI3K) and RhoGTPase cdc42. 
 
Complement C3 opsonizes microorganisms for enhanced phagocytosis via mainly CR3 
and the related complement receptor 4 (CR4). In addition, cross-linking of CR3 
inhibits IL-12 production although the signaling mechanism(s) concerned is not known. 
In this study, we investigate CR3 and CR4 signaling after expression of these C3 
receptors on HEK 293T cells. DH5 opsonized with normal serum (DH5C3+) 
activated CR3, but not CR4, culminating in NF-B activation and IL-8 production. 
CR3 activation was not elicited when DH5 was opsonized with C3-deficient sera 
(DH5C3-) or pre-incubated in normal serum with anti-C3 antibodies. CR3-mediated 
NF-B activation in response to DH5C3+ was inhibited by dominant negative Rac 
(N17Rac). DH5C3+ and DH5C3- were both ingested by dendritic cells (DCs), but 
DH5C3- induced 1.8 folds more IL-12 from DCs than DH5C3+. The Rac inhibitor 
NSC23766 and the PI3K inhibitor LY294002 both enhanced DH5C3+, but not 
 ix
DH5C3-, induction of IL-12 from DCs suggesting inhibition of IL-12 production by 
opsonic C3 involves Rac and PI3K. However, the two inhibitors exhibited no 
synergistic enhancement of DH5C3+-induced IL-12 production. IFN- abrogates all 
these inhibitory effects. These results revealed a potent inhibitory role for opsonic C3 
on bacteria on IL-12 production, among other opsonins, and a role for Rac and PI3K in 
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Nucleotide containing adenine, cytidine, guanine and thymine are abbreviated as A, C, 
G and T. The single-letter and three-letter codes are used for amino acids. Three-letter 
names are used for restriction enzymes which reflect the microorganisms from which 
they are derived. Other abbreviations are defined where they first appear in the text and 
some of the frequently used ones are listed below. 
 
BCS  bovine calf serum 
BSA  bovine serum albumin 
bp  base pair 
cDNA  complementary DNA 
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min  minute 
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PBS  phosphate buffered saline 
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PRR(s) pattern recognition receptor(s) 
RNA  ribonucleic acid 
RPMI RPMI-1640 culture medium developed by Roswell Park Memorial 
Institute  
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
sec  second 
TBS  Tris-buffered saline 
TLR(s) toll-like receptor(s) 
TNF  tumour necrosis factor 
Tris  tri-hydroxymethyl-aminomethane
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Chapter 1 Introduction  
1.1 Innate Immunity 
The ability of an organism to defend against microbial infection and disease depend upon 
a functional immune system. The immune response initiated by vertebrates to any 
invading microorganism consists of two components: innate and adaptive immunity. 
Innate immunity appeared early in evolution and is thought to have predated the adaptive 
immune response; the former is present in all multicellular organisms, whereas the latter 
evolved four hundred million years ago and is found only in the vertebrates. These two 
distinct "arms" of the immune system work closely together to combat disease, infection, 
and re-infection in vertebrates.  The adaptive immune response, which comprises of 
humoral antibody-mediated immunity and T-cell mediated cellular immunity, is highly 
specific but generally takes 4-7 days to be fully activated. Adaptive immunity is also 
characterized by immunologic memory, and once activated by a particular antigen will 
provide lasting protective immunity against that antigen.  In contrast, the innate immune 
response is considered non-specific but rapidly initiated, usually within minutes in 
response to a pathogenic invasion. The majority of invading pathogenic microorganisms 
broadly classified under viruses, bacteria, fungi and parasites are effectively eliminated 
within hours by innate immune defences. Consequently, the innate immune system is the 
first line of defence against microbial infections when physical barriers such as skin and 
mucosal surfaces are breached. The acquired specific immune response comes into play 
only if the invading microbes manage to evade the innate defenses and avoid destruction.  
 
One key distinction between the innate and adaptive immune systems lies in the type of 
receptors used for immune recognition (Medzhitov and Janeway, 2000).  The adaptive 
immune system relies on the T-cell and B-cell receptors for antigen recognition. The 
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receptors on a particular T or B cell, generated somatically during lymphocyte 
development, are structurally unique and specific for a particular antigen because of the 
random nature of VDJ gene segment recombination during the process of receptor gene 
rearrangement.  However, the repertoire of receptors present in the entire population of 
lymphocytes is, in contrast, large and extremely diverse. Consequently, the probability of 
an individual lymphocyte with receptors specific for a particular encountered antigen is 
greatly enhanced. Receptor-antigen intereactions would subsequently trigger the 
activation and proliferation of that particular lymphocyte cell.  This process of clonal 
selection and expansion is the hallmark of the adaptive immune system.  In contrast, 
innate immune recognition is mediated by germline-encoded receptors and therefore 
necessitate that the specificity of each receptor be genetically predetermined, that is all 
receptors of a particular class expressed by cells of a given type have identical 
specificities (Medzhitov and Janeway, 2000). It is impossible to express an innate 
immune receptor to recognize every probable antigen because of the limitations imposed 
by the number of genes a particular organism can encode in the genome.  Consequently, 
the innate immune receptors, evolving through the process of natural selection, 
concentrating on the recognition of a few, highly conserved structures present in a large 
group of microorganisms. These invariant structures, referred to as pathogen associated 
molecular patterns (PAMPs), are essential products of microbial physiology and hence 
survival (Janeway, 1989; Medzhitov and Janeway, 2002)). The receptors of the innate 
immune system that evolved to recognize PAMPs are known as pattern recognition 





1.2 Pathogen-associated molecular patterns (PAMP) 
PAMPs are evolutionarily conserved molecular structures essential to microbial 
physiology and hence survival of the micro-organisms. These invariant structures are 
uniquely present on microbes and, as such, are perceived by the innate immune system 
as molecular signatures of infection (Medzhitov and Janeway, 2002). Some PAMPs 
such as lipopolysaccharide (LPS), peptidoglycan (PGN) and lipoteichoic acid (LTA) 
form integral constituents of the bacterial cell wall, while others such as viral double-
stranded RNA (dsRNA) and unmethylated CpG dinucleotides of bacterial DNA are 
microbial-specific nucleic acids. The recognition of these PAMPs by PRRs allows the 
immune system to discriminate between “infectious non-self” and “non-infectious self” 
and enable the host organism to mount an immune response to eradicate the invading 
microbes.   
 
Bacteria are generally classified into two major groups based on the differential staining 
characteristics of their cell wall composition, namely Gram-positive and -negative 
bacteria (Figure 1.1A). Gram-negative bacteria have an outer membrane surrounding a 
thin PGN cell wall. The outer membrane is composed of phospholipids, lipoproteins 
and LPS.  In contrast, Gram-positive bacteria lack an outer membrane and have a 
relatively thicker PGN cell wall (Figure 1.1A). Interwoven in the PGN cell wall are 
glycoconjugates teichoic acids (TA) and lipoteichoic acids (LTA) which extend through 
and beyond the PGN cell wall. A unique exception to the two groups of bacterial cell 
envelope described is that of the genus Mycobacterium.  The mycobacterial cell 
envelope is composed of a thick waxy mixture of lipids and polysaccharides that 
surrounds the PGN cell wall (Figure 1.1A). This waxy outer sheath is characterized by a 
high content of long chain fatty acids such as mycolic acid, and glycolipids like 
 4



























Figure 1.1. Bacterial cell surface PAMPs   
(A) Schematic representations of the general structure of the cell envelope of Gram-positive bacteria, 
Gram-negative bacteria, and Mycobacterium. (B) Schematic representation of the chemical structure 
of lipopolysaccharide (LPS). The core is covalently bound to the lipid A moiety through an acidic 
sugar, usually 3-deoxy-D-manno-oct-2-ulopyranosonic acid (Kdo), and this sugar is essential for most 
endotoxins. The core region adjacent to lipid A (inner core) generally contains heptose residues 
(Hep), which are frequently substituted by phosphate (P), pyrophosphate or diphosphoethanolamine. 
Neutral or amino hexoses such as D-glucose, D-galactose, D-glucosamine, D-galactosamine or N-
acetyl derivatives usually make up the outer core.  Abbreviations: GlcN, N-acetylglucosamine; zig-
zag lines, fatty acids. (C) Schematic representation of the composition of peptidoglycan  (PGN). The 
basic structure consists of long glycan chains that are cross-linked via peptide chains. Breakdown 
products muramyl dipeptide (MDP) and g-D-glutamyl-meso-diaminopimelic acid (iE-DAP), which 
act as ligands for NOD2 (‘nucleotide-binding oligomerisation domain 2’) and NOD1, respectively, 
are indicated in the red and blue boxes. Abbreviations: GlcN, N-acetylglucosamine; mDAP, meso-
diaminopimelic acid; MurN, N-acetylmuramic acid. Reproduced from Pluddemann et.al. (2006) 
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LPS is the heat-resistant, major cell wall component of most Gram-negative bacteria 
(Figure 1.1B). The basic structure of LPS consists of a hydrophobic membrane-
anchoring lipid A moiety and a extracellularly-exposed hydrophilic glycosidic region, 
which is divided into an oligosaccharide core with approximately 10-12 
monosaccharides and a polysaccharide O-chain made up of repeating subunits of 
various monosaccharides (Caroff and Karibian, 2003). Some bacterial species lack the 
O-chain in the LPS structure and display a rough colony morphology (rough LPS) while 
those with the O-chain have a smooth colony appearance (smooth LPS). The chemical 
composition and structure of the O-chains can vary extremely between and within 
bacterial species, with variations in the nature and number of sugar residues within a 
repetitive unit as well as the linkages and number of repeats. This chemical and 
structural diversity accounts for most of the heterogeneity of LPS molecules and forms 
the basis of serotype specificity of individual bacterial strains (Pluddemann et al., 2006). 
In contrast to the O-chain, the structure of lipid A is highly conserved among Gram-
negative bacteria, and consists of β(1→6)-linked, position 1 and 4’phosphorylated 
disaccharide of D-glucosamine that is acylated at positions 2, 3, 2′, and 3′, involving six 
fatty acid chains.  
 
The main structural scaffold that maintains the shape and integrity of both Gram-postive 
and Gram-negative bacteria is the crosslinked polymer peptidoglycan (PGN) (Figure 
1.1C). It consists of linear glycan chains made up of alternating -1, 4-linked N-
acetylglucosamine and N-acetylmuramic acid subunits that are crosslinked via short 
peptide chains normally containing D-alanine, D-glutamic acid and 
mesodiaminopimelic acid, forming a rigid three-dimensional meshwork-like layer. 
Although structurally similar, the PGN layer in Gram-positive bacteria (20-80 nm) is 
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significantly thicker than Gram-negative bacteria (7-8 nm) (Fig. 1A). In addition, the 
PGN layer of Gram-negative bacteria is convalently attached to the inner and outer 
membrane via lipoproteins while that of Gram-positive bacteria contain charged 
polymers LTA, TA, teichuronic acids and lipoglycans.  Some of these polymers, such as 
teichuronic acids, are covalently linked to the PGN backbone while others like LTA are 
tethered to a lipid anchor moiety (Pluddemann et al., 2006). LTAs are amphipathetic 
molecules typically consisting of a 1,3-phosphodiester-linked polymer of 
glycerophosphate linked covalently to either a glycolipid or a phosphatidyl glycolipid, 
thus resulting in a structure with a backbone of repeating negative charges. Together 
with PGN, LTA and TA are the major cell envelope components of most Gram-positive 
bacteria; LTA and TA constituting more than 50% of the dry weight of the cell 
envelope in some species (Baddiley, 1989). 
 
The key to an effective innate immune system is the ability to discriminate between 
these infectious non-self PAMPs from non-infectious self antigens, and this precept 
forms the basis of the Self and Non-Self (SNS) model of immunity (Janeway, 1989). 
However, some PRRs do not only recognize exogeneous (non-self) ligands but also 
certain endogeneous ligands that have either become biochemically modified or 
released from immune privileged sites under abnormal physiological circumstances.   
The question that comes to mind would be why PRRs need to respond to endogeneous 
molecules since they should be view as non-infectious self and therefore not dangerous. 





The danger hypothesis (Matzinger, 1994; Matzinger, 1998; Matzinger, 2002), in its 
simplest form, states that the immune system responds to challenge or an antigen only if 
the threat is determined to be dangerous. This implies that the immune system is not 
concerned with discriminating between self and non-self, but is rather concerned with 
sensing the presence of danger. The PRRs, therefore, recognize molecular structures 
that pose a threat to disrupt the homeostatic balance of tissues under steady-state rather 
than simply the presence of “foreign entities”.  In the case of exogenoeus infectious 
ligands, the danger signal comes from the invading pathogens themselves. For 
endogeneous ligands, the trigger to activate the immune system is derived from the 
possible risk of tissue damage presented by abnormally modified proteins or from the 
exposure of immunological “sequestered” proteins abnormally released. Consequently, 
recognition of PAMPs by PRRs is only part of a wider homeostatic clearance 
mechanism that allows multicellular organisms to maintain a constant internal 
environment.  In view of this hypothesis, various endogeneous ligands of PRRs 
examined in this dissertation will also be included in the discussion. 
 
1.3 Pattern recognition receptors (PRR) 
The basis of innate immune system activation is pattern recognition (Janeway and 
Medzhitov, 2002).  To accomplish this, the cells of the innate arm of immunity bear 
germ-line encoded PRRs that recognize PAMPs. The innate immune cells, particularly 
the antigen-presenting cells (APCs) such as macrophages and dendritic cells (DCs), 
employ a myriad of different PRRs that can be cell membrane-associated, in intracellular 
compartments, or secreted into the blood stream and tissues to facilitate the recognition 
of PAMPs (Medzhitov and Janeway, 1997).   
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The cell surface PRRs includes two major groups: those that capture pathogens and 
subsequently mediate phagocytosis and endocytosis, and those that sense pathogens and 
activate signaling pathways that result in inflammation (Aderem and Underhill, 1999; 
Janeway, 1989). The former group of receptors, known as phagocytic/endocytic 
receptors, includes the mannose receptor (MR), scavenger receptors (SRs) and 
complement receptors (CRs), while the latter group, the signaling/sensing receptors, is 
represented by the Toll-like receptors (TLRs).  These cell surface PRRs form the main 
focus of this dissertation. 
 
The secreted PRRs or pattern recognition molecules (PRM) include the pentraxins (PTX) 
like C-reactive protein (CRP), serum amyloid protein (SAP) and PTX3 (Bottazzi et al., 
2006; Gewurz et al., 1995), collectins such as lung surfactant proteins A (SP-A) and D 
(SP-D) and mannose-binding lectin (MBL) (Gupta and Surolia, 2007; Kishore et al., 
2006; Takahashi et al., 2006), complement components such as C1q (Ghai et al., 2007) 
and C3 (Sahu and Lambris, 2001), Lipopolysaccharide(LPS)-binding protein (LBP) and 
CD14 (Fenton and Golenbock, 1998; Schutt, 1999). Upon binding to target cell surfaces, 
these secreted PRRs can act as opsonins and tag their target cell for destruction via the 
complement cascade or facilitate the interaction of target cell with specific 
phagocytic/endocytic PRRs on APCs for uptake, degradation and antigen processing.  In 
view of this, the phagocytic/endocytic PRRs can therefore be further classified into those 
that bind directly to microorganisms such the mannose receptor (Stahl and Ezekowitz, 
1998) and scavenger receptors (Gough and Gordon, 2000; Krieger, 1997), and those that 
interact with PRMs in complex with their ligands. The latter group of receptors is 
represented by complement receptors, collectin receptors and membrane associated GPI-
anchored CD14 (Aderem and Underhill, 1999).  
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Several PRRs are located in the cytosol to facilitate the detection of intracellular 
pathogens and induce responses that block their replication.  Cytoplasmic PRRs can be 
grouped into three families: the interferon (IFN)-inducible proteins, caspase-recruiting 
domain (CARD) helicases, and nucleotide-binding oligomerization domain (NOD)-like 
receptors (NLRs) (Lee and Kim, 2007). The IFN-inducible proteins such as double-
stranded RNA (dsRNA)-activated protein kinase (PRK) (Clemens and Elia, 1997; Stark 
et al., 1998) and 2`-5`-oligoadenylate synthase (OAS) (Behera et al., 2002; Kumar and 
Carmichael, 1998) and the CARD helicases like retinoic acid-inducible protein I (RIG-I) 
mediate antiviral defence through the recognition of viral RNA (dsRNA and uncapped 
5’-triphosphate RNA). In contrast, the NLRs comprising of the NOD proteins, NOD1 
and 2 (Tattoli et al., 2007) and the Nacht leucine-rich repeat protein (NALP) subfamily 
(Tschopp et al., 2003) primarily initiate antibacterial defence (Inohara et al., 2005; 
Martinon and Tschopp, 2005). The NLRs recognize a diverse range of exogeneous 
ligands including gamma-D-glutamyl-meso-diaminopimelic acid (iE-DAP), muramyl 
dipeptide (MDP) and bacterial RNA.  
 
1.4 Sensing/signaling PRRs  
1.4.1 Toll-like receptors (TLR) 
The Toll-like receptors (TLR) comprise an ancient family of sensing PRRs that is 
evolutionarily conserved from invertebrates to vertebrates. To date, 10 expressed human 
TLR family members (TLR 1-10) have been identified (Chuang and Ulevitch, 2001; 
Chuang and Ulevitch, 2000; Rock et al., 1998). The TLRs are type I transmembrane 
proteins that possess varying numbers of extracellular N-terminal leucine-rich repeat 
(LRR) motifs, followed by a cysteine-rich region, a transmembrane domain, and an 
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intracellular domain homologous to that of the human interleukin (IL)-1 receptor (IL-
1R) and, as such, is known as the Toll/IL-1 R (TIR) domain (Gay and Keith, 1991).    
 
1.4.1.1 TLR ligands and leucine-rich repeat (LRR) domain 
Most exogeneous ligands recognized by TLRs are classified as PAMPs. For example 
TLR4 recognises LPS (Poltorak et al., 1998) whereas TLR5 interacts with flagellin 
(Hayashi et al., 2001). TLR2 recognises PGN, LTA and lipoarabinomannan 
(Schwandner et al., 1999; Underhill et al., 1999), and also collaborate with TLR1 and 
TLR6 to discriminate between of triacyl and diacyl lipopeptides respectively (Takeuchi 
et al., 2001; Takeuchi et al., 2002). Other TLRs are implicated in the recognition of 
microbial nucleic acids; TLR9 is essential in bacterial unmethylated CpG DNA 
recognition (Hemmi et al., 2000) whereas TLRs 7/8 and TLR 3 interact with viral 
single- and double-stranded RNA (Alexopoulou et al., 2001; Heil et al., 2004). 
 
The mechanism of ligand recognition by TLRs is not clear and there is no direct 
evidence to show that ligands of TLRs physically interact with the ectodomains of the 
receptors.  Nevertheless, the LRR motif present in the ectodomain all TLRs was 
proposed to be involved in ligand binding (Bell et al., 2003; Matsushima et al., 2007).  
The LRR motif consists of a 24 amino acid repeated sequence with characteristically 
spaced hydrophobic residues (Takahashi et al., 1985), of which an 11 amino acid 
segment  LXXLXLXXNXL (“L” is Leu, Ile, Val, or Phe and “N” is Asn, Thr, Ser, or 
Cys and "x" is any amino acid) within the consensus sequence is highly conserved 
(Matsushima et al., 2007). The LRR domain is predicted to form a horseshoe-shaped 
solenoid that contains an extensive beta-sheet on its concave surface, and numerous 
putative ligand-binding insertions (Bell et al., 2003). 
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1.4.1.2 Toll/IL-1 Receptor (TIR) domain and TLR-mediated signaling pathways 
The TIR domain is essential for intracellular signal transduction processes following 
ligand-mediated activation of TLRs.  This domain is involved in homophilic and 
heterophilic protein-protein interactions and recruits cytosolic TIR domain-containing 
adaptor molecules (Kopp and Medzhitov, 1999).  Four adaptor molecules are known to 
play a role in TLR-mediated signaling : Myeloid differentiation 88 (MyD88), MyD88 
adaptor like (MAL)/TIR domain-containing adaptor protein (TIRAP), TIR domain-
containing adaptor protein inducing IFN- (TRIF)/TIR domain-containing adaptor 
molecule (TICAM) and TRIF-related adaptor molecule (TRAM) (McGettrick and 
O'Neill, 2004). The differential recruitment of these adaptor proteins by different TLRs 
form the basis for specificity in the signaling pathways activated by the receptors,  
although IL-1R, IL-18R and most members of the TLR family, except TLR3, transduce 
signals by recruiting MyD88 via their TIR domain (Akira and Takeda, 2004). Two TLR 
signaling pathways can be discerned, namely the myeloid differentiation factor 88 
(MyD88)-dependent and the MyD88-independent signaling pathways (Kawai and 
Akira, 2007).  The former pathway involving MyD88 activates the transcription factors 
nuclear factor B (NF-B) and activator protein 1 (AP-1), and culminate expression of 
various pro-inflammatory mediators in response to bacteria and other microbes while 
the latter pathway utilizes TRIF and TRAM to induce type I interferon (IFN) production 
against viral infection. The MyD88-dependent pathway is well-defined and will be 
dicussed in detail.  
 
The MyD88-dependent pathway is schematically illustrated in Figure 1.2. MyD88 
contains a C-terminal TIR domain and an N-terminal death domain (DD). The DD of 
MyD88 interacts and activates the serine/threonine kinases IL-1R associated kinase 1 
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(IRAK1) and 4 (IRAK4) (Li et al., 2002; Wesche et al., 1997), resulting in the 
subsequent recruitment of tumour necrosis factor receptor-associated factor 6 (TRAF6) 
to the complex (Cao et al., 1996). TRAF6 is an E3 ubiquitin ligase which facilitate the 
synthesis of lysine 63-linked polyubiquitin chains on downstream target proteins and 
TRAF6 itself (Deng et al., 2000). The IRAK1/IRAK4/polyubiquitinated TRAF6 
complex dissociates from MyD88 and interacts with a mitogen-activated protein kinase 
kinase kinase (MAPKKK), TGF--activated kinase 1 (TAK1) which exist in complex 
with two adaptor proteins, TAK1-binding protein (TAB) 1 and TAB2 at the cell 
membrane (Jiang et al., 2002; Wang et al., 2001). The association of the two complexes 
induces phosphorylation of TAB2 and TAK1, resulting in the translocation of 
TAK1/TAB1/TAB2 complex along with TRAF6 from the cell membrane into the 
cytosol (Jiang et al., 2002). TAK1 is activated by ubiquitination and subsequently 
activate the IB kinase (IKK) complex made up of the catalytic subunits IKK and 
IKK, and a regulatory subunit NF-B essential modulator (NEMO) (DiDonato et al., 
1997; Zandi et al., 1997). In a latent state, NF-B is sequestered in the cytoplasm bound 
to the inhibitor of B (IB) alpha (IκBα) (Gilmore, 1999).  The activation of the IKK 
complex leads to the phosphorylation, polyubiquitination and 26S proteosome-mediated 
degradation of IB, culminating in the release and translocation of NF-B from 
cytoplasm into the nucleus to activate the transcription of various proinflammatory 
genes (Chen et al., 1995).  
 
TAK1 is also plays a role in the activation of mitogen-activated protein (MAP) kinases. 
TAK1 can phosphorylate MAP kinase kinase (MAPKK) 4 (MKK4) and 6 (MKK6), 
which, in turn, can activate p38 and c-jun NH2-terminal kinase (JNK) MAPK signaling 
pathways (Johnson and Lapadat, 2002). These MAPKs can then activate the 
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transcription factor, activation protein 1 (AP-1) (Shaulian and Karin, 2002), which 

















1.5 Endocytic/phagocytic PRRs. 
The endocytic/phagocytic PRRs can be divided into two groups, the non-opsonic 
receptors which recognize PAMPs directly, and the opsonic receptors which bind to 
opsonins such as complement components, collectins and pentraxins deposited on the 
surfaces of non-self and altered-self targets. 
 
Figure 1.2. The MyD88-dependent signaling pathway.  Each TLR family member has its specific 
signaling pathway. MyD88-dependent pathway possessed by all the TLR family members, except for 
TLR3, is a common pathway to induce inflammatory cytokines. MyD88 is recruited to the cytoplasmic 
tail of activated TLR and associates via the TIR domain. Subsequently, IRAKs and TRAF 6 are recruited 
and activated in a signaling complex. The phosphorylation of TAK1 by IRAKs activates the former 
kinase which, in turn phosphorylate IKK complexes.  IKK then phosphorylates IB leading to 
ubiquitinylation and proteasome-mediated degradation of the latter, and the release of activated NF-B. 
NF-B subsequently translocate into the nucleus to activate the transcription of various pro-inflammatory 























































































Macrophages express a number of opsonic PRRs that effect recognition and uptake of 
opsonized targets.  These PRRs include the C1q receptor (C1qR) that can bind surface-
bound complement C1q (Malhotra et al., 1993) and collectins (MBL, SP-A and bovine 
conglutinin) (Malhotra et al., 1990), the C-type lectin receptor Dectin-1 which associate 
with pentraxin 3 (PTX3)-opsonized zymosan (Diniz et al., 2004) and, interestingly, also 
fungal cell wall carbohydrates (-glucan and mannan) directly (Herre et al., 2004), and 
the family of complement receptors (CRs). The are currently five known CRs belonging 
to three gene superfamilies, the short consensus repeat (SCR) module proteins 
complement receptor 1 (CR1) (Fearon, 1980) and CR2 (Nadler et al., 1981), the 2 
integrin family members CR3 (Springer et al., 1979) and CR4 (Sanchez-Madrid et al., 
1983), and the immunoglobulin Ig-superfamily member, complement receptor of Ig 
superfamily (CRIg) (Helmy et al., 2006). The dissertation will focus on the  integrin 
CRs in line with the PRRs investigated in this study.   
 
The nonopsonic endocytic/phagocytic PRRs are predominantly made up of receptors 
from two major families, the C-type lectin receptors (CLRs) (Robinson et al., 2006) and 
the scavenger receptors (SR).  The CLRs are soluble or membrane-associated molecules 
that are able to bind mannose- or galactose-type sugar residues in a calcium dependent 
manner via carbohydrate recognition domains (CRDs) present on these receptors 
(McGreal et al., 2004).   The transmembrane CLRs include the mannose receptor family, 
Dectin-1 and 2, DC-specific intercellular adhesion molecule-3 grabbing non-integrin 
(DC-SIGN), murine DC SIGN-related (DC-SIGNR) 1-4, langerin, DEC-205 and blood 
DC antigen-2 (BDCA-2) (Robinson et al., 2006). The secreted soluble CLRs include the 
collectins comprising of MBL, SP-A and SP-D, conglutinin, collectin liver 1 (CLL1), 
collectin placenta 1 (CL-P1), collectin of 43 kDa (CL-43) and collectin of 46 kDa (CL-
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46) (van de Wetering et al., 2004).  The SRs are a heterogeneous family of 
transmembrane glycoproteins divided into eight classes (Class A to H). These receptors 
play important roles in the clearance of modified low density lipoproteins (LDL) as well 
as in the recognition of various PAMPs. As with the opsonic receptors, this group of 
receptors would be the focal point of discussion in the dissertation in view that one of 
the SRs, SR-A, was investigated in this study. 
 
1.6 Complement receptors and complements 
The discussion on complement receptors is preceeded by a brief overview of the 
complement system including the associated complement components and pathways 
activated during an immune response involving the system.  
 
 1.6.1 Complement system 
Complement activity is established by the interplay of 30-40 soluble plasma and cell 
surface proteins that proceeds through a series of proteolytic and complex-forming 
biochemical steps and culminate in the destruction and clearance of a target cell or 
molecule (Walport, 2001). Three routes of complement activation are recognized: the 
classical (antibody-mediated) pathway, the mannose binding lectin (MBL) pathway and 
the alternative pathway.  Although each pathway has a unique combination of initiating 
proteins, all three converge in the activation of the complement component C3 and a 
common lytic pathway involving the formation of the membrane attack complex 
(MAC) on the target cell surface. The various complement pathways are schematically 





























Figure 1.3. Various pathways of complement activation. The three activation pathways of 
complement: the Classical, Mannose-Binding Lectin, and Alternative Pathways. The three pathways 
converge at the point of cleavage of C3. The classical pathway is initiated by the binding of the C1 
complex to antibodies bound to the bacterial cell surface. C1s first cleaves C4 and then cleaves C2, 
leading to the formation of a C4b2a enzyme complex (classical pathway C3 convertase). The mannose-
binding lectin pathway is initiated by binding of the complex of MBL and MASP1and MASP2 to arrays 
of mannose groups on the bacterial cell surface. MASP2 acts as a protease like C1s, and facilitate 
classical pathway C3 convertase formation. The alternative pathway is initiated by the covalent binding 
of a small amount of C3b to hydroxyl groups on cell-surface carbohydrates and proteins and is activated 
by low-grade cleavage of C3 in plasma. This C3b binds factor B, a protein homologous to C2, to form a 
C3bB complex. Factor D cleaves factor B bound to C3b to form the alternative pathway C3 convertase 
C3bBb. The C3 convertase enzymes cleave many molecules of C3 to C3b, which bind covalently 
around the site of complement activation. Some of this C3b binds to C4b2a and C3bBb to form C5 
convertase enzymes which cleave C5  into C5a and C5b. C5b recruits C6, C7, C8 and several C9 to 
form the MAC. Reproduced from Walport (2001) 
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The classical complement pathway is activated by by antibody-antigen complexes. 
Human IgM and IgG isotypes except IgG4 in complexes with antigens are strong 
activators of this pathway (Cooper, 1985) by associating with the complement 
component C1 which comprising of subunits C1q, C1r and C1s (C1qC1r2C1s2) 
(Ziccardi and Cooper, 1977). C1q binds to the constant region (Fc) of immunoglobulin 
in these complexes and facilitates the activation of the serine proteases, Clr and C1s 
(Ziccardi and Cooper, 1976). Activated C1s then cleaves C4 into C4a and C4b 
fragments, exposing a highly reactive thiolester in C4b that enable the fragment to 
covalently bind target surfaces with hydroxyl (-OH) or amino (-NH2) acceptor groups.  
 
Activated C1s also splits C2 into C2a and C2b. The larger enzymatically active C2a 
fragment associates with surface-bound C4b to form the classical pathway C3 
convertase, C4b2a (Muller-Eberhard et al., 1967), which can enzymatically generate 
large quantities of C3a and C3b from native C3. Reminiscent of C4b, C3b can 
effectively bind target surfaces via its thiolester group.  
 
In addition to cleaving C3, C4b2a can also recruit C3b to form the C5 convertase, 
C4b2a3b (Cooper and Muller-Eberhard, 1970), which then cleaves C5 into C5a and 
C5b. The presence of C5b at the target surface triggers the formation of the MAC that 
result in target cell lysis. Surface-bound C5b associates with C6, C7, C8 and one to 
several C9, which polymerizes into a concentric tube or pore through the membrane 
bilayer. Numerous pores within the lipid membrane allow free diffusion of water, ions 
and small molecules, resulting in a loss of osmolarity and subsequently cell lysis. 
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The key difference between the MBL and classical pathways of complement activation 
is their mode of initiation. Instead of antibody-antigen complexes interacting with C1q, 
the former pathway is activated by MBL binding specifically to mannose-containing 
carbohydrates predominantly present on bacterial membranes or viral envelopes.  Upon 
binding to specific polysaccharide molecules, MBL can recruit and activate MBL-
associated serine proteases (MASP) 1 and 2, akin to the activation of C1r and C1s by 
C1q. The MBL-MASPs complex is also a potent activator of C4 and C2, from which 
the two pathways converge resulting in identical downstream events.  
 
The alternative complement pathway is initiated via the slow spontaneous hydrolysis of 
the thiolester bond in C3 in a process termed “tickover” at an estimated rate of 0.2-0.4% 
of C3 plasma pool/hour (Muller-Eberhard, 1988; Pangburn et al., 1981), generating a 
conformationally altered C3 designated C3(H2O) (Isenman et al., 1981) which can form 
a Mg2+-dependent complex with the plasma protein, factor B. This C3(H2O)B complex 
is activated by the plasma protease factor D, which proteolytically cleaves factor B into 
Ba and Bb fragments.  The enzymatically active Bb remains bound to C3(H2O) to form 
the fluid phase “initiation C3 convertase” C3(H2O)Bb (Pangburn and Muller-Eberhard, 
1980; Pangburn et al., 1981).   
 
The function of the “initiation C3 convertase” is to cleave C3 into C3a and C3b, and 
C3b would subsequently be deposited on target surfaces near the site of complement 
activation.  The surface-bound C3b can then recruit factor B and, following factor D 
mediated cleavage, form the alternative pathway C3 convertase C3bBb.  This 
convertase can recruit and cleave further C3 molecules, generating more C3 convertase 
in a self-sustaining cycle of C3 activation. This positive amplification loop is the key 
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defining feature of the alternative complement pathway (Muller-Eberhard and Gotze, 
1972). C3bBb can also proceed to, like the classical pathway C3 convertase C4bC2a, 
interact with a C3b molecule to form the C5 convertase, C3bBb3b (Daha et al., 1976; 
Medicus et al., 1976) and culminate in the formation of MAC. 
 
The fact that the alternative pathway is initiated by a fluid phase convertase could 
potentially result in the indiscriminant deposition of C3b on the surfaces of both 
pathogens and host cells, and thus trigger autologous complement attack. Host cell 
damage via complement activation is prevented by a group of complement regulatory 
proteins (CRP), such as the serine/threonine factor I and members of the regulators of 
complement activation (RCA) family that include C4b-binding protein (C4BP) and 
factor H present in plasma, and the host cell membrane-associated receptors, membrane 
cofactor protein (MCP/ CD46), decay accelerating factor (DAF/CD55), complement 
receptor 1 (CR1/CD35) and complement receptor 2 (CR2/CD21) (Hourcade et al., 
1989).  Factor I prevents C3 convertase formation by cleaving C3b into inactivated 
form iC3b in the presence of C3b-binding cofactors CR1 (Iida and Nussenzweig, 1981; 
Ross et al., 1982), CR2 (Mitomo et al., 1987) and MCP (Seya and Atkinson, 1989), and 
serum factor H (Ross et al., 1982; Zipfel et al., 1999) which binds sialic acid and 
heparin uniquely present on host cell surfaces (Meri and Pangburn, 1990). CR1 (Iida 
and Nussenzweig, 1981) and serum factor H (Zipfel et al., 1999) can also compete with 
factor B for binding to C3b on the cell surface during C3 convertase formation while 
DAF displaces Bb or C2a from existing C3 convertases (Fujita et al., 1987). The 
regulatory activity of C4BP is confined to the classical/lectin pathways. C4BP exhibits 
decay accelerating activity by displacing C2a from the C3 convertase C4b2a and is a 
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cofactor for factor I in the cleavage of C4b into C4c and C4d fragments (Chung and 
Reid, 1985).  
 
1.6.1.1 Complement component C3  
The complement proteins C3 is paramount for complement activation. Human C3 is a 
key complement protein that facilitates the classical as well as alternative pathway of 
complement activation. It is the most abundant complement component in serum with 
average concentration of 1-2 mg/ml (Sahu and Lambris, 2001).  C3, along with C4 and 
C5, are structurally homologues and belong to the 2-macroglobulin superfamily. 
Structurally, the glycoprotein comprises of a 115 kDa -chain linked to a 75 kDa -
chain by a single disulphide bond and non-convalent forces.  The primary structure as 
deduced from cDNA sequence consists of 1663 amino acids including a 22 amino acid 
signal peptide (de Bruijn and Fey, 1985). The protein is synthesized as a single chain 
pre-pro-molecule with the and -chains linked by a tetra-arginine sequence, which is 
removed by a furin-like enzyme during post-translational modification (Misumi et al., 
1991). 
 
Early molecular modeling of C3 based on X-ray scattering data depicts the molecule as 
a two-domain structure with a flat ellipsoid associated with a smaller flat domain, with 
the two domains moving closer together following proteolytic activation and removal of 
C3a fragment (Perkins and Sim, 1986). The crystal structure of C3 has since been 
elucidated (Janssen et al., 2005) (Figure 1.4). The core of and  chains of C3 
molecule is formed by eight macroglobulin (MG) domains. The  chain comprises of 
MG1-5 and part of MG6 (MG6) while the chain is made up of MG7-8, part of MG6 
(MG) and the rest of the other domains found in the C3 molecule. MG1-5 and MG6 
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(both and  chain segments) form a core ring structure ( ring). The small helical C3a 
domain is connected to the N-terminus of the chain via the ’NT linker.  Inserted into 
the core of the chain are the CUB (C1r/C1s, Uegf and Bone morphogenetic protein-1) 
and thioester (TED) domains. The C345C domain at the C-terminus of the chain was 
identified by homology to a similar domain in C5b that is required for MAC formation 
(Thai and Ogata, 2003). The function of C3 is regulated by conformational changes 
induced by sequential proteolytic cleavages (Janssen et al., 2005). Upon cleavage, 
thechain undergoes major domain rearrangements while the -ring remains fairly 
stable (Janssen et al., 2006; Janssen et al., 2005).  As shown in Figure 1.4, MG7 and 
MG8 rotate about to swap places with each other while the C345C domain swivels 
sideways and downwards, resulting in a torque motion on the internal disulphide bond-
containing anchor region which alters the conformation of the latter region from an -
helix (in C3) to a -hairpin (in C3b). The ’NT linker also undergoes a drastic 
relocation, moving through the central hole of the  ring and becomes exposed on the 
other side of the molecule (Janssen et al., 2006). The CUB domain also moves 
downwards and outwards, along with the TED, towards the  ring structure. The 
movement of the TED results in the exposure the thioester bond (Cys988-Gln991) within 
the TED of C3b (Tack et al., 1980). The exposed thioester bond, in turn, facilitates the 
covalent association of C3b with target surfaces via ester or amide linkage with suitable 
acceptor groups (Law et al., 1979).  
 
One of the important characteristic of C3 is its ability to bind covalently to acceptor 
molecules on cell surfaces via the thioester bond (Law et al., 1979). The thioester bond 
is the product of an intramolecular transacylation between the thiol group of cysteine 
and the -amide group of the glutamine within the C3 sequence Gly-Cys988-Gly-Glu-
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Gln991-Asn (Levine and Dodds, 1990). This thioester moiety, which is sensitive to 
nucleophilic attack, is protected within a hydrophobic pocket in the TED in C3 but 
becomes exposed in the C3b fragment. The transiently exposed thioester bond with 
half-life of 100 s can then participate in a transacylation reaction with nucleophilic 
groups (OH or NH2 group) present on cell surfaces, complex carbohydrates or immune 
complexes (Levine and Dodds, 1990). The half-life of surface-bound C3b is also 
relatively short, approximately 90 sec, due to its rapid cleavage into iC3b and further C3 
degradation products by the specific serine proteinase, factor I (Figure 1.5). The 
significantly longer half-life of iC3b, approximately 35 min, suggests that the latter is 
the major C3 fragment mediating immune clearance in vivo (Ross et al., 1985b; Ueda et 
al., 1994b). As discussed in later sections, surface-bound iC3b on target particles is 
recognized by complement receptors, which would then rapidly facilitate the 













Figure 1.4.  Ribbon diagrams of human component C3 and C3b.  Ribbon representation of native C3 
(right) and C3b (left).  The macroglobulin domains (1-8) are individually colour-coded and labeled 
accordingly, as are the CUB (indigo), TED (dark green) and C345C (crimson ) domains.  The intact 
thioester (red spheres), anchor region (grey), linker/LNK region (khaki), anaphylatoxin/ANA (bright red) 



























Figure 1.5. Activation and degradation of complement C3. Complement C3 is composed of  a 115 
kDa chain linked to a 75 kDa -chain by a single disulphide bond and non-convalent forces. 
Classical and alternative pathway C3 convertases cleave C3 into two fragments, a smaller C3a and 
larger C3b fragment. Factor I and various co-factors (including Factor H) are responsible for the 
formation of iC3b and the release of a small C3f fragment.  Factor I and other proteases further cleave 
iC3b into other C3 degradation products i.e. C3c, C3dg, C3d and C3g. The cleavage sites are 
indicated by thin dark arrows with the enzyme(s) involved. The location of the thiolester bond is 
indicated with a closed balloon. The molecular weights of the polypeptides are calculated on the basis 
of their deduced amino acid sequences.  Adapted from Sahu & Lambris (2001) 
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1.6.2 Complement Receptor 3 (CR3, CD11b/CD18, Mac-1, M2) 
Complement receptor type 3 (CR3, M2, CD11b/CD18, Mac-1 and Mo1) is a  
heterodimeric molecule belonging to the leukocyte-restricted 2 integrin family.  The 
family comprises of four members, CD11a/CD18 (LFA-1, L2), CD11c/CD18 (CR4, 
X2) and CD11d/CD18 (D2) (Ross, 2000).  All members of this family commonly 
share the -subunit or CD18. The genes of all  subunits are clustered on choromosome 
16p (Corbi et al., 1988b; Shelley et al., 1998), while that of 2 is on chromosome 21q22 
(Marlin et al., 1986).   
 
Expression of CR3 is primarily on mononuclear phagocytes such as monocytes, 
macrophages and dendritic cells, although expression of this receptor is also detected on 
neutrophils, natural killer (NK) cells, eosinophils, CD8+ T cell subsets and CD5+ B 
cells.  Based on the diverse immune functional roles ascribed to CR3, it would be no 
exaggeration to proclaim this receptor the archetypal component of innate immunity 
(Ehlers, 2000) since it was identified some 30 years ago (Springer et al., 1979). Two of 
these functional roles established for the receptor, that of cell-cell/cell-matrix adhesion 
and complement-mediated microbial/immune complex recognition and clearance, are 
central to an effective innate immune response (Ross, 2000).  CR3 is involved in cell-
cell and cell-matrix adhesion, mediating the migration of myeloid leukocytes and NK 
cells out of the blood vessels and into inflammatory sites by generating a high affinity 
binding site for the intercellular adhesion molecule-1 (ICAM-1) expressed by activated 
endothelium. As a complement receptor, CR3 interacts with microorganisms and 
immune complexes opsonized with iC3b, resulting phagocytosis (Ingalls et al., 1997), 
pro-inflammatory cytokine production (Cuzzola et al., 2000; Medvedev et al., 1998), 
reactive oxygen species (ROS) generation (Gordon et al., 1989; Husemann et al., 
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2001b; Matsuno et al., 1998) and cytotoxic degranulation (Cain et al., 1987; Vetvicka et 
al., 1996).  Moreover, CR3 can also serve in nonopsonic recognition of certain 
microorganisms by interacting directly with microbial cell surface molecules (Cywes et 
al., 1996; Garcia et al., 2005; Relman et al., 1990; Russell and Wright, 1988; Wright 
and Jong, 1986).  The physiological importance of the 2 integrins is underscored by the 
severe pathological phenotype manisfested by individuals with the disease leukocyte 
adhesion deficiency (LAD), which stems from mutational defects in the common 2 
chain (Crowley et al., 1980). LAD patients present high neutrophil counts in the blood 
during infection, suffer from recurrent bacterial and fungal infection and exhibit 
impaired wound healing with dystrophic scars from skin injuries (Mathew et al., 2000; 
Shaw et al., 2001).  
 
CR3 comprises is a 170 kDa type I transmembrane glycoprotein, termed subunit, that 
associates noncovalently with the 95 kDa subunit (Arnaout et al., 1988; Corbi et al., 
1988a). Based on the crystal structure of the integrin V3 (Figure 1.6) , the N-terminal 
region of integrin -subunits contains seven homologous tandem repeats that fold into a 
 propeller configuration (Xiong et al., 2001). Some of these -subunits, including the 
2 integrins, possess an I (inserted) domain (A domain) inserted between  sheets 2 and 
3 of the -propeller domain (Luo et al., 2007).  This domain, made up of approximately 
200 amino acids, is critical for ligand binding (Diamond et al., 1993; Lee et al., 1995; 
Springer, 1997). The region C-terminal to the  propeller is termed the leg of the -
subunit, and comprises of the thigh, calf-1 and calf-2 domains.  A small Ca2+ binding 
loop located between the thigh and calf-1 domains, namely the genu, is a key pivot 
point for conformational changes in the subunit during receptor activation.  The 
topology of the subunit is more complex. The N-terminal region of the subunit 
 26
contains a 240 amino acid  I domain (Tuckwell and Humphries, 1997) which 
associates with the  propeller of the -subunit and is also involve in ligand binding 
(Goodman and Bajt, 1996; Luo et al., 2007). The  I domain is inserted in the hybrid 
domain, which in turn, is inserted in the plexin/semaphoring/integrin (PSI) domain 
(Bork et al., 1999) (Figure 1.6 ). The remainder of the  leg is built from four integrin 
















1.6.2.1 Ligand promiscuity of CR3 
A salient characteristic of CR3 is its broad capacity for the recognition of diverse 
ligands (Ehlers, 2000). More than thirty protein and non-protein molecules have been 
reported to associate with CR3, with the majority of these ligands listed in Table 1.1.  
Figure 1.6.  Ribbon drawing of the 
extracellular segment of crystallized 
integrin v3 illustrating various 
domains of the  and  subunits. The 
 heterodimeric structure is common 
to all integrins. The  subunit (blue) 
includes seven N-terminal homologous 
repeats organized into a -propeller, 
thigh, calf-1 and calf-2 domains.  Four 
Ca2+ binding sites at the bottom of the 
propeller and another at the genu are 
shown (pink). The inactive integrin is 
folded over at the genu but becomes 
extended upon activation. The  subunit 
contains an I/A domain inserted into a 
loop on the top of the hybrid domain, 
which is linked to the PSI, EGF1-4 and 
TD domains. The PSI (gray) and EGF 
1-2 (pink) domains are not resolved and 
tracings show their approximate 
locations.   Reproduced from Xiong et. 
















The molecular basis for CR3 substrate recognition is not fully known, although the I 
domain on the M subunit and the I-like domain on the 2 subunit are involved. 
(A) Endogeneous ligands  Reference  
iC3b/C3dg/C3d (Arnaout et al., 1983) 
ICAM-1  (Diamond et al., 1990) 
ICAM-2 (Xie et al., 1995) 
ICAM-4 (Hermand et al., 2000) 
Fibrinogen (Wright et al., 1988)  
Fibronectin (Lishko et al., 2003) 
Collagen (Walzog et al., 1995) 
Factor X (Altieri and Edgington, 1988) 
Factor H (DiScipio et al., 1998) 
Heparin sulphate (Diamond et al., 1995) 
Elastase (Cai and Wright, 1996) 
Haptoglobin (El Ghmati et al., 1996) 
High molecular weight kininogen (Sheng et al., 2000) 
Myeloperoxidase (Johansson et al., 1997) 
E-selectin (Kotovuori et al., 1993) 
Cysteine-rich 61 (Cyr61) (Schober et al., 2002) 
Connective tissue growth factor (Schober et al., 2002) 
CD14 (Zarewych et al., 1996) 
Fc receptor type III (Galon et al., 1996) 
Urokinase-type plasminogen activator receptor (uPAR) (Xue et al., 1994) 
CD23 (Lecoanet-Henchoz et al., 1995) 
Thy-1 (CD90) (Wetzel et al., 2004) 
Platelet glycoprotein Ib (Simon et al., 2000) 
Junctional adhesion molecule-3 (JAM-3) (Santoso et al., 2002) 
(B) Exogeneous/microbial ligands   
LPS (Escherichia coli) (Wright and Jong, 1986)   
LPS (Salmonella Typhimurium) (van Bruggen et al., 2007) 
-glucan/Zymosan (Ross et al., 1985a) 
Heat shock protein 60 (Histoplasma capsulatum)  (Long et al., 2003) 
Hookworm Neutrophil inhibitory factor (NIF) (Moyle et al., 1994) 
Lipoprotein OspA & B (Borrelia burgdorferi) (Garcia et al., 2005) 
M5 Protein (Group A streptococci) (Weineisen et al., 2004) 
Adenylate cyclase toxin/ACT (Bordetella pertussis) (Perkins et al., 2007) 
Filamentous haemagglutinin (Bordetella pertussis) (Relman et al., 1990) 
Lipophosphoglycan/LPG (Leishmania mexicana) (Talamas-Rohana et al., 1990) 
Acylpolygalactoside/APG (Klebsiella pneumoniae) (Kouassi et al., 1992) 
Fimbriae (Porphyromonas gingivalis) (Wang et al., 2007) 
gp63 (Leishmania promastigote) (Russell and Wright, 1988) 
Mycobacterium tuberculosis (Cywes et al., 1996) 
Candida albicans (Forsyth and Mathews, 1996)  




Table 1.1. Ligands of the integrin complement receptor 3 (CR3). 
CR3 lignds are classified into (A) Endogeneous and (B) Exogeneous/microbial. Endogeneous ligands 
include ECM proteins, plasma proteins involved in complement activation and coagulation, co-
receptors (particularly GPI-anchored receptors) and counter-receptors. Exogeneous/microbial ligands 
are generally protein molecules on microbes that interact with CR3 to gain entry into the cell or 
molecules classified as PAMPs. The keyhole limpet haemocyanin is an exception in the exogeneous 
ligand list because it is non-microbial in origin.  
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1.6.2.2 Inserted (I) and I-like domains in ligand recognition 
Most of the protein ligands, of both endogeneous and exogeneous/microbial origins, 
bind to the specialized I domain of the  subunit (Diamond et al., 1993; Ueda et al., 
1994b; Zhou et al., 1994), which was first identified in the von Willebrand factor 
(Girma et al., 1987). The crystal structures of the I domains of M, L and X have been 
elucidated (Lee et al., 1995; Qu and Leahy, 1995; Vorup-Jensen et al., 2003). The 
domain has a Rossman fold-like structure composed of a central hydrophobic  sheet 
surrounded by six or seven amphipathic  helices. The domain also contain a conserved 
coordination locus for Mg2+ and Mn2+, the “metal ion dependent adhesion site” 
(MIDAS), consisting of the sequence DXSXS together with downstream non-
contiguous Asp and Ser/Thr residues (Perkins et al., 1994). The metal binding site in 
CR3 is coordinated by Asp140, Ser142, Ser144 in the DXSXS motif and two 
conformationally proximal residues Thr209 and Asp242 (Lee et al., 1995). The function of 
the MIDAS is to provide a scaffold for high affinity binding of divalent cations which, 
in turn, help to maintain correct conformation of the I domain (Xiong and Zhang, 2001), 
and to also contribute directly in ligand binding by interacting with acidic residues of 
the ligand (Xiong et al., 2002a).  
 
CR3 is the principal receptor expressed on phagocytic leukocytes that mediate the 
binding and subsequent uptake of iC3b-opsonized targets (Agramonte-Hevia et al., 
2002; Ehlers, 2000). The functional domain involved in iC3b recognition have been 
mapped to the I domain (Diamond et al., 1993; Michishita et al., 1993; Ueda et al., 
1994b).  Amino acid substitutions within the MIDAS (Asp140 and Asp242) of the I 
domain abolished the cation-dependent binding of CR3-transfected COS cells to iC3b, 
without impairing subunit association or surface receptor expression (Michishita et al., 
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1993).  Blocking antibodies against the I domain also inhibit FITC-labeled iC3b coated 
erythrocytes from adhering to cultured neutrophils (Diamond et al., 1993) while a 
recombinant I domain peptide (Cys128 to Gly321) was able to bind to iC3b directly in a 
divalent cation dependent manner (Ueda et al., 1994b). The iC3b binding region was 
further defined into three regions (Pro147-Arg152, Pro201-Lys217 and Lys245-Arg261) using 
a series of mutant receptors in which short segments of the I domain of M was replaced 
by corresponding segments of L (Zhang and Plow, 1999). The structurally similar L 
does not bind iC3b although it also possesses an I domain (Arnaout, 1990). These 
identified regions surrounds the cation binding site within the MIDAS motif of the I 
domain and was predicted to form the iC3b binding pocket (Zhang and Plow, 1999).   
 
Although studies have demonstrated the importance of the I domain in ligand binding, 
one perplexing question that remains is the “binding blueprint” that the domain adopts 
to recognize a range of ligands that share no obvious structural similarities. For 
example, do all CR3 ligands bind to the established iC3b binding pocket? Zhang and 
Plow (1999) postulated that M I domain contain distinct, overlapping but nonidentical 
binding pockets for various CR3 ligands.  It was demonstrated that the surface-exposed 
D-5 loop-5 helix segment (Lys245-Arg261) of the M I domain, particularly 
D248PLGY, was responsible for binding affinity to fibrinogen, NIF and iC3b 
(Yakubenko et al., 2002; Zhang and Plow, 1999), while another region R281QELNTI in 
helix 6 of the domain was essential for fibrinogen binding but not iC3b or NIF (Zhang 
and Plow, 1999). In addition to the I domain, other regions of the  subunit, and also 
the 2 subunit, have been shown to play a role in ligand binding. By utilizing a function-
blocking antibody CBRM1/32, which recognizes an epitope on the -propeller of  M 
subunit,  five different segments lying in the fourth “blade” (residues Asp398 to Thr451) 
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of the M -propeller (W4) to be involved specifically with iC3b recognition 
(Yalamanchili et al., 2000).   
 
The  subunit of CR3 may also be involved in the iC3b recognition. The 2 subunit 
possesses a conformational correct I-like domain between residues 125-385 with a Ca2+ 
binding MIDAS motif (Huang et al., 1997; Huang et al., 2000; Xiong and Zhang, 2001).  
Mutations of specific residues Asp134, Ser136 and Ser138 within the MIDAS motif did not 
affect heterodimer formation or surface expression but abrogate the binding of iC3b 
(Bajt et al., 1995; Zhang and Plow, 1996). It was also demonstrated that a recombinant 
I-like domain peptide transiently expressed on COS-7 cells confer adherence to 
immobilized iC3b (Goodman et al., 1998).  By swapping short amino acid sequences 
located in the I-like domain between the highly homologous 1 and 2 integrins, three 
non-contiguous segments critical for iC3b binding were identified : Gln199-Ala203, 
Leu225-Leu230 and Gly305-His309  (Xiong et al., 2002b). Synthetic peptides corresponding 
to Gln199-Ala203 and Gly305-His309 bound immobilized iC3b. These four segments were 
found to reside in close proximity to one another in the three dimensional conformation 
of the I-like domain, consistent with sequences involved in ligand recognition (Xiong et 
al., 2002b).  Li and Zhang (2003) proposed that iC3b recognition by CR3 requires three 
independent ligand binding domains : the M I domain, the 2 I-like domain and the W4 
blade of the M -propeller and that these individual binding sites located in close 
proximity to each other in three-dimensional space to form a composite iC3b binding 
pocket. High affinity ligand binding would require optimal orientation of these three 
ligand binding sites probably achieved through conformational changes of the two 
integrin subunits during inside-out signaling of the receptor.  
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1.6.2.3 Integrin bi-directional signaling 
Integrins constitute the critical link between cell-cell, cell-extracellular matrix and, in 
some cases, cell-microbe interactions by binding to distinct but often overlapping 
combination of ligands.  Besides serving a structural/mechanical role by acting as 
anchoring points or facilitating the uptake of microbes, these receptors are also crucial 
information sensing and transducing devices. Upon ligand binding, integrins are able to 
initiate signaling cascades from the extracellular milieu into the cell via so-called 
“outside-in signaling”. In addition, these receptors also respond to intracellular signals 
generated by other receptors, termed “inside-out signaling”, by undergoing 
conformational changes in structure that result in the alteration in binding affinity for 
extracellular ligands.   
 
1.6.2.3.1 Inside-out signaling of integrins 
A central feature of integrins is their capacity to change rapidly and reversibly their 
adhesive functions by modulating their ligand-binding affinity, achieved through the 
interactions of the short cytoplasmic integrin tails with intraceullar proteins which 
trigger restructuring of the ligand-binding pocket through long-range conformational 
changes in the ectodomains of the receptors. Crystal structure studies of integrins reveal 
that these receptors adopts a knee-bent conformation in the inactive state, but becomes 
extended in a “switchblade-like” manner following activation via intracellular signals to 
faciliate ligand binding (Figure 1.7)(Xiong et al., 2001).  
 
Affinity switching in activated integrins is believed to be triggered intracellularly by the 
association of certain motifs in the integrin cytoplasmic tails (e.g. NPxY/F motifs in the 
 subunit tail), to actin cytoskeleton associated proteins such as talin, paxillin and 
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viculin (e.g. PTB-like F3 FERM domain of talin)(Yan et al., 2001). However, the 
regulation and recruitment of these proteins to the cytoskeleton to facilitate integrin 
activation, is poorly understood (Arnaout et al., 2005). Binding of these proteins to the 
integrin tail, nevertheless, induces spectral perturbation in the membrane-proximal 
region of the integrin, that is, the separation of the cytoplasmic and transmembrane 
segments, and the release of the hybrid domain from its restraining interface with the 
leg domains, which allows the domain to swing outwards and pull down the 7 helix of 
the  I domain (Arnaout et al., 2005). Such a conformational change switches the  I 
domain to high affinity state, and this, in turn, facilitate structural changes in the I 
domain from an inactive, closed to the active, open conformation (Shimaoka et al., 
























Figure 1.7 Inside-out signaling of integrins.  A model for long-range allosteric changes in an I-
domain containing integrin following inside-out signaling.  The inactive integrin is folded with the 
headpiece bent over the stalk region at the genu.  Inside-out signals resulting from interactions 
between integrin tails and cytoskeletal proteins activate the integrin, resulting in straightening and 
separation of the integrin legs and alteration in the orientation of the propeller, I and I/A domain, 
facilitating ligand binding. The  subunit legs are flexible and are shown in the predominant (solid) 
and rare (dashed lines) orientations.  Reproduced from Luo et .al. (2007). 
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1.6.2.3.2 Outside-in signaling of integrins. 
The general characteristics of outside-in signaling shared by members of the integrin 
family include the propensity for clustering and association with the cytoskeletal and 
signaling complexes, the activation of key signaling cascades particularly those leading 
to MAP kinases and phosphatidylinositol-3-kinase (PI3K) activation, and the regulation 
of cell spreading, shape, and migration through activation of the Rho family of small 
















Integrins generate intracellular signals upon interaction with ligands or counter-
receptors on other cells. However, cytoplasmic tails of integrins are comparatively short 
and devoid of enzymatic features (Giancotti and Ruoslahti, 1999). Integrins signal via 
Figure 1.8 Outside-in signaling of integrins. The major outside-in signaling pathways and the key 
signaling intermediates are shown. The activated pathways lead to important effects on cell behaviour 
mediated by integrins, often acting in concert with G protein-coupled or kinase receptors for soluble 
factors. The major intracellular, integrin-associated links between integrins and these signaling pathways 
are contained within the pink-purple pentagon beneath the clustered integrins. Details of the interactions 
of these linker/adaptor proteins and the signaling pathways are elaborated in the text. Reporduced from 
Hynes (2002). 
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adaptor proteins such as talin, paxillin and viculin that connect the receptor to the actin 
cytoskeleton. The clustering of integrins on the cell membrane upon ligand binding 
promotes the assembly of actin filaments, and the formation of the integrin-cytoskeletal 
complex facilitates the recruitment of various non-receptor tyrosine kinases (TK) to this 
multi-protein “signaling platform” to initate downstream signaling cascades. TKs 
involved in integrin signaling include the src kinases, p58c-FGR (Fgr), p59/61HCK (Hck) 
and p53/56LYN (Lyn), p72SYK (Syk) tyrosine kinase and members of the focal adhesion 
kinase (FAK) family, such as p125FAK, focal adhesion kinase-related protein B (fakB) 
and Pyk2 (Giancotti and Ruoslahti, 1999). P125FAK is activated by most integrin 
signaling pathways (Giancotti and Ruoslahti, 1999) via autophosphorylation at Tyr397, 
generating a binding site for the Src homology 2 (SH2) domain of the src family of 
kinases (Schaller and Parsons, 1994; Schlaepfer et al., 1994) and the p85 subunit of 
PI3K (Chen and Guan, 1994). The activated PI3K then phosphorylate and activated 
protein kinase B (Akt) which play an important role in cell survival while src kinases 
phosphorylates a number of proteins in the focal adhesion multi-protein complex 
including paxillin and tensin (Fuortes et al., 1994), the  guanosine 5’-triphosphate 
(GTP) nucleotide exchange factor (GEF) Vav (Zheng et al., 1996) and a docking protein 
p130CAS. The tyrosine phosphorylation of p130CAS recruits the SH2/SH3 adaptor 
proteins Crk and Nck via their SH2 domain (Schlaepfer et al., 1997; Vuori et al., 1996). 
Through their SH3 domains, Crk or Nck can then interact with the proline-rich motif 
present in mSOS (mammalian son of sevenless), a GEF specific for the small GTP-
binding protein (GTPase) Ras.  The GEF mSOS would, in turn, activate Ras and the 
downstream MAP kinases, extracellular signal regulated kinase (ERK) 1 and 2 and 
subsequently the transcription factor complex activator protein 1 (AP-1) to effect gene 
transcription (Schlaepfer et al., 1994).  
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The src kinase-mediated phosphorylation of the GEF Vav initiates various signaling 
cascades that culminate in cell proliferation, apoptosis, gene transcription and actin 
cytoskeleton rearrangement associated with cell motility.  Vav activates a group of 20-
30 kDa monomeric GTPases of the Rho family such as  Rho/Rac/cdc42 (Brown et al., 
2006).  Small GTPases act as molecular switches by cycling between active GTP-bound 
and inactive guanosine diphosphate (GDP)-bound conformation, and GEFs promote the 
activation of GTPases by facilitating the exchange of GTP for GDP.  In the active GTP-
bound state, Rho GTPases perform their regulatory function through conformation-
specific interactions with target effector proteins that include serine/threonine kinases, 
tyrosine kinases, lipid kinases, lipases, oxidases and scaffold proteins (Bishop and Hall, 
2000; Jaffe and Hall, 2005). Rho GTPases affect gene transcription through the 
activation of NF-B and the MAP kinases, c-Jun N-terminal kinases (JNKs) and p38 
mitogen-activated protein kinase (MAPK). At least four MAP kinase kinase kinases 
(MAP3Ks) are direct targests of Rho GTPases; the serine/threonine mixed lineage 
kinase 2 (MLK2), MLK3 and mitogen-activated protein kinase and ERK kinase kinase 
4 (MEKK4) interacts with Rac and cdc42 whereas MEKK1 associates with all Rho 
GTPases (Burbelo et al., 1995; Gallagher et al., 2004; Teramoto et al., 1996). These 
MAP3Ks will, in turn, trigger phosphorylation-dependent MAP kinase signaling 
cascades involving JNK and p38 MAP kinases and culminate in AP-1 activation.  
 
1.6.3 Complement receptor 4 (CR4, CD11c/CD18, X2) 
The complement receptor type 4 (CR4) is a heterodimeric integrin composed of the 150 
kDa X subunit and the common 2 subunit (Lanier et al., 1985). The cellular and tissue 
expression of CR4 appear to be similar to CR3; the receptor is primarily expressed 
myeloid cells, NK cells, activated B cells, some subsets of cytotoxic T cells and 
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platelets (Hogg et al., 1986; Keizer et al., 1987; Miller et al., 1986; Postigo et al., 1991). 
However, the levels of expression of the two receptors may differ in various cell types.  
The level of expression of CR4 on culture-derived macrophages was reported to be 
eight times more than that on monocytes while that of CR3 did not differ significantly 
(Myones et al., 1988). Immunostaining of various tissues revealed that CR4 is the most 
abundant C3 receptor on tissue macrophages (Myones et al., 1988).  CR4 expression 
was also found to be upregulated in myelomonocytic cell lines such as HL60 and U937 
during differentiation following phorbol 12-myristate 13-acetate (PMA) stimulation 
(Miller et al., 1986; Noti and Reinemann, 1995). In contrast, neutrophils predominantly 
express CR3 and CR1 but little CR4. Interestingly, human Kupffer cells also express 
more CR3 and CR1 in comparison with CR4 (Hinglais et al., 1989) 
 
The functional roles of CR4 are not as well characterized as that of CR3 and LFA-1. 
Antibodies to the X subunit have been used to effectively inihibit monocyte adhesion 
to endothelial cells, neutrophil adhesion to serum-coated surfaces, chemotaxis of 
peripheral blood monocytes and the phagocytosis of latex particles (Anderson et al., 
1986; Keizer et al., 1987; te Velde et al., 1987). The ligand specificity of CR4 appears 
to resemble that of CR3.  Several studies have suggested that CR4, like CR3, have the 
capacity to bind complement fragment iC3b (Malhotra et al., 1986; Micklem and Sim, 
1985; Myones et al., 1988; Ross et al., 1992), fibrinogen (Choi and Nham, 2002; Loike 
et al., 1991; Nham, 1999; Postigo et al., 1991), ICAM-1 (Diamond et al., 1993), LPS 
(Ingalls and Golenbock, 1995; Wright and Jong, 1986), soluble FcR III (Galon et al., 
1996), heparin (Diamond et al., 1995; Vorup-Jensen et al., 2005; Vorup-Jensen et al., 
2007), Thy-1 (Choi et al., 2005) and CD23 (Lecoanet-Henchoz et al., 1995). These 
studies were, however, not conclusive as data presented tend to be conflicting. For 
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example, although CR4 was identified via iC3b-Sepharose chromatography (Micklem 
and Sim, 1985), neither COS or CHO cells transfected with CR4 were able to bind to 
iC3b (Bilsland et al., 1994; Diamond et al., 1993). Further investigations led, 
surprisingly, to the discovery that although human CR4 transfected into COS cells did 
not bind iC3b coated erythrocytes, COS expressing a chimeric receptor comprising of 
human X subunit and a chicken 2 subunit were able to bind to iC3b coated particles 
(Bilsland et al., 1994). This implies that the X subunit must adopt a particular 
conformation to acquire the capacity to bind iC3b and presumably, the chicken 2 
subunit facilitates this in transfected cells whereas the human  subunit does not. 
 
1.7 Scavenger receptors 
Scavenger receptors (SR) are a structurally and functionally heterogeneous family of 
membrane glycoproteins that are mainly expressed on the cell surface of macrophages, 
endothelial cells and smooth muscle cells. This family of receptors were discovered by 
Brown and Goldstein in an attempt to understand how cholesterol from low density 
lipoproteins (LDL) accumulates in atherosclerotic plagues of patients with familial 
hypercholesterolemia (FH) (Goldstein et al., 1979).  FH individuals have a mutation in 
the gene specifying the LDL receptor, which result in the inhibition of LDL uptake by 
extrahepatic parenchyma cells and consequently abnormally high levels of LDL in the 
blood plasma (Goldstein and Brown, 1977). This excess of plasma LDL is eventually 
degraded via an alternative pathway in which the hepatic Kupffer cells and other tissue 
macrophages, rather than the hepatic parenchyma cells, facilitate LDL uptake 
(Goldstein et al., 1979). Because this mechanism acts on plasma LDL that has 
circulated for an abnormally protracted period of time in vivo, the macrophages may 
recognize some form of LDL that has become denatured or chemically modified. Brown 
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and Goldstein demonstrated that receptor-mediated mechanisms were responsible for 
the uptake of the large quantities of acetylated LDL (acLDL) by mouse peritoneal 
macrophages, which culminated in the conversion of the macrophages into cells packed 
with esterified cholesterol, characteristic of lipid-laden foam cells present in 
atherosclerotic plaques (Goldstein et al., 1979). The term “scavenger” receptor was 
designated for the distinct high affinity cell surface receptor that binds and internalizes 
modified LDLs such as acLDL, malondialdehyde-modified LDL (mdaLDL) and 
oxidized LDL (oxLDL) (Goldstein et al., 1979; Shechter et al., 1981) 
 
Although all members of the scavenger receptor family were originally defined by their 
ability to recognize modified LDLs, these receptors have heterogeneous molecular 
structures. These receptors are therefore related by biological property rather than by 
sequence homology. Many of the receptors have rather broad ligand binding 
capabilities, and thus lead to them being described as “molecular flypaper” (Krieger, 
1992; Krieger et al., 1993). Most of the characterized ligands are polyanionic molecules, 
although many polyanions fail to bind (Krieger and Herz, 1994), indicating that there 
are specific structural and charge requirements for ligand binding. Based on their 
multidomain structure, these receptors can be classified into eight classes in an 
alphabetic scheme from A to H (Pluddemann et al., 2007) (Fig.1.9).  The first class, 
Class A, includes class A scavenger receptor (SR-A) with three isoforms SR-AI 
(Kodama et al., 1990), SR-AII (Rohrer et al., 1990) and SR-AIII (Gough et al., 1998), 
the Macrophage receptor with a Collageneous structure (MARCO) (Elomaa et al., 
1995), the Scavenger Receptor with C-type Lectin I and II (SR-CL I and II) (Nakamura 
et al., 2001a; Nakamura et al., 2001b), and SCARA5 (Jiang et al., 2006). The class B 
SRs consists of CD36 (Greenwalt et al., 1992; Tandon et al., 1989a; Tandon et al., 
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1989b), the high-density lipoprotein (HDL) receptors SR-BI (Acton et al., 1996; Acton 
et al., 1994) and SR-BII (Webb et al., 1997), CLA-1 or human homologue of SR-BI 
(Calvo and Vega, 1993) and Drosophila receptor Croquemort (Franc et al., 1996). The 
Drosophila SR-CI belongs to class C (Pearson et al., 1995), and CD68/macrosialin 
(Holness et al., 1993; Holness and Simmons, 1993) forms class D.  Class E consists of 
one member, the lectin-like oxidized LDL-receptor 1 (LOX-1) (Sawamura et al., 1997; 
Yoshida et al., 1998) while scavenger receptor expressed by endothelial cells I (SREC-
I) (Adachi et al., 1997) and II (Ishii et al., 2002) make up class F. Class G comprises of 
scavenger receptor for phosphatidylserine and oxidized lipoprotein (SR-PSOX) 
(Shimaoka et al., 2000). The final class, Class H, includes Fasciclin (Fas-1), epidermal 
growth factor (EGF)-like, laminin-type EGF-like and Link domain containing receptor -
1 (FEEL-1) and -2 (FEEL-2) (Adachi and Tsujimoto, 2002; Irjala et al., 2003; Politz et 
al., 2002). All of the known SRs have been implicated in host defence and tissue 
homeostasis, and as such, are bona fide PRRs.  The fact that most SRs recognize 
chemically modified LDLs indicates that the receptors respond to danger signals posed 
by the physiologically abnormal lipoproteins.  
 
The involvement of many SRs in innate immunity and tissue homeostasis is well-
documented.  The innate immune roles of SRs were established based mainly on in vitro 
transfected cell-line experiments as well as knock-out mice studies. A number of SRs 
have been demonstrated to bind and mediate phagocytosis of Gram-positive and Gram-
negative bacteria. SRs involved in microbial recognition and clearance include SR-A 
(Dunne et al., 1994; Peiser et al., 2000), MARCO (Elomaa et al., 1995; Elomaa et al., 
1998), SR-CL I and II (Nakamura et al., 2001a), SCARA5 (Jiang et al., 2006), CD36 
(Stuart et al., 2005), dSR-CI (Ramet et al., 2001), LOX-1 (Shimaoka et al., 2001), SR-
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PSOX (Shimaoka et al., 2003), FEEL-1/2 (Adachi and Tsujimoto, 2002).  In addition, 
some of these receptors were also reported to bind various PAMPs.  SR-A and MARCO 
were shown to bind LPS and LTA (Dunne et al., 1994; Peiser et al., 2000) while CD36 
was found to interact with LTA and the R-enantiomer of macrophage-activating 
lipopeptide 2 (MALP-2) (Hoebe et al., 2005). MALP-2 is a diacylated lipoprotein 
derived from Mycoplasma pneumonia which facilitates the activation of the TLR2-
TLR6 heterodimer.  
 
Within the theme of tissue homeostasis, a few of the SRs, such as SR-A (Araki et al., 
1995; El Khoury et al., 1994), CD36 (Ohgami et al., 2001a; Ohgami et al., 2002) , SR-
BI (Ohgami et al., 2001b), LOX-1 (Jono et al., 2002) and FEEL-1/2 (Tamura et al., 
2003), have been shown to bind AGE-BSA in vitro and could potentially be involved in 
the recognition and uptake/clearance of AGE metabolic by-products in vivo. In addition 
to AGE products, some SRs were also demonstrated to be involved in the 
uptake/clearance of apoptotic cells. Most of the implicated SRs were found to bind 
phosphatidylserine (PS)-containing liposomes but it remains unclear whether these 
receptors recognize PS exposed on the apoptotic cell surfaces. The list of SRs involved 
in this homeostatic process include SR-A (Platt et al., 1998; Platt et al., 1999; Platt et 
al., 1996; Terpstra et al., 1997), CD36 in conjuction with the vitronectin receptor, v3 
integrin and the glycoprotein, thromobospondin (TSP) (Savill et al., 1993; Savill et al., 
1992), SR-BI (Kawasaki et al., 2002; Murao et al., 1997; Shiratsuchi et al., 1999), 
Croquemort (Franc et al., 1996; Franc et al., 1999a; Franc et al., 1999b), CD68 
(Ramprasad et al., 1995; Sambrano and Steinberg, 1995), LOX-1 (Murphy et al., 2006; 
Oka et al., 1998), SR-PSOX (Minami et al., 2001; Shimaoka et al., 2000) and possibly 
SREC (Zhou et al., 2001).  In view of the receptors investigated in this dissertation, only 
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1.7.1 Scavenger receptor Class A (SR-A) 
SR-A, also known as the acLDL receptor, was the first member of the scavenger 
receptor family to be identified following purification from bovine lung extract via 
affinity chromatography (Kodama et al., 1988). The full length bovine SR-A cDNA was 
initially cloned (Kodama et al., 1990; Rohrer et al., 1990). Subsequently, murine 
(Freeman et al., 1990), human (Matsumoto et al., 1990) and rabbit (Bickel and Freeman, 
1992; Doi et al., 1993) SR-A cDNAs were also cloned. The sequences of the receptors 
share 60-81% identity (Ashkenas et al., 1993). 
Figure 1.9. Schematic representation of the domain architecture of different members of the 
scavenger receptor family. The receptors are grouped into classes based on structural homology 
although between the different classes, they are structurally diverse. The different domains are 
indicated in the key.  Reproduced from Pluddemann et.al (2007). 
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SR-A expression is initially reported to be restricted to macrophages, being absent on 
monocytes, neutrophils and various DC subsets (Hughes et al., 1995; Peiser et al., 2002; 
Tomokiyo et al., 2002). The receptor was immunohistochemically detected in various 
tissue macrophages (Naito et al., 1991; Tomokiyo et al., 2002).  Monocytes, however, 
do express SR-A upon differentiation into macrophages (Gough et al., 1999; Naito et 
al., 1991; Tomokiyo et al., 2002). Expression of SR-A has also been reported in murine 
mast cells (Brown et al., 2007), murine bone marrow-derived and splenic DCs (Becker 
et al., 2006),  murine sinusoidal endothelial cells (Hughes et al., 1995), rabbit aortic 
endothelial cells (Daugherty et al., 1997) and rabbit smooth muscle cells within 
atherosclerotic plaques (Li et al., 1995; Pitas, 1990).  
 
1.7.1.1 SR-A Structure 
 SR-A is a trimeric transmembrane glycoprotein consisting of six distinct domains: an 
N-terminal cytoplasmic, a transmembrane, and an extracellular region composed of a 
short spacer, -helical coiled-coil, collagen-like and a varying isoform-specific C-
terminal domain (Figure 1.10) (Ashkenas et al., 1993; Kodama et al., 1990; Rohrer et 
al., 1990). Each trimeric receptor consists of a disulphide-linked dimer and a 
nonconvalently associated monomer (Penman et al., 1991).  Three different isoforms of 
SR-A exist, namely SR-A type I (SR-AI), SR-A type II (SR-AII) and SR-A type III 
(SR-AIII), and these isoforms vary only in their C-terminal domain.  SR-AI has a 110 
amino acid scavenger receptor cysteine-rich (SRCR) domain, a highly conserved 
protein motif found in many other proteins of immunological significance (Freeman et 
al., 1990; Resnick et al., 1994) while SR-AII has a short domain of 6-17 amino acids 
which is relatively unconserved between species. SR-AIII is a non-functional variant 
that has altered intracellular protein processing and is trapped within the endoplasmic 
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reticulum (Gough et al., 1998). The various isoforms are generated by alternative 
splicing of a single gene product (Emi et al., 1993; Freeman et al., 1990; Kodama et al., 
1990; Rohrer et al., 1990). The human SR-A gene was localized to band p22 on 
chromosome 8 and consists of 11 exons (Emi et al., 1993). SR-AI is generated through 
the splicing of exon 8 to exon 10/11 that contain the SRCR domain, while SR-AII 
results from the splicing of exon 8 to exon 9. SR-AIII arose from the splicing of exon 8 
directly onto exon 11 of the SR-A gene, resulting in a novel, shorter SRCR domain 
consisting of only 44 amino acids. When expressed in CHO cells along with SR-AI or 
SR-AII, SR-AIII manifest a dominant negative effect by inhibiting acLDL uptake, 
suggesting the presence of SR-AIII may be a mechanism for the regulation of SR-A 
activity in macrophages. In support of this hypothesis, SR-AIII mRNA was 
predominantly detected in advanced atherosclerotic lesions of cholesterol-fed rabbits 




























Figure 1.10.  Structural 
diagram of SR-A type I 
(SR-AI) trimer illustrating 
various domains.  The 
domain organization of the 
SR-AI is depicted. SR-A is a 
type II transmembrane 
receptor. The N-terminal 
cytoplasmic domain is 
relatively short but may have 
a role in regulating both 
receptor trafficking and 
internalization. There is a 
short spacer region following 
the transmembrane domain. 
The -helical coiled-coil 
domain is responsible for 
trimerization of the receptor 
while the collageneous 
domain plays an important 
role in ligand binding.  The 
function of the C-terminal 
SRCR domain is unknown. 
Adapted from Platt et.al 
(2002) 
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The topological structure of SR-A was previously proposed to be an extended or 
straight stalk. However, transmission electron microscopy (TEM) studies have showed 
that the -helical coiled-coil and the collageneous domains are connected by an 
extremely flexible hinge that allows a variable angle from 0 to 180 degress between the 
two domains (Resnick et al., 1996). At neutral pH, rotary metal-shadowed images of the 
receptor visualized via TEM showed the hinge angle between the two domains was 0 
degree, resulting in juxtaposition of the domains (Figure 1.11). In contrast, the receptor 


















Figure 1.11.  Models of SR-AI and 
SR-AII with dimensions based on 
negatively stained and rotary metal-
shadowed samples visualized by 
electron microscopy. (A) Extended 
forms. Dimensions (mean ± S.D.) are 
based on the measurements of >100 
negatively stained images. The angle 
between the two fibrous domains 
(hinge angle) ranged from 20 to 180°, 
with 80% of the values >100°. Similar 
dimensions were obtained from 
measurements of >100 extended 
molecules observed using metal 
shadowing following exposure to low 
pH (indicated in parentheses). Widths 
of the metal-shadowed molecules were 
difficult to measure and, if marked by 
an asterisk, represent a best estimate 
where metal correction is relatively 
great. (B) Compact forms. Dimensions 
(mean ± S.D.) are based on the 
measurements of >58 metal-shadowed 
images. Reproduced from Resnick et.al 
(1996). 
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1.7.1.1.1 Cytoplasmic domain of SR-A  
The cytoplasmic domain of SR-A plays an important role in regulating SR-A function.  
Deletion of the cytoplasmic tail of murine SR-A, that is residue 1 to 55 (SR-Adel 1-55), 
greatly reduced the expression of the receptor while retaining the last six amino acid 
(SR-Adel 1-49) restored protein expression (Kosswig et al., 2003). The SR-Adel 1-49 
receptors failed to facilitate acLDL endocytosis but were still able to promote cell 
adhesion, indicating that these amino acids (a.a. 50-55) of the cytoplasmic domain are 
required for both receptor post-transcriptional processing/cell surface trafficking as well 
as receptor-mediated cell adhesion.  By comparison, the first 49 amino acids of the 
domain are required for ligand-receptor internalization; these residues possibly form 
internalization signal motifs or phosphorylation sites that trigger ligand uptake upon 
receptor activation.  
 
An V22XFD25 internalization motif in the cytoplasmic domain of SR-A has been 
identified to be essential for clathrin coated pit-mediated endocytosis and for the 
trafficking of the receptors to the cell surface (Fong and Le, 1999; Morimoto et al., 
1999). Another internalization motif, a conserved di-leucine motif (Leu31-32), was also 
reported to play a role in the endocytosis of acLDL (Chen et al., 2006b). Deletion of the 
di-leucine structure resulted in a significant decrease in acLDL uptake but not binding 
to SR-A transfected CHO cells (Fong and Le, 1999).  
 
In addition to internalization motifs, receptor phosphorylation events have been shown 
to regulate cell surface expression well as ligand internalization. The protein kinase 
inhibitor staurosporine was found to inhibit the internalization of acLDL-bound SR-A 
on murine peritoneal macrophages (Fong, 1996).  The cytoplasmic tail contains 3 
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conserved phosphorylation sites: Ser21, Thr30 and Ser49. AcLDL internalization was 
reported to be accompanied by serine, but not threonine phosphorylation based on site-
directed mutagenesis experiments replacing Ser21 and Ser49 with alanine to eliminate the 
phosphorylation sites (Fong and Le, 1999). Alanine substitution of Ser21 increased 
uptake of acLDL while that of Ser49 (or substituting Ser48 of human SR-A with 
aspartate) reduce the rate of receptor internalization (Heider and Wintergerst, 2001).   
 
1.7.1.1.2 Transmembrane domain of SR-A  
The transmembrane domain of SR-A consists of a stretch of hydrophobic amino acids 
that anchors the receptor in the membrane. A conserved proline (Pro67) was found to 
affect the packing of trimers in the membrane (Platt et al., 2002).  
 
1.7.1.1.3 Spacer domain of SR-A  
A cysteine residue Cys83 in the spacer domain is postulated to be involved in receptor 
dimer formation; the dimer of which noncovalently associates with a monomer to form 
the resultant trimeric receptor.  However, the disulphide-linked dimer formation was 
reported to be not required for trimer formation and SR-A function (Penman et al., 
1991). The substitution of Cys83 with a glycine residue resulted in the assembly of these 
mutant receptors into trimers of nocnovalently associated monomers with normal 
receptor activity. 
 
1.7.1.1.4 -helical coiled-coil domain of SR-A 
The -helical coiled-coil domain of SR-A has been demonstrated to be essential for 
trimer formation (Doi et al., 1993). The domain consists of 23 “heptads” repeats in the 
sequence (a-b-c-d-e-f-g)n. The first (a) and fourth (d) amino acids of these repeats have 
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hydrophobic aliphatic side chains (leucine, isoleucine and valine), and form an 
interhelical hydrophobic core holding together the trimeric helix (Doi et al., 1993). A 
discontinuity of the heptad repeats has been identified at Asn203 and this divides the -
helical coiled-coil domain into two functional subdomains with different stabilities 
(Kodama et al., 1990; Suzuki et al., 1997b).  Using recombinant peptides of the two 
sub-domains, it was revealed that the N-terminal half of the domain (-N) retains its 
ability to form a stable three-stranded coiled coil, whereas the C-terminal half (-C) 
shows a monomeric, random structure at physiological pH. However, when the -C 
peptide is trimerized at the N terminus by chemical ligation and subjected to acidic pH, 
the peptide could also form a coiled coil structure (Suzuki et al., 1997b).  
 
 The N-terminal half of the domain is essential for stable trimer formation and a specific 
seven-residue trigger sequence (Ile173- Ser179) appears to be required (Frank et al., 
2000). The trigger sequence contains isoleucine residues at the hydrophobic a and d 
postions of the heptad repeats, and these residues have been known to play a role in the 
specification of the oligomerization state of coiled coil structures (Harbury et al., 1993). 
Salt bridge interactions, known to contribute to coiled coil stability (Spek et al., 1998), 
can also form between Asp174 and Lys178, and Glu175 and Lys178.   
 
The C-terminal end of the domain appears to determine pH dependent conformational 
changes that might play a part in ligand dissociation (Suzuki et al., 1997b). The 
conformation of the chemically trimerized -C peptide is a -helical coiled-coil 
structure at pH 5, whereas the structure is random or disordered at pH 7 (Suzuki et al., 
1997b). Specifically, a buried glutamate (Glu242) in the hydrophobic core of this domain 
is thought to be responsible for this conformational change (Suzuki et al., 1999). It was 
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proposed that interhelical electrostatic repulsions by negatively charged acidic residues 
like glutamate in -C destabilize the coiled coil structure at neutral pH (Suzuki et al., 
1997b; Suzuki et al., 1999). In contrast, these residues are protonated at low pH, thus 
alleviating the repulsive forces and stabilizing the the coiled coil structure.  The pH-
dependent, dual conformational nature of -C region could provide an explanation to 
the folded, compact structure of SR-A described by Resnick et.al (1996) under 
physiological, conditions. The receptor might bend around the -C region which is 
disordered and hence flexible at neutral pH.  In contrast, the -C region adopts a more 
rigid coiled coil structure at acidic pH, and consequently, the receptor has an extended 
structure.  The extended state of the receptor is believed to facilitate the dissociation of 
ligands at low pH in the acidic environment of endosomes (Naito et al., 1991; Resnick 
et al., 1996). 
 
 Interestingly, ligand dissociation was also found to depend on residue His260 within c-
terminal end of -helical coiled-coil (Doi et al., 1994). Substitution of His 260 with a 
leucine residue retains the receptor’s ability to bind ligand but abolishes the ability to 
release the ligands in the lysosomes at low pH, suggesting that the residue allosterically 
controls the pH dependent ligand release from the collagen-like domain (Doi et al., 
1994). It is presently unclear how this histidine residue influences conformational 
changes of the coiled coil domain. By His260 with a leucine residue in the synthetic -C 
region peptide, Suzuki et.al (1999) demonstrated that these His260-substituted 
monomeric peptides were able to form a triple-stranded coiled coil structure at acidic 
pH without the need of chemical linker-mediated oligomerization.  It is believed that 
His260 might reduce the stability of the coiled coil structure to make the -C region 
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more susceptible to pH dependent conformational changes mediated by acidic residues 
such as Glu242.  
 
1.7.1.1.5 Collageneous domain of SR-A 
The collageneous domain of SR-A has 23 (human) or 24 (bovine, rabbit, mouse) Gly-
Xaa-Yaa tripeptide repeats that assemble into a collageneous triple helix (Doi et al., 
1994; Kodama et al., 1990; Penman et al., 1991).  Positively charged lysine and 
possibly arginine residues in position Y of these repeats are proposed to play a key role 
in ligand binding, interacting with the negatively charged polyanionic ligands (Kodama 
et al., 1990; Rohrer et al., 1990).  In particular, the C-terminal 22 amino acids of the 
domain (Gly320 to Ser342 of bovine SR-A) are highly conserved among bovine, human, 
rabbit and mouse SR-A (Ashkenas et al., 1993), and contain a lysine cluster (Lys327, 
Lys334, Lys337 and Lys340 in bovine SR-A) that forms a postively charged groove, which 
could interacts with the polyanionic ligands (Doi et al., 1993). Truncated mutants 
lacking the conserved lysine cluster are unable to bind modified liporoteins (Acton et 
al., 1993; Dejager et al., 1993; Doi et al., 1993). Point mutations studies that substituted 
the conserved lysines against alanine, demonstrated that substitution of Lys337 abolishes 
acLDL degradation and an additional substitution of either Lys334 or Lys340 also 
abolishes oxLDL degradation (Doi et al., 1993).  
 
A synthetic peptide, (GPO)4GKTGKPGLNGQKGQKGEK(GPO)3C (O represent 
hydroxyproline), that contain the ligand binding region (Gly323 to Gly340) of the bovine 
SR-A collageneous domain has revealed that the trimeric structure is necessary for 
ligand binding. While the N-terminal cross-linked trimeric form of the peptide can bind 
acLDL, the single stranded peptide cannot (Tanaka et al., 1996; Tanaka et al., 1993).  
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Yamamoto et.al (1997) demonstrated that the lysine cluster mediates not only ligand 
binding, but also ligand specificity. Like the natural receptor, binding of acLDL to the 
trimeric peptide is inhibited by SR-A ligands such as dextran sulphate, fucoidan, poly 
(I) and poly (G) but not poly (C) and native LDL (Yamamoto et al., 1997).  
 
The structural conformation of the collageneous domain is not only crucial for ligand 
binding but also for the release of the ligands following endocytosis.  Another synthetic 
peptide (POG)3PKGQKGEKG(POG)4, which contain a nine residue sequence that 
correspond to the human SR-A collageneous domain lysine cluster (residue 333-341) 
(underlined in sequence), was demonstrated to adopt a stable triple-helical conformation 
at pH higher than 4.5 (Anachi et al., 1995).  At high pH, ionization of the side chain of 
the glutamate residue in one peptide chain enable the formation of an ion pair with one 
of the three positively charged lysine residues of another peptide chain, which stabilizes 
the triple helix structure. At low pH, as would be the case in the endosomes, the tertiary 
structure of the domain is destabilized because the glutamate residue is not negatively 
charged, resulting in charge repulsion between positively charged lysine residues and 
release of receptor-bound ligands. 
 
In addition to inter-peptide ion pair formation, one of the lysine residues from one 
peptide chain can also form hydrogen bonds with a glutamine residue of another chain, 
thereby further stabilizing the triple-helical association of the synthetic peptides. 
Molecular modeling predicted that of the total of nine lysine residues present in three 
peptide chains, six of these lysine residues are involved in ion pair formation or 
hydrogen bonding with glutamate residues while the remaining three residues are 
unpaired. It was postulated that these unpaired lysine residues are involved in ligand 
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binding (Anachi et al., 1995). It was demonstrated that the synthetic peptide associate 
with tetraplex nucleic acids, specifically polyinosinic acid (poly (I)) but not single- or 
double-stranded nucleic acids, exhibiting the polyribonucleotide discrimination property 
of native SR-A (Mielewczyk et al., 1996; Pearson et al., 1993).  
 
 
1.7.1.1.6 Cysteine-rich domain (SRCR) of SR-A 
 
The carboxy-terminal domain of SR-A type I consists of 110 amino acids containing 6 
cysteine residues (Kodama et al., 1990), termed the scavenger receptor cysteine-rich 
(SRCR) domain. The function of the SRCR domain of SR-AI is to date undefined. 
Nevertheless, this domain is an ancient and highly conserved protein module which 
defines a superfamily of either soluble or membrane-bound receptors predominantly 
expressed by cells of haematopoietic origins i.e. macrophages, DCs and lymphocytes as 
well as some non-haematopoietic cells like epithelial cells of the digestive, respiratory 
and urinary tract, at either the embryonic or adult stages (Freeman et al., 1990; Sarrias et 
al., 2004).  The SRCR superfamily can be divided into two major groups based on the 
number and pattern of cysteine residues in the domains, namely Group A and B. All of 
the group A domains contain 6 cysteine residues while most of those of group B have 8 
cysteine residues in the domain (Resnick et al., 1994). There is currently no unifying 
functional role for all of the members of the SRCR superfamily, but many of these 
proteins have been implicated in the development of the immune system and in the 
regulation of innate and adaptive immune responses (Aruffo et al., 1997). SR-A, 
MARCO and SCARA5, belong to group A along with other proteins with immune 
functions such as Factor I and Mac-2 binding protein (M2BP). Some members of group 
B also play important roles in immunity, particularly CD5 and CD6. Both these type I 
membrane glycoproteins are exclusively expressed by lymphocytes and appear to be 
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involved in regulating lymphocyte activation and differentiation (Gimferrer et al., 2003; 
Perez-Villar et al., 1999). 
 
A functional role for a SRCR domain was first established in CD6 (Aruffo et al., 1997). 
The SRCR domain of CD6 was found to interact with activated leukocyte-cell adhesion 
molecule (ALCAM) or CD166 (Bowen et al., 1996; Bowen et al., 1995; Patel et al., 
1995; Whitney et al., 1995). The extracellular domain of CD6 is composed of three 
group B SRCR domains (Sarrias et al., 2004).  Binding studies demonstrated that SRCR 
domain 3 of CD6, particularly surface-exposed residues Asn 345, Asn 346 and Gln 352, 
interacts with with V1 Ig-like domain of ALCAM (Bodian et al., 1997; Skonier et al., 
1997). 
 
The crystal structure of the SRCR domain of M2BP has been determined. M2BP is a 
tumour-associated antigen and matrix protein that possesses a group A SRCR domain. 
The structure revealed a curved six-stranded -sheet cradling an -helix (Hohenester et 
al., 1999) (Figure 1.11).  The-helix and the concave face of the curved -sheet form 
an extensive hydrophobic core of the domain.  The solvent-exposed face of the 
structure, in particular the region encompassing strand A-C known as the -meander, 
carries a number of charged residues (Arg7, Asp10, Arg18 and Glu20) that build up a 
notable network of hydrogen bonds and salt bridges which are known to influence 
protein stability and maintain the structural conformation of the domain (Hohenester et 
al., 1999).  The polar residues Arg7 and Glu20 were found to be highly conserved based 
on structure-based sequence alignment analysis between other group A/B SRCR 
domains and CD6 SRCR domain; these two residues form an ion pair on the solvent-
exposed face of the -meander (Hohenester et al., 1999). Another conserved charged 
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residue, Arg18, located in Strand B along with two other residues Gln16 and Gly17 form 
hydrogen bonds with residues on the C-terminal strand F, necessitating a pronounced 

















1.7.1.2 Ligand Binding Properties of SR-A 
The broad, high affinity ligand property of SR-A is a major distinguishing feature of the 
receptor which underlies its contribution to a multitude of biological processes (Krieger 
et al., 1993; Krieger and Herz, 1994; Platt and Gordon, 1998)(Table 1.2).  
 
 
Figure 1.12.  Two orthogonal 
views of the Mac-2 Binding 
Protein (M2BP) SRCR domain 
structure in the form of ribbon 
diagrams.  The domain consists of a 
curved six-stranded sheet that 
forms a “cup” around a -helix. -
strands are in green and are labeled 
sequentially A–F; the -helix is in 
pink. Disulfide bridges are in yellow 
and the sequence numbers of 
cysteine residues are indicated. 
Reproduced from Hohenester et.al 
(1999). 
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SR-A Ligand Reference 
oxLDL (Maxeiner et al., 1998) 
acLDL (Goldstein et al., 1979) 
malondialdehyde LDL (Shechter et al., 1981) 
(Haberland et al., 1982) 
Fucoidan (Brown and Goldstein, 1983) 
Dextran sulphate (Brown and Goldstein, 1983) 
Carragheenan (Brown and Goldstein, 1983) 
Polyvinyl sulphate (Brown et al., 1980) 
Maleylated bovine serum albumin (mal-BSA) (Takata et al., 1989) 
(Haberland and Fogelman, 1985) 
Phosphatidylserine/Apoptotic cells (Platt et al., 1996) 
Poly Guanylic acid (Poly (G)) 
Poly Inosinic acid (Poly (I)) 
(Pearson et al., 1993) 
LPS/ Gram negative bacteria 
 
(Hampton et al., 1991) 
(Peiser et al., 2000) 
LTA/ Gram positive bacteria 
 
(Dunne et al., 1994) 
(Greenberg et al., 1996) 
Double stranded RNA (dsRNA)  
(Poly I:C) 
(Limmon et al., 2008) 
Glycated collagen IV (El Khoury et al., 1994) 
Amyloid beta protein 
 
(El Khoury et al., 1996) 
(Santiago-Garcia et al., 2001) 
(Paresce et al., 1996) 
Advanced glycated end products (AGE) (Araki et al., 1995) 
ECM Proteoglycans  
– Aggrecan, biglycan and decorin 
(Santiago-Garcia et al., 2003) 
Heat shock protein Hsp110 & Grp170 (Facciponte et al., 2007) 
Crocidolite asbestos (Resnick et al., 1993) 
Silica (Hamilton et al., 2000) 
(Kobzik, 1995) 
Sialic acid/mucin (Inoue et al., 1999) 
Table 1.2 Ligands of the scavenger receptor class A (SR-A). 
 
The diverse array of SR-A ligands include chemically modified endogeneous molecules 
such as oxLDL, AGE products and amyloid beta protein, molecules derived from 
environmental sources like silica particles and crocidolite asbestos, and molecules of 
microbial origins such as LPS and LTA. Although the precise structural requirements 
for SR-A ligand binding have not be determined, all known SR-A ligands are 
macromolecular and polyanionic. As alluded to earlier in Section 1.7, the latter property 
alone is insufficient to confer recognition by the receptor because not all polyanions are 
SR-A ligands (Krieger et al., 1993).  For example, both dextran sulphate and 
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chondroitin sulphate are negatively charged sulfated polysaccharides but only dextran 
sulphate is a SR-A ligand (Brown and Goldstein, 1983).  Some progress has, however, 
been to explain these differences in binding affinity. Analysis of polyribonucleotide 
structures conferring binding specificity to SR-A revealed a base quartet-stabilized four-
stranded helix (G-tetrads) to be a necessary structural determinant for binding (Pearson 
et al., 1993).  Polyinosinic acid (Poly (I)) and polyguanylic acid (Poly (G)) but not 
polycytidylic acid (Poly (C)) and polyadenylic acid (Poly (A)) are able to form stable 
G-tetrads and thus bind efficiently to SR-A. The spatial distribution of the negatively 
charged phosphates in the polyribonucleotide quadruplexes was proposed to provide a 
charged surface appropriate for SR-A binding. 
 
Besides its broad ligand binding specificity, SR-A also exhibits two other unique ligand 
binding properties namely nonreciprocal cross-competition (NRCC) and 
species/receptor isoform-dependent dual high/low acLDL binding affinity. NRCC 
occurs when one ligand efficiently competes for receptor binding of a second ligand but 
the latter does not or only partially competes with the former to bind. Possible 
explanations for NRCC include the presence of multiple binding sites on a single 
receptor or the existence of multiple receptor conformations with differing binding 
properties (Freeman et al., 1991). For SR-A, NRCC was observed in the binding of 
modified LDLs, acLDL and oxLDL by macrophages (Arai et al., 1989; Sparrow et al., 
1989) and by CHO cells overexpressing either bovine SR-AI or II (Freeman et al., 
1991).  In transfected CHO cells, the binding of oxLDL to SR-A is efficiently competed 
for by excess acLDL, but when the situation is reversed, inhibition is only partial 
(Freeman et al., 1991). Contrastingly, oxLDL was an effective competitor for both 
oxLDL and acLDL binding to cultured macrophages while acLDL only partially 
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inhibited oxLDL interactions (Sparrow et al., 1989). The discrepancy in data between 
cultured macrophages and transfected cell lines remains unresolved although one likely 
possibility is the presence of other SRs on macrophages that could contribute the 
modified LDL binding.  
 
Ashkenas et.al (1993) reported that murine SR-AI and II isoforms do not exhibit 
identical ligand binding properties.  At a concentration of 1mg/ml, ReLPS was able to 
completely inhibit acLDL binding to SR-AII but not SR-AI; acLDL binding to SR-AI 
was partially reduced at 61% inhibition (Ashkenas et al., 1993).  Additionally, ReLPS 
also reduced acLDL binding to bovine SR-AII A to a similar extent as murine SR-AI at 
about 60% inhibition while it did not inhibit binding to bovine SR-AI.  The inhibitory 
effects of LPS in competitive ligand binding were therefore both receptor isoform and 
species dependent. It was postulated that the two isoforms of SR-A exhibit two classes 
of binding for acLDL, that of high and low affinity. In the case of murine SR-AI and 
bovine SR-AII, ReLPS at a concentration of 1mg/ml inhibited all of the high, but little 
of the low affinity binding, and hence result in partial binding inhibition. In contrast, the 
same concentration of ReLPS can block both high and low affinity binding to murine 
SR-AII but neither in the case of bovine SR-AI (Ashkenas et al., 1993).  The nature of 
the dual high/low affinity binding property of SR-A is currently unknown although it 
has been suggested that each receptor molecule may have multiple, nonidentical binding 
sites with two different affinities for acLDL. Alternatively, the receptor may have 
multiple identical sites that exhibit negative cooperativity of binding. In the latter 
model, the initial binding of large ligands like ReLPS or acLDL to an assembly of 
receptors with closely spaced identical binding sites sterically hinders the subsequent 
binding of additional ligand molecules (Ashkenas et al., 1993). 
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1.7.1.3 Physiological roles of SR-A  
1.7.1.3.1 Modified lipoprotein endocytosis and atherosclerosis 
As mentioned previously in Section 1.7, SRs are defined by their ability to endocytose 
modified LDLs. Unlike the LDL receptor, the endocytic activities of SRs are not 
downregulated by rising intracellular cholesterol concentrations, and thus provide a 
mechanism for massive cholesterol uptake (Goldstein et al., 1979). Macrophages 
present along the arterial walls are postulated to mediate the uptake of modified LDLs 
via SRs, resulting in the intracellular accumulation of cholesteryl esters and the 
transformation of these cells into lipid-laden foam cells, that are characteristic of those 
in atherosclerotic plaques (Brown and Goldstein, 1983; Brown and Goldstein, 1990; 
Krieger, 1992).   
 
The contribution of a specific SR to modified LDL endocytosis has been initially 
difficult to define in vivo because macrophages possess different SRs with overlapping 
activities.  This issue has since been seemingly addressed through the generation of 
mice deficient in certain SRs. SR-A, in particular, was the first SR implicated in 
atherosclerosis based on studies involving SR-A knockout (SR-A-/-) mice (Babaev et al., 
2000; Suzuki et al., 1997a). The in vitro uptake of acLDL by peritoneal macrophages 
from these mice was found to be only 20% of that of wild-type cells (Suzuki et al., 
1997a). The contribution of SR-A to the development of atherosclerosis was assessed in 
vivo by crossing SR-A-/- mice with those lacking apolipoprotein E (ApoE-/- mice), 
generating a double knock-out mice model (SR-A-/- ApoE-/-).  ApoE is a major high-
affinity ligand for lipoprotein receptors such as low- and very low density lipoprotein 
receptors (LDLR/VLDLR), and its absence in mice results in hyperlipidemia and 
atherosclerosis when subjected to a cholesterol-rich diet.  In comparison to ApoE-/-mice, 
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SR-A-/- ApoE-/- mice displayed 58% reduction in lesion formation (Suzuki et al., 
1997a). Additionally, mutant mice lacking both SR-A and LDLR (SR-A-/- LDLR-/-) also 
manifested a 22-28% reduction in atherosclerotic lesion area (Sakaguchi et al., 1998).  
However, macrophages are the major, but not the only, cell type that express SR-A. In 
order to dissect the impact of SR-A expressing macrophages on atherosclerotic lesion 
formation, Babaev et.al (2000) generated mice specifically chimeric for macrophage 
SR-A. LDLR-deficient mice were irradiated and transplanted with fetal liver cells 
(FLCs) of either the SR-A+/+ or SR-A-/- genotype. After lethal irradiation, FLC 
transplantation will result in reconstitution of the entire hematopoietic system (Tocci et 
al., 1994). The chimeric LDLR-/- mice transplanted with SR-A-/- FLCs showed a 60% 
reduction in lesion area of the proximal aorta compared with those transplanted with 
SR-A+/+ cells (Babaev et al., 2000).  These studies collectively support a proatherogenic 
role for SR-A, particularly in the foam cell formation and atherosclerotic lesion 
development. 
 
Though compelling, this “atherosclerosis paradigm” suggesting the association between 
receptor and disease has been challenged by recent findings (Moore et al., 2005).  It was 
found that atherosclerosis was not ameliorated by the loss of SR-A in SR-A-/- ApoE-/- 
mice as aortic sinus lesions in these mice were unexpectedly more extensive than those 
of ApoE-/- counterparts although these mice manifest reduction in peritoneal 
macrophage lipid uptake in vivo (Moore et al., 2005), consistent with findings of 
previous studies (Kunjathoor et al., 2002; Suzuki et al., 1997a; Van Eck et al., 2000).  
These findings demonstrate that lipid uptake by macrophages occurs in the absence of 
SR-A, and indicate that alternative compensatory lipid uptake mechanisms, possibly via 
other SRs, may contribute to macrophage cholesterol ester accumulation in vivo.   
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1.7.1.3.2 Cell-cell and cell-extracellular matrix adhesion  
Macrophages migrate into tissues and sites of infection/inflammation by expressing 
various adhesion receptors which allow them to be in contact with other cells or the 
ECM (Hogg and Landis, 1993), one of these receptors being SR-A. The murine SR-A 
antibody 2F8 was found to inhibit divalent cation-independent adhesion of macrophages 
to tissue culture plastic in the presence of serum (Fraser et al., 1993), suggesting that 
there is an unidentified ligand present in serum.  In addition, peritoneal macrophages 
derived from SR-A-/- mice displayed delayed adherence and spreading in vitro (Suzuki 
et al., 1997a) while fewer Kupffer cells were isolated from the liver of SR-A-/- mice 
compared to wildtype littermates, suggesting that SR-A may facilitate either adhesion or 
differentiation of those macrophages (van Velzen et al., 1999). The transient 
transfection of SR-A into weakly adherent epithelial cell lines also conferred an 
adhesive phenotype (Robbins and Horlick, 1998).  
 
The adhesive properties of SR-A have been suggested to contribute to the pathogenesis 
of atherosclerosis by facilitating the retention of circulating macrophages near lesions 
(Platt and Gordon, 1998).  SR-A was reported to only promote adhesion in activated 
macrophages in vitro, mirroring the state of microphages present  at the inflamed vessel 
wall (van Velzen et al., 1999). Additionally, SR-A mediated adhesion can also signals 
changes in the biological properties of the adherent cell (Platt and Gordon, 1998). 
Stimulation of macrophages with SR-A ligands is known to induce proinflammatory 
cytokines, chemokines and growth factors, which can alter the microenvironment of the 
atherosclerotic lesions by promoting further influx of immune cells and proliferation of 
smooth muscle cells, and thus facilitate disease progression (Krieger and Herz, 1994).  
 60
SR-A mediated adhesion was also proposed to initate a sequence of potentially 
damaging inflammatory events that contribute to the pathology of Alzheimer’s disease 
(AD).  A pathological hallmark of the disease is the senile plaques in the brain, 
containing -amyloid (A) fibrils, microglia and astrocytes (Dickson et al., 1993). SR-
A was found to bind 1-42 amyloid fibrils in vitro and SR-A expressing microglial 
cells were found to endocytose amyloid  aggregates, resulting in the induction of 
reactive oxygen species (ROS) and pro-inflammatory cytokines (Christie et al., 1996; El 
Khoury et al., 1996; Paresce et al., 1996). It was hypothesized that deposition of A 
fibrils in the brain of patients promote the adherence of microglial cells via SR-A and 
the subsequent secretion of pro-inflammatory cytokines and ROS that damage 
neighbouring neurons. Like atherosclerosis, the in vitro data did not however reflect the 
in vivo milieu.  It was reported that the elimination of microglial SR-A expression did 
not exacerbate amyloid protein deposition or neurodegeneration in human amyloid 
protein precursors (hAPP) transgenic mice that are prone to the development of AD-like 
amyloid plaques (Huang et al., 1999). The discrepancy in findings between in vivo 
knockout mice and in vitro cell culture-based studies in relation to SR-A and AD is 
presently not reconciled. 
 
In addition to atherosclerosis and AD, SR-A has also been implicated in the 
pathogenesis of vascular disease associated with diabetes and ageing because the 
receptor can adhere to both glucose-modified collagen IV (El Khoury et al., 1994) and 
advanced glycation end (AGE) products (Araki et al., 1995). Accumulation of AGE 
products in human tissues, as a result of non-enzymatic glycation of arterial basement 
membrane proteins, occurs during the process of ageing and in age-related disorders 
such as diabetes and atherosclerosis (Nakamura et al., 1993). Immunohistochemical 
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studies demonstrated localization of AGE products in atherosclerotic lesions of 
coronary artery (Kume et al., 1995) and in cardiac tissues of diabetic patients 
(Nakamura et al., 1993).  The ability of SR-A to recognise AGE products was 
established from reports that SR-A II expressing CHO cells are able to bind and 
endocytose AGE-bovine serum albumin (AGE-BSA) (Araki et al., 1995). SR-A-/- 
macrophages showed reduced endocytic capacity for AGE-BSA and glycolaldehyde 
modified BSA (GA-BSA) compared with wild-type littermates (Nagai et al., 2000; 
Suzuki et al., 1997a). Wild type but not SR-A-/- macrophages are also able to bind to 
and endocytose glycolaldehyde modified LDL (Jinnouchi et al., 1998) while SR-A was 
also found to be responsible for the adherence of human macrophages to plastic surface 
of culture dishes coated with glucose-modified bovine type IV collagen but not native 
collagen IV (El Khoury et al., 1994). These findings suggest a role for SR-A in the 
development of vascular atherogenic lesions observed in diabetic individuals. SR-A 
may promote monocyte adhesion to glucose-modified basement membrane proteins in 
the intima of arteries and thereby enhance the accumulation of these cells at the site (El 
Khoury et al., 1994). The interaction of glycated proteins with SR-A on macrophages 
may also result in the secretion of proinflammatory cytokines and growth factors 
(Kirstein et al., 1990), consequently stimulating the influx of monocytes and neutrophils 
into the intima and enhancing the proliferation of smooth muscle cells (El Khoury et al., 
1994).  
 
1.7.1.3.3 Antimicrobial host defence 
The involvement of SR-A in antimicrobial host defence was proposed based on 
observations that the receptor binds the lipid A moiety of LPS. Bovine SR-AI and II 
transfected CHO cells are able to bind to lipid IVA, the bioactive precursor of lipid A 
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(Hampton et al., 1991). The binding and uptake of lipid IVA by macrophage-like RAW 
264.7 cells was inhibited by SR-A ligands such as fucoidan, poly (I), malBSA and 
dextran sulphate while the SR-A antibody 2F8 inhibited LPS binding to murine 
macrophages (Hampton et al., 1991; Kobayashi et al., 2000).  Peritoneal macrophages 
from SR-A-/- mice were shown to less efficient in binding LPS than those from wildtype 
mice (Kobayashi et al., 2000). Additionally, SR-A-/- mice were also found to be more 
susceptible to LPS-induced endotoxin shock than wildtype littermates, producing more 
TNF- and IL-6 in response to LPS (Haworth et al., 1997). It was postulated that SR-A 
may play a protective role in host defence by scavenging LPS and reducing the release 
of proinflammatory cytokines in the process. The validity of this hypothesis has, 
however, been challenged by other studies reporting that SR-A facilitate, rather than 
impede, the development of endotoxic shock (Kobayashi et al., 2000). This controversy 
will be further elaborated and discussed in Section 3.1. 
  
In view that LPS is a ligand of SR-A, Peiser et.al (2000) demonstrated that SR-A could 
also effectively bind E coli. SR-A transfected CHO cells bound Gram negative E. coli 
more avidly than control cells while bone marrow-derived macrophages from SR-A-/- 
mice bound and ingest fewer bacteria than those from wildtype mice (Peiser et al., 
2000).  Besides E coli, SR-A was shown to interact with other Gram negative bacteria 
such as Listeria monocytogenes (L. monocytogenes). SR-A-/- mice were more 
susceptible to infection with L. monocytogenes with more bacteria accumulating in the 
liver and spleen of these mice compared to wildtype controls (Suzuki et al., 1997a). 
Liver Kupffer cells from SR-A-/- mice displayed impaired phagocytosis and killing of 
the bacteria and hepatic granulomas were more extensive in these mice (Ishiguro et al., 
2001).  
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SR-A was also found to interact with various Gram positive bacteria such as 
Staphylococcus aureus (S. aureus), Streptococcus pyogenes, Streptococcus agalactiae, 
Enterococcus hirae and L. monocytogenes (Dunne et al., 1994). SR-A-/- mice were 
found to be more susceptible to S. aureus infection compared to wildtype controls 
because SR-A-/- macrophages were less efficient in clearing bacteria from the infection 
site (Thomas et al., 2000). A soluble 35S-labeled bovine SR-A was found to bind to 
LTA, and the binding of the soluble receptor to maleylated BSA beads was also 
inhibited by LTA in a dose-dependent manner, suggesting the SR-A interact with LTA 
on Gram positive bacteria (Dunne et al., 1994). Greenberg et.al (1996) demonstrated 
that SR-A bind to different LTA structures with varying avidity depending on their 
spatial distributions and densities of negative surface charge. By removing the ester-
linked alanine from the polyglycerophosphate backbone of  S. aureus LTA to render the 
molecule more negatively charged, it was reported that the binding avidity for SR-A 
increased four-fold. In contrast, the zwitterionic LTA of Streptococcus pneumoniae with 
neutral net charge and positively charged Clostridium innocuum LTA did not bind SR-
A, demonstrating that a net negative charge is necessary for binding of these 
macroamphiphiles to the receptor (Greenberg et al., 1996).   
 
1.7.1.3.4 Apoptotic cell clearance  
Apoptosis or programmed cell death is an important physiological mechanism by which 
large numbers of redundant cells are removed in the host organism.  The recognition, 
uptake and degradation of apoptotic cells by macrophages proceed rapidly, prior to the 
lost of apoptotic cell membrane integrity and cell lysis, and therefore prevent the 
exposure of neighbouring cells to potentially toxic or immunogenic intracellular 
contents of dying cells (Fadok et al., 2001; Platt et al., 1998). The phagocytosis of 
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apoptotic cells shares with microbial clearance a common theme, that of pattern 
recognition.  Like microbes, the cell surface molecules of apoptotic cells differ and are 
distinguishable from that of the normal, healthy host cells. As postulated by the Danger 
hypothesis, both “infectious non-self” microbes and “altered self” apoptotic cells pose a 
threat to the host and must therefore be eliminated. Consequently, common recognition 
systems are involved in the clearance of both microbes and apoptotic cells.  
 
The general consensus derived from studies attempting to identify apoptotic cell 
receptor(s) on macrophages is that apoptotic cell clearance does not appear to account 
for by a single receptor-ligand intereaction and that SR-A is one of such receptors (Platt 
et al., 1998; Platt et al., 1999; Platt et al., 2002; Savill et al., 1993). Phagocytosis of 
apoptotic thymocytes by thymic or peritoneal macrophages from SR-A-/- mice was 
significantly less than wildtype controls (Platt et al., 1999; Platt et al., 1996; Terpstra et 
al., 1997). In addition, the SR-A antibody 2F8 and SR-A ligands including fucoidan, 
malBSA and Poly (I) also significantly inhibited apoptotic thymocyte uptake by thymic 
macrophages (Platt et al., 1996). With compelling in vitro evidence to support a role for 
SR-A in apoptotic cell clearance, it was therefore surprising that terminal 
deoxynucleotidyltransferase-mediated UTP end labeling (TUNEL) analyses of 
apoptotic thymocyte clearance in vivo failed to show an accumulation of apoptotic 
corpses in SR-A-/- mice, consistent with impaired clearance (Platt et al., 2000). 
Additionally, SR-A-/- mouse embryos were found to develop normally without 
retardation in footplate remodeling, a developmental process that is dependent on cells 
in particular regions of the ear undergoing apoptosis and subsequently cleared 
(Komohara et al., 2005). These discrepancies in data are presently unexplained although 
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receptor redundancy has been suggested to be involved (Platt et al., 2002; Platt et al., 
2000). 
 
1.7.1.3.5 Bone remodeling or osteogenesis regulation  
The status of SR-A as a multifunctional receptor involved in a myriad of biological 
processes was validated by a recent finding that the receptor is involved in the 
regulation of osteogenesis via the influence of osteoclast differentiation, bone cells of 
monocyte/macrophage lineage that resorb calcified bone (Lin et al., 2007).   
 
Investigations into the effects of SR-A gene deletion on bone development was 
prompted following intital observations that SR-A-/- mice have a 40% greater body 
weight than wildtype littermates, and that this disparity was not attributed to differences 
in percent fat and lean body mass but rather bone mineral density and content (Lin et al., 
2007).  Micro-computed tomography analyses revealed that total volume, bone volume 
as well as trabecular number, thickness and connectivity were significantly greater in 
SR-A-/- mice compared to wildtype controls . Interestingly, fewer osteoclasts were noted 
in SR-A-/- mice compared to wildtype mice, suggesting that low bone turnover due to 
reduced numbers of osteoclasts could explain the increase in bone density and content 
of the mutant mice.  It must, however, be noted that the link between SR-A and 
osteoclast development and differentiation is only circumstantial. The authors reported 
that the addition of the souble extracellular domain of SR-A to RAW 264.7 cells 
induced a concentration-dependent increase in cell differentiation although this effect 
was lost in the presence of receptor activator of nuclear factor-B (RANK) ligand 
(RANKL) (Lin et al., 2007). 
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1.8 Aims of study 
Most immune cells express a myriad of cell surface-associated, soluble and cytosolic 
PRRs.  The functional roles of many of these PRRs do overlap and, consequently, many 
of these PRRs do co-operate to elicit and efficient yet appropriate immune response.  
However, such functional complexities do confound interpretations of data obtained 
from studies investigating the specific role(s) each PRR plays in a particular immune 
process, in relation to receptor-ligand interactions, the initiated signaling cascades, and 
the induction of expression of various target genes.   
 
The overall aims of this study is to  
(1)  Assess the possibility of establishing a method for the investigation of the 
functional properties (such as ligand binding and receptor signaling) of a particular PRR 
in “isolation” from other PRRs.  To this end, a particular PRR will be exogeneously 
expressed in human embryonic kidney (HEK) 293T cells, which do not express most 
PRRs, by transient transfection of a vector harbouring the gene of the receptor.  
 
(2)  Investigate the ligand binding/recognition and signaling properties of two major 
endocytic/phagocytic PRRs, namely the scavenger receptor SR-A and the complement 
receptor CR3 exogeneously expressed on 293T cells.  As CR3 is classified as an 
opsonic PRR while SR-A is a non-opsonic PRR, a comparison would be made to 
establish similarities and identify differences in the signaling intermediates and pro-
inflammatory genes (in terms of cytokines) activated.  A comparison of signaling 
pathways activated and cytokines induced by endocytic/phagocytic PRRs (i.e. CR3 and 
SR-A) and sensing/signaling PRRs (i.e. TLR4) will also be carried out.  
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(3)  Translate findings obtained from exogeneously expressed PRR on 293T cells into 
“practice” i.e. validate these signaling pathways in dendritic cells or macrophages to 
explain the functional roles a particular PRR plays in modulating a particular immune 




















Chapter 2 MATERIALS AND METHODS 
2.1 Buffers and media 
The preparation of media and solutions, unless otherwise described in this chapter is 
given in the Appendix. 
 
2.2 Molecular biology 
2.2.1 RNA manipulation 
2.2.1.1 Isolation of total RNA  
Total RNA from primary immune cells and cell lines was extracted using the TRIZOL 
reagent (Gibco BRL Life Technologies, Rockville, MD). Briefly, 1ml of TRIZOL 
reagent was added to 2x106 cells. After 5 min at room temperature, 0.2 ml of 
chloroform was added and vigorously mixed. After 2 min, the mixture was centrifuged 
at 4C for 15 min at 12,000 rpm. The aqueous phase was transferred to a fresh tube and 
0.5 ml of isopropyl alcohol was added to precipitate RNA by incubating for 10 min at 
room temperature. RNA was pelleted by centrifugation for 10 min at 12,000 rpm, 
washed with 1ml 75% (v/v) ethanol and air-dried. The RNA pellet was dissolved in 20 
l of diethyl pyrocarbonate (DEPC)-treated water and stored at -80C.  
 
2.2.1.2 Quantitation of RNA 
2 l of a purified RNA sample were diluted in 0.5 ml of DEPC-treated water and optical 
density (OD) was measured at 260 nm (OD260) and 280 nm (OD280) using a DU 640B 
spectrophotometer (Beckman, Fullerton, CA). RNA concentration, in μg/ml, was 
calculated based on the equation 1OD260 = 40 g/ml. RNA purity was determined by the 
OD260/OD280 ratio. Only samples with an OD260/OD280 ratio greater than 1.7 were used.  
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2.2.1.3 Reverse transcription 
RNA reverse transcription (RT) was performed using the Advantage RT-for-PCR Kit 
(Clontech Laboratories, Palo Alto, CA). Briefly, RNA (0.2-1.0 g) was mixed with 1 l 
random hexamers and 1 l oligo (dT) 18 primers, heated  for 2 min at 70C min and 
rapidly chilled on ice. RT was then performed in 20 l reaction volume containing 
MMLV reverse transcriptase, RNase inhibitor, dNTPs and reaction buffer for 1hr at 
42C. The reaction was terminated by heating at 94C for 5 min and cDNA was either 
used immediately or stored at -80C.  
 
2.2.2 Gene/plasmid DNA cloning  
2.2.2.1 DNA primer synthesis  
 
Primers used in polymerase chain reaction (PCR) (See Section 2.2.2.2) for the cloning 
of various genes were designed using the following general guidelines: (i) incorporation 
of appropriate restriction enzyme cutting site in the primer sequence, avoiding 
restriction sites present in the target gene and the vector other than the multiple cloning 
site (MCS). The Webcutter 2.0 software (http://www.firstmarket.com/cutter/cut2.html) 
was used identify these restriction sites.   (ii) primer melting temperature (Tm) should be 
between 52oC – 62oC and (iii) primer length of between 20 base pair (bp) to 40bp 
depending on whether the appropriate Tm is achieved. The DNAStar PrimerSelect 
software (DNAStar, Madison, WI) was used to avoid primer dimer and hairpin loop 
formation in primer design. Primers for PCR and site-directed mutagenesis designed are 
described in Section 2.2.4. These primers were synthesized by Research Biolabs 




2.2.2.2 Polymerase chain reaction (PCR) 
PCR was used in the cloning procedures to exponentially amplify, mutate or subclone 
target gene DNA sequences. Two types of DNA polymerases were used in PCR 
reactions. Pfu DNA polymerase (Promega, Madison, WI) was used for the cloning of 
DNA sequences from cDNA samples because the polymerase has 3’  5’ proof-
reading activity, which ensures high fidelity of the amplified DNA fragments generated 
in the reaction. Taq DNA polymerase (Promega, Madison, WI) was used in PCR 
reactions to identify and verify cloned DNA sequences in plasmid vectors. 
 
 PCR was performed in 50l reaction volume containing reaction buffer, dNTPs (0.2 
mM), primers (0.5 M each), Taq or Pfu DNA polymerase (1-2 U) and cDNA (1g) or 
plasmid DNA (50-100 ng) template. Thermal cycling was carried out in a DNA thermal 
cycler (MJ Research, Waltham, MA) with 1 cycle of denaturation (94oC for 45 sec) 
followed by 35 cycles  of denaturation (94oC for 45 sec), primer annealing (50-65oC for 
45 sec) and extension (72oC for a defined period), and 1 cycle of extension (72oC for 10 
mins). 
 
The PCR primer annealing temperature used is 2oC below the lower Tm of the pair of 
primers. The extension time for a particular PCR reaction depends on the the length of 
the amplified target sequence and the polymerase used. For Taq polymerase, extension 
was carried out at 1 min/kb of expected DNA products, whilst for Pfu polymerase, it 





2.2.2.3 Ethanol precipitation of DNA 
DNA was precipitated by adding 1/10 volume of 3M sodium acetate (pH 5.2) and 2.5 
volumes of ice cold 100% ethanol to the DNA sample and incubating at -80ºC for 30 
min. The precipated DNA was then centrifuged at 13,000 rpm for 20 mins, washed with 
70% (v/v) ethanol, air-dried and dissolved in autoclaved deionized water. 
 
2.2.2.4 Restriction endonuclease digestion  
Restriction digestion of PCR products or plasmid vectors was performed in a total 
reaction volume of 20-50 μl containing restriction enzyme buffer, 2-5 μg DNA, 10-25U 
of specific restriction enzyme (10U/l) and 10 µg/µl of acetylated BSA at 37oC for 2 
hours. The digested DNA fragments were subsequently separated by gel electrophoresis 
and purified as described in the following sections. 
 
2.2.2.5 DNA agarose gel electrophoresis 
Separation and analysis of PCR products and plasmids was achieved by agarose gel 
electrophoresis. 1% (w/v) molecular grade Seakem LE agarose (Cambrex, Rockland, 
ME) in Tris-Acetate-EDTA (TAE) buffer (See Appendix) was prepared by boiling 
mixture at 100oC.  Upon cooling to 60oC, ethidium bromide (Bio-Rad, Hercules, CA) 
was added to a concentration of 0.5 g/ml   (See Appendix).  The melted agarose was 
then allowed to solidify and placed in an electrophoresis unit containing TAE buffer. 
DNA samples were mixed with 10 x DNA loading dye (See Appendix) and loaded into 
the wells of the gels.  The sizes of the electrophoretically separated DNA fragments 
were ascertained with the 1 Kb Plus DNA Size Standard (Gibco BRL Life 
Technologies, Rockville, MD). Gel electrophoresis was performed using a Hoefer HE 
33 mini horizontal submarine unit (GE Healthcare, Piscataway, NJ) at 100V. The gels 
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were then visualized under a UV illuminator and photographed using a Polaroid MP-4 
Land camera and Polaroid type 667 film (Polaroid Corporation, UK). 
 
2.2.2.6 Isolation of DNA from agarose gels 
The GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, Piscataway, NJ) 
was used for the isolation and purification of DNA from agarose gels. Briefly, the 
desired DNA band in the gel was excised, placed into an autoclaved eppendorf tube and 
weighed. 10 l of capture buffer was then added per 10 mg of the gel slice and 
incubated at 60oC for 15 min. The mixture was subsequently transferred to a GFX 
column, incubated for 5 min and centrifuged at 13,000x g for 30 sec in an Eppendorf 
microcentrifuge 5424 (Eppendorf, Hamburg, Germany). The column was then washed 
with 500 l of wash buffer. 50 l of autoclaved deionized water was then added to the 
column, incubated for 10 min and the column-bound purified DNA eluted by 
centrifugation at 13,000X g for 1 min into an autoclaved eppendorf tube. 
 
2.2.2.7 Quantitation of DNA 
DNA was quantitated using the Hoefer DyNA Quant 200 fluorometer (GE Healthcare, 
Piscataway, NJ.  2 ml of assay buffer containing 0.1 g/ml of bisbenzimide Hoechst No. 
33258 trihydrochloride dye (GE Healthcare, Piscataway, NJ) in 1x TNE (See Appendix) 
was used as blank. 2 l of calf thymus DNA standard (100 μg/ml) (Sigma-Aldrich, St 
Louis, MO) was then added into the assay buffer for calibration. Subsequently, 2 l of 
DNA sample in 2 ml of fresh assay buffer was used for quantitation with concentration 




2.2.2.8 DNA ligation 
DNA ligation is carried out in 20 l ligation reaction volume with 1 l of  400U/l T4 
DNA ligase and T4 DNA ligase buffer (New England Biolabs, Ipswich, MA) overnight 
at 16oC. The molar ratios between digested inserts (target gene fragment) and plasmid 
vector ranged from 3:1 to 5:1 in terms of absolute quantity, that is, 300 ng of digested 
insert and 100 ng of plasmid vector. 
 
2.2.2.9 Preparation of competent cells 
The Escherichia coli (E. coli) strain DH5 (Invitrogen, Carlsbad, CA) was used for 
plasmid propagation (Hanahan, 1983).  Working stocks of DH5 were grown as 
colonies on Luria-Bertani (LB) agar plates (See Appendix) and stored at 4oC. For long 
term storage, the bacteria were cryopreserved in LB medium (See Appendix) containing 
20% glycerol at -80oC. 
 
A single colony of DH5α was inoculated into 10 ml LB broth (See Appendix) and 
cultured overnight at 37ºC on a shaking platform at 200 rpm.  2 ml of the overnight 
culture was transferred to 200 ml of fresh LB broth in a 1 L conical flask and cultured 
for approximately 2 hours at 37ºC with shaking at 200 rpm. When the OD600 of the 
culture has reached 0.5, the culture was cooled on ice for 10 mins and then centrifuged 
at 3000 rpm for 10 min at 4ºC. The cell pellet was re-suspended in 10 ml of 0.22 m 
filtered, ice-cold 0.1M CaCl2 and then centrifuged at 2500 rpm for 5 mins at 4º C. The 
pellet was again re-suspended in ice-cold CaCl2 solution, incubated on ice for 30 min, 
and centrifuged at 2500 rpm for 5 mins at 4º C. Following centrifugation, the pellet was 
re-suspended in 2 ml of ice-cold CaCl2 solution containing 14% glycerol (v/v), 
aliquoted into pre-chilled sterile 1.5 ml eppendorf tubes and stored at -80ºC. 
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2.2.2.10 Transformation of competent cells 
Competent cells in -80ºC storage were immediately placed on ice to thaw.  Either 100 
ng of plasmid DNA or 10 l of a ligation reaction was added to the tube of competent 
cells and incubated on ice for 30 min. The cells were then heat-shocked for 90 sec at 
42oC and immediately transferred on ice for 5 min. 300 l of LB media was added and 
the cells were further cultured for 1 hr at 37oC on a shaking platform at 200 rpm. 50l 
fractions of the transformed cells were plated on LB plates with ampicillin (100 g/ml) 
(LA plates) and cultured overnight at 37oC.  
 
2.2.2.11 Methods for the identification of positive clones 
Two methods are employed for the identification of bacterial clones that have been 
successfully transformed with the plasmid vector containing the target gene:  
(i) PCR 
(ii) Restriction enzyme digestion 
 
To identify positive clones by PCR, twenty transformant colonies on the LA agar plate 
were each inoculated in 1 ml LB broth containing 100g/ml ampicillin (LA broth). 
After 6 hr of culturing at 37oC on a shaking platform at 200 rpm, PCR in 20 μl reaction 
volumes was performed using 1 μl of each of the bacterial culture as template and 
appropriate primers. 10 μl of each PCR product was subjected to agarose gel 
electrophoresis and positive clones were identified under UV illumination based on the 
expected fragment size of amplified DNA. Plasmid DNA was isolated from the positive 




To identify positive clones by restriction enzyme digest, five transformant colonies on 
LA agar plate were each inoculated into 10 ml LA broth. Plasmid DNA was isolated 
from the cultures as described in Section 2.2.2.12 and g of each of these isolated 
plasmids was digested with appropriate restriction enzymes, and electrophorized on 
agarose gels. Positive clones were identified under UV illumination based on expected 
fragment size of digested DNA.  
 
2.2.2.12 Rapid isolation of plasmid DNA 
The Wizard(R) Plus SV Minipreps DNA Purification System (Promega Co, Madison 
WI) was used for small scale isolation of plasmid DNA. Briefly, a single colony of 
transformed bacteria was inoculated in 10 ml LA broth. After overnight culture, bacteria 
were centrifuged at 3000 rpm for 5 mins.  The pellet was then re-suspended in 250 μl of 
re-suspension solution, lysed in 250 μl of lysis solution for 5 mins, incubated for 
another 5 min with 10 μl of an alkaline protease solution and neutralized with 350 μl of 
neutralization buffer. The cell lysates were centrifuged at 13,000 rpm for 10 min and the 
supernatant subsequently transferred to a spin column. The column was washed twice 
with wash solution and column-bound DNA was eluted with 100 l of deionized water 
into a fresh tube by centrifugation.  
 
2.2.2.13 Plasmid purification for transfection 
QIAGEN plasmid Maxi kit (QIAGEN GmbH, Hilden, Germany) was used for the 
purification of high grade plasmids required for transfection studies. Briefly, a single 
transformed bacteria colony was picked from a LA plate and inoculated into a starter 
culture of 2-5 ml of LA broth. The culture was grown for 8 hr at 37oC with shaking at 
200 rpm. This starter culture was diluted 1/500 into 250 ml of LA broth and cultured for 
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12-16 hr at 37oC with shaking at 200 rpm. The bacterial cells were harvested by 
centrifugation at 6,000x g for 15 min at 4oC and re-suspended in 10 ml of resuspension 
buffer P1 containing 100 g/ml RNase A. 10 ml of lysis buffer P2 was then added, 
mixed thoroughly and incubated for 5 min at room temperature. 10 ml of ice-chilled 
neutralization buffer P3 then added immediately mixed and incubated on ice for 20 min. 
The cell lysate was centrifuged at  20,000x g for 30 min at 4oC. The supernatant was 
collected into a fresh centrifuge tube and re-centrifuged at  20,000x g for 15 mins at 
4oC. A QIAGEN-tip 500 column was pre-equilibrated with 10 ml of equilibration buffer 
QBT before the supernatant was applied to the column and allow to drain by gravity. 
The column was then washed twice with 30ml wash buffer QC before the resin-bound 
DNA was eluted with 15 ml of elution buffer QF. To precipitate the eluted DNA, 10.5 
ml isopropanol was added and centrifuged at  15,000x g for 30 min at 4oC. The DNA 
pellet was washed with 5 ml of 70% (v/v) ethanol at room temperature and centrifuged 
at  15,000x g for 10 min. The DNA pellet was air-dried, dissolved in autoclaved 
deionized water and stored at -20oC. 
 
2.2.2.14 Site-directed mutagenesis 
QuikChange XL Site-directed Mutagenesis Kit (Stratagene, La Jolla, CA) was used to 
introduce point mutations in the DNA sequence of a cloned target gene or vector 
plasmid.  These mutations were necessary to generate novel restriction enzyme cutting 
sites in the DNA sequence for the transfer of DNA fragments from one vector plasmid 
to another in the cloning of chimeric proteins. Mutations were also required to change a 
particular codon into a stop codon to generate a truncated form of the protein of interest, 
or into a codon for another amino acid and assess whether such an amino acid 
substitution affects protein function.  In the latter case, the codon for alanine was often 
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used as a replacement because alanine is a small amino acid commonly found in most 
proteins with no particular steric requirement and occurs in all manner of secondary 
structures (Wells, 1991). Primers used are designed according to the considerations 
listed in the kit manual. 
 
The mutagenesis PCR is carried out in a 50 μl reaction volume containing 10 ng of 
plasmid DNA (10 ng), primers (125 ng each), dNTP mix, QuikSolution, reaction buffer 
and Pfu Turbo DNA polymerase (2.5 U/μl). PCR cycling parameters consists of 1 cylce 
of denaturation (95o C for 1 min), followed by 18 cycles of denaturation (95oC for 50 
sec), primer annealing (60oC for 50 sec) and extension (68oC for an appropriate duration 
based on 2 min/kb of plasmid length), and 1 cycle of extension (68oC for 7 min). The 
reaction product was then treated with 1 μl of DpnI restriction enzyme (10 U/μl) at 37oC 
for 1 hr to digest the parental, non-mutated DNA. 2-5 l of DpnI-treated DNA was then 
used to transform the kit provided XL10-Gold ultra-competent cells.  
 
2.2.2.15 DNA Sequencing  
The fluorescence-based dideoxy sequencing reactions was carried out in a 20 l 
reaction volume consisting of 200-300 ng of purified plasmid DNA, 5 pmol of primer 
and 6 l of Bigdye Terminator v3.1 cycle sequencing mix (Applied Biosystems, Foster 
City, CA). Cycle sequencing using DNA thermal cycler (MJ Research, Waltham, MA) 
was performed over a total of 25 cycles, each comprising of denaturation (96oC for 30 
sec), primer annealing (50oC for 15 sec), and extension (60oC for 4 min). The 
sequencing products were precipitated by adding 2 l of 3 M sodium acetate (pH 4.6) 
and 50 l of 95% (v/v) ethanol on ice for 15 min and then pelleted by centrifugation at 
13,000 rpm for 30 min. The pellets were washed once with 100 l of 70% (v/v) ethanol 
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and air-dried. The air-dried pellets were re-suspended in 10 l of Hi-DiTM formamide 
(Applied Biosystems, Foster City, CA), heated for 2 min at 95oC and subjected to 
polyacrylamide gel capillary electrophoresis using the ABI PRISM® 3100 genetic 
Analyzer (Applied Biosystems, Foster City, CA). Sequence data obtained were 





2.2.3 Commercial vectors  
The commercial vectors used in this study are listed in Table 2.3. Primers with 
sequences that flank the multiple cloning site (MCS) of pcDNA3.1 vector are used for 
sequencing purposes.  
 





Description Primers flanking the 
MCS for sequencing  





A 5.5 kb cloning vector for CMV 
promoter-driven constitutive 
protein expression.  Expressed 
protein can be incorporated  with 
C-terminal myc/His-tags  
T7 (upstream MCS):  
taatacgactcactataggg 







A 5.7 kb reporter vector that 
expresses the  firefly luciferase 




pRL-CMV  Promega 
(Madison, WI) 
A 4 kb control reporter that 
expresses the Renilla luciferase 








2.2.4 Construction of expression vectors   
2.2.4.1 Expression vectors of wild-type/native receptors  
 
Full-length cDNA encoding human SR-AI and SR-AII were amplified from RNA 
isolated from human macrophages using the listed primer pairs (Table 2.2) subsequently 
cloned into the pcDNA3.1 Myc/His vector to generate pSR-AI and pSR-AII vectors. To 
express receptors with a C-terminal myc/His tag (pSR-AI-MH and pSR-AII-MH), the 
stop codons in pSR-AI and pSR-AII were mutated into serine and alanine codons 
respectively via site-directed mutagenesis. The 5’-3’ forward primers (the reverse 
primers are exactly complementary) to generate the mutations are included in Table 2.2.  
 
The pTLR2, pCD14, pTLR4 and pMD2 vectors were constructed as previously 
described (Chen et al., 2004; Zhong et al., 2005). The CR3 and CR4 expression vectors 
for the M, X and 2 subunits were kindly provided by Dr Alex Law, University of 
Oxford, UK (Al-Shamkhani and Law, 1998). 
 
Table 2.2 Primers used in the construction of various wild-type/native PRR receptor 







Primers (5’….3’) : 
Forward (Sense) primer /  
Reverse (Antisense) primer 
Restriction 
sites on  
pcDNA3.1 
pSR-AI NM_138715 cgaggtaccgccaccatggagcagtgggatcac /  
cgcatcgggcccttataaagtgcaagtgactcc 
KpnI/ApaI 
pSR-AII NM_002445 cgaggtaccgccaccatggagcagtgggatcac / 
cgcatcttcgaattaagagggccctgccctaa 
KpnI/SfuI 
pTLR4 NM_138554 gcttggtaccgggccactgctgctcac / 
gaagggccctcagatagatgttgcttcctg 
KpnI/ApaI 
pCD14 NM_000591 cggggtaccaccatggagcgcgcgtcc / 
gagtctagattaggcaaagccccgggc 
KpnI/XbaI 
pMD2 AB018549 cggggtaccaccatgttaccatttctgtttttttc / 
gaagggccctctaatttgaattaggttggtgta 
KpnI/ApaI 
pTLR2 U88878 cggggtaccaccatgccacatactttgtggatg / 
gaagggccctaggactttatcgcagctc 
KpnI/ApaI 
pSR-AI-MH NM_138715 ggagtcacttgcactttatcagggcccttcgaacaaaaac N.A. 
pSR-AII-MH NM_002445 catattagggcagggccctctgcattcgaacaaaaactcatc N.A. 
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2.2.4.2 SR-AI collageneous domain mutant receptors 
The vectors for various collageneous domain mutant receptors were generated via site-
directed mutagenesis using pSR-AI-MH vector as template.  Specific positively-charged 
residues (lysine or arginine) in the domain are converted to non-polar alanine either 
individually or in groups. The list of primers used to generate the various mutant vectors 
is provided in Table 2.3. These mutant receptors possess a myc/His tag which would 
enable verification of cell surface expression of these receptors on transfected cells 
using anti-myc antibody. 
  
Table 2.3 Primers used in site-directed mutagenesis to generate various SR-AI 








SR-AI-K332A ccaggaaattctggaccagcaggccagaaaggggaaaag aaa (Lys) gca (Ala) 
SR-AI-K335A ggaccaaaaggccaggcaggggaaaaggggagtgg aaa (Lys) gca (Ala) 
SR-AI-K338A ccaaaaggccagaaaggggaagcggggagtggaaacacattaac aag (Lys) gcg (Ala) 
SR-AI-
K332/335A 






ccagcaggccagaaaggggaagcggggagtggaaacacattaac aaa (Lys)…. 





































A vector encoding mutant SR-AI that lacks the entire collageneous domain (SR-AI-dColl) 
was constructed by introducing two BamHI restriction sites in pSR-AI, one at the 
predicted first residue of the collageneous domain and one at the last residue of the 
domain as depicted in Figure 2.1.  
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The two forward (5’….3’) primers used to create the BamHI restriction sites are as 
follows:  
















2.2.4.3 SR-AI cysteine-rich (SRCR) domain mutant receptors 
The generation of vectors for various SRCR domain mutant receptors was achieved via 
site-directed mutagenesis (Table 2.4). A SRCR domain-deleted mutant receptor (SR-AI-
dCys) was also generated by replacing the lysine residue at the end of the linker region 
with a STOP codon.  To construct the SR-AI-dCys with a myc/His tag (SR-AI-dCys-
MH), an ApaI restriction site has to be introduced in place of the first two residues (Val-
Figure 2.1.  Schematic illustration of the generation of SR-AI collageneous domain-deleted 
mutant expression vector.  Two BamHI restriction sites are created via site-directed mutagenesis at 
the ends of the collageneous domain sequence. The domain is removed with BamHI and the excised 
ends ligated with T4 DNA ligase. 
Short linker region 




L   I   Q   G   P   P 
tta    att    caa    ggt   cct    cct 
G   S   G   N   T   L 
ggg    agt   gga    aac   aca   tta 
Convert to 
  gga tcc 
(BamHI restriction site) 
Convert to 
   gga tcc 
(BamHI restriction site) 
Amino acid sequence 
Nucleotide sequence 
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Arg) of the SRCR domain as shown in Figure 2.2. Another ApaI restriction site is 
present downstream of the SR-AI gene in the MCS of the pcDNA3.1A vector, but 
upstream and in-frame with the myc/His tag sequence.  The SRCR domain sequence is 
removed and the excised ends ligated, hence joining the linker region to the myc/His 
tag.     
 
The forward (5’….3’) primers used to create the ApaI restriction site is as follows:  
5’cattaactccatttacggggcccctggtcggtgggagcggc3’ 
 
Table 2.4 Primers used in site-directed mutagenesis to generate various SR-AI 








SR-AI-dCys cattaactccatttacgtaagttcgactggtcggtggg aaa (Lys) taa (STOP) 
SR-AI-G361P gggagcggccctcacgagccgagggtggagatactccac ggg (Gly) ccg (Pro) 
SR-AI-E364A cctcacgaggggagggtggcgatactccacagcggccag gag (Glu) gcg (Ala) 
SR-AI-
G361P/E364A 
















Linker region SRCR domain 
 F    T    K     V    R    L 
Linker region and SRCR domain of full-length SR-AI 




ggg ccc Myc/His tag 
ApaI restriction site on 
pcDNA3.1A vector in-
frame with myc/His tag 
Figure 2.2.  Schematic illustration of the generation of SR-AI SRCR domain-deleted mutant 
expression vector with myc/His tag.  An ApaI restriction site is created via site-directed 
mutagenesis to replace the codon sequences of the first two residues of the SRCR domain. Another 
ApaI restriction site is present downstream of the SR-AI gene in the MCS of the pcDNA3.1A vector, 
and is in-frame with the myc/His tag. The domain is removed with ApaI and the excised ends ligated 
with T4 DNA ligase. 
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2.2.4.4 SR-AI cytoplasmic domain mutant receptors 
The SR-AI-d1-45 expression vector, in which the first 45 amino acid of the N-terminal 
cytoplasmic domain is deleted, was generated with a forward primer that incorporates a 
KpnI restriction site followed by a start codon (ATG) before Leu46 (Table 2.5). Using 
this forward primer and the reverse primer constructed to clone the full-length SR-AI 
(Table 2.2) in a PCR reaction, we have generated a mutant receptor in which the 
cytoplasmic domain begins with Leu46.  
 
The SR-AI-dCytoKKK vector expresses a mutant receptor which has the entire 
cytoplasmic domain deleted.  The sequence of the forward primer used to generate this 
vector consists of a KpnI restriction site, followed by a start codon (ATG), three lysine 
residues, an alanine spacer and the first 5 amino acid of the transmembrane domain 
(Table 2.5). The same reverse primer (Table 2.2) used to generate SR-AI-d1-45 was 
employed in a PCR reaction to clone SR-AI-dCytoKKK. 
 
Table 2.5 Primers used in the construction of SR-AI-d1-45 and SR-AI-dCytoKKK 
cytoplasmic domain mutant receptor vectors 
 
Expression vector Primers (5’….3’) : 




SR-AI-d1-45 cgaggtaccaccatggccaaactgaagtccttcaaagc / 
cgcatcgggcccttataaagtgcaagtgactcc 
KpnI/ApaI 




The SR-AI-S48A vector, in which serine 48 is replaced by an alanine residue, was 
generated by site-directed mutagenesis with the listed forward primer (Table 2.6). The 
SR-AI vector was used as template in the PCR reaction. SR-AI-d1-45-S48A was 
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generated in a similar manner using the listed forward primer (Table 2.6) and SR-AI-d1-
45 vector as template. 
 
Table 2.6 Primers used in site-directed mutagenesis to generate SR-AI-S48A and 
SR-AI-d1-45-S48A cytoplasmic domain mutant receptor vectors 
 




SR-AI-S48A cccttcaagagaaactgaaggccttcaaagctgcactg tcc (Ser) gcc (Ala) 
SR-AI-d1-45-S48A ccaccatggccaaactgaaggccttcaaagctgcactg tcc (Ser) gcc (Ala) 
 
2.2.4.5 Construction of soluble SR-AI (psSR-AI-MH) expression vector 
To create soluble SR-AI (sSR-AI) which only possesses the extracellular domains of the 
receptor, a BamHI restriction site was introduced in place of the last two residues of 
transmembrane domain of the SR-AI-MH vector via site-directed mutagenesis (Figure 
2.3).  The forward primer to introduce BamHI site is as follows: 
5’ ctcattggaatagtggcagctggatccctgaagtgggaaacgaag 3’ 
 
The sequence of the extracellular domains of SR-AI was excised from the SR-AI-MH 
vector using BamH1 and ApaI (restriction site is present at 3’ end of SR-AI-MH gene 
sequence) and inserted into a pcDNA3.1A vector that contain a pre-protrypsin signal 
peptide incorporated in the MCS (kindly provided by Dr Tay Puei Nam, National 
University of Singapore) as shown in Figure 2.3. The inserted sequence comprising of 
the SR-AI extracellular domains is downstream of and in-frame with the signal peptide 
sequence in the vector. The signal peptide of pre-protrypsin, a secreted protein, will 





















2.2.4.6 Construction of soluble SRCR domain (SRCR) expression vector 
The construction of the soluble recombinant SRCR domain of SR-AI (psSRCR-MH) 
employs a similar strategy as described for sSR-AI.  A KpnI restriction site is 
introduced in place of the last residue of the collageneous domain and the first residue 
of the linker region in the SR-AI-MH vector as shown in Figure 2.4. The SRCR domain 
was excised with KpnI and ApaI and inserted into the expression vector containing the 
pre-protrypsin signal peptide.  The forward primer used to introduce Kpn I site is as 
follows:   5’ gaaaggggaaaaggggagtggtaccacattaactccatttacg  3’ 
 
5’ aag ctt aa ttc acc atg tct gca ctt ctg atc cta gct ctt gtt gga gct gca gtt gct ggt acc gag ctc gga tcc 3’ 
Pre-protrypsin signal peptide 
Transmembrane 
domain Spacer domain 
A    Q    L    L    K    W 
Transmembrane and spacer domains of full-length SR-AI 




Hind III BamHI 
Ligate extracellular 
domains of SR-AI 
downstream of signal 
peptide sequence  
KpnI 
Figure 2.3. Schematic illustration of the generation of soluble SR-AI (psSR-AI-MH) expression 
vector. The secreted, soluble form of SR-AI was generated by replacing the cytoplasmic and 
transmembrane domains with the pre-protrypsin signal peptide. The signal peptide will facilitate the 
secretion of the recombinant protein from transfected cells. The recombinant sSR-AI has a myc/His tag 











2.2.4.7 Expression vectors of CR3 mutant receptors 
The M and 2 subunit cytoplasmic domain-deleted mutant receptor vectors were 
generated by site-directed mutagenesis. A STOP codon was introduced in wild-type 
subunit vectors to replace the third residue in the cytoplasmic domain (N-terminal end), 
near the transmembrane domain of the respective receptor subunits (Table 2.7). 
 Table 2.7 Primers used in site-directed mutagenesis to generate M and 2 subunit 
cytoplasmic domain-deleted mutant receptor vectors  
 




CD11b-dCyto gtacaagctcggcttcttctagcggcaatacaaggacatg aag (Lys) tag (STOP) 
CD18-dCyto ctggtcatctggaaggcttagatccacctgagcgacctc ctg (Leu) tag (STOP) 
 
2.2.4.8 Dominant negative expression vectors 
 The dominant negative MyD88 (a.a.152–292)(MyD88DN) vector was constructed as 
previously described (Zhang et al., 2002) (Table 2.8). The N-terminal Death domain of 
MyD88 is removed in MyD88DN while its TIR domain remains intact. Consequently, 
the molecule is able to interact with TIR domain-containing receptors but does not 






G    S    G    N    T    L    T    P    F    T    K    V    R    L 
ggg agt gga aac aca  tta  act  cca ttt  acg  aaa gtt  cga ctg  
Convert to 
ggt acc 
(KpnI restriction site)  
Linker Region 
Figure 2.4. Schematic illustration of the generation of soluble SRCR domain (psSRCR-MH) 
expression vector. The secreted, soluble form of SRCR domain was generated by ligating the sequence 
of the domain downstream (3’) and in-frame to the pre-protrypsin signal peptide. The signal peptide 
will facilitate the secretion of the recombinant protein from transfected cells. The recombinant sSRCR 
has a myc/His tag to permit protein purification.  
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 The Rho GTPase dominant negative mutants were kind gifts from Dr Alan Hall 
(University of Cambridge, UK).  In both RacDN and Cdc42DN vectors, threonine 
residue at position 17 is replaced by an asparagine residue.  A similar amino acid 
substitution was effected in RhoADN but at position 19.  
 
Table 2.8 List of dominant negative vectors used in the present study including 








Restriction sites on 
pcDNA3.1 ligated 
into (5’/3’) 
pMyD88DN U84408 gtggaattccaccatggaccccctggggcatatg / 
gaagggcccgggcagggacaaggcctt
EcoRI/ApaI 
RacDN AF498964 - - 
Cdc42DN NM_001791 - - 
RhoADN NM_001664 - - 
 
2.3 Cell biology 
2.3.1 Human embryonic kidney (HEK) cell-line culture  
The human embryonic kidney (HEK) 293T cells, obtained from the American Type 
Culture collection (ATCC) (Rockville, MD), were used for the transient transfection of 
various expression vectors in functional studies. These cells were maintained in 
Dulbecco's Modified Eagle's Medium (DMEM) (Sigma-Aldrich, St Louis, MO) 
supplemented with 10% bovine calf serum (BCS) (HyClone, Logan, UT), 2 mM L-
glutamine (Invitrogen, Carlsbad, CA), 1mM sodium pyruvate (Hyclone, Logan, UT),  
100 units/ml penicillin and 100 g/ml streptomycin (Invitrogen, Carlsbad, CA)  (termed 
complete DMEM) in a humidified incubator at 37°C in the presence of 5% CO2.   
 
The 293T cells were sub-cultured every 3 days at a ratio 1:4 as recommended by ATCC. 
Culture medium was removed and the cells gently washed with 1x PBS (See Appendix) 
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before 2 ml of trypsin/0.5 mM EDTA (Sigma-Aldrich, St Louis, MO) was added and 
incubated for 1-2 mins at 37°C.  8 ml of complete DMEM was then added and the cell 
clusters were dispersed by repeated pipetting. The cells were seeded at desired densities 
in new T-75 flasks.  
 
To prepare cell stocks for long term cryostorage, cells were pelleted at 300x g for 5 min 
and then re-suspended to a density of 0.5_1x107 cells/ml in complete DMEM. DMSO in 
complete DMEM was added the cell suspension to a final concentration of 10% DMSO. 
The cell suspension was left to stand at room temperature for 5 min and then transferred 
to cryogenic vials (Nalge Nunc International A/S, Roskilde, Denmark). The vials were 
frozen at -80oC overnight and then transferred to liquid nitrogen for storage.  
 
2.3.2 Monocyte-derived dendritic cells (DCs) in vitro culture  
2.3.2.1 Isolation of human peripheral blood monocytes 
Peripheral blood leukocytes were obtained from the National University Hospital 
(NUH) Blood Donation Centre, Singapore in the form of buffy coat preparations 
derived from healthy donors. Monocytes were isolated from the buffy coats essentially 
as previously described with minor modifications (Lu et al., 1996). Briefly, the buffy 
coats were diluted two-fold in 1X PBS. 30 ml of diluted blood is layered on 12 ml 
Ficoll-Paque in a 50 ml tube (Amersham Bioscience Corp., Piscataway, NJ) and 
centrifuged for 30 min at 400x g without brake. Peripheral blood mononuclear cells 
(PBMCs) were collected from the gradient interface, re-suspended in 50 ml of PBS and 
pelleted down by centrifugation at 200X g for 15 min to remove platelets. This washing 
step was repeated once, followed by two washes at 100x g each for 10 min. The washed 
cells were re-suspended in 60 ml of RPMI medium containing 5% (v/v) BCS, 2 mM L-
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glutamine, 1mM sodium pyruvate, 100 units/ml penicillin and 100 g/ml streptomycin, 
divided into three T75 cell culture flasks and cultured for 2 hr at 37oC.  Non-adherent 
cells, mainly lymphocytes, were removed by repeated washing of the cells with 10 ml 
warm RPMI containing the above-mentioned supplements. The adherent fraction, 
mainly monocytes, was harvested by gentle scraping with a rubber policeman. 
Monocytes isolated by this method were ~95% pure as judged by the expression of 
CD14 by flow cytometry. 
 
2.3.2.2 Generation of DCs from blood monocytes 
The isolated monocytes were cultured in 6-well tissue culture plates at a density of 
1x106/ml in RPMI containing 10% (v/v) BCS, 100 units/ml penicillin, 100 g/ml 
streptomycin, 2mM L-glutamine and 1mM sodium pyruvate and 0.0012% (v/v) β-
mercaptoethanol. The cells were cultured for 6 days in the presence of 20 ng/ml GM-
CSF (R & D Systems Inc, Minneapolis, MN) and 40 ng/ml of IL-4 (R & D Systems Inc, 
Minneapolis, MN) to differentiate the cells into DCs. Every other day, half volume of 
the culture medium was removed and replenished with fresh media containing the 
above-mentioned cytokines at the stated concentrations.  
 
 
2.3.3 Microbial and molecular stimuli used in the present study 
2.3.3.1 Bacterial strains used as stimuli  
 
The following bacterial strains were used to stimulate DCs and plasmid-transfected 
293T cells in functional studies.  
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E. coli DH5, Staphylococcus aureus (S. aureus) and Bacillus subtilis (B. 
subtilis)(ATCC) were grown as colonies on LB agar plates and stored at 4oC. A 
transformed strain of DH5 expressing green fluorescent protein (GFP) (DH5-GFP) 
(kindly provided by Dr Yunn Hwen Gan, National University of Singapore) was 
cultured on LA agar plates. The bacteria strains were re-streaked on fresh plates every 
month. For long term storage, the bacteria were cryopreserved at -80oC in LB medium 
containing 20% glycerol. For the various functional studies, a single colony of each 
bacterial strain on a culture plate is selected and cultured overnight with shaking at 200 
rpm in 37oC incubator. The cells are harvested the following day at OD600 readings of 
0.3-0.4. 
 
The Mycobacterium bovis (M. bovis) bacillus Calmette Guerin (BCG) Connaught strain 
(Aventis Pasteur Ltd, Toronto, Canada) was purchased as a freeze-dried preparation that 
is viable upon culture media reconstitution.  The mycobacteria was cultured at 37oC in 
7H9 Middlebrook medium (Difco) supplemented with 10% ADC (Albumin-dextrose-
catalase) supplement (0.85% (w/v) NaCl, 5% (w/v) BSA, 2% (w/v) dextrose and 
0.003% (w/v) catalase), 0.05% (v/v) Tween 80 and 0.2% (v/v) glycerol. 
 
 
2.3.3.2 Molecules/PAMPs  
The origins and working concentrations of various PAMPs and molecules used in this 





Table 2.9 Molecular/PAMP stimuli used in this study  
Stimuli Origin Supplier  Working 
concentration 
Lipotechoic acid (LTA) Staphylococcus aureus InvivoGen                




Escheriachia Coli  
O5:55 
Sigma-Aldrich            







San Diego, CA 
0.5 μg/ml 
Fucoidan Fucus vesiculosus Sigma-Aldrich            




Sigma-Aldrich           




2.3.4 Pharmaceutical inhibitors 
The molecular target and working concentration of pharmaceutical inhibitors used in 
this study are listed in Table 2.10. These inhibitors were dissolved in either nuclease-
free water or DMSO.  
 
Table 2.10 Pharmaceutical inhibitors used in the present study 





LY 294002 Phosphatidylinositol 3-kinase (PI3-K) 






Wortmannin Phosphatidylinositol 3-kinase (PI3-K) 
Covalently binds to the ATP-binding 





NSC23766 Interferes Rac1 interaction with the 
Rac-specific guanine nucleotide 






toxin B (DTxB)  
 
General inhibitor of RhoGTPases 50 ng/ml Sigma-Aldrich 
St Louis, IL 
Cytochalasin D Disrupts actin cytoskeleton 2 M Sigma-Aldrich 
St Louis, IL 
-methylcyclodextrin 
(MCDextrin) 
Depletes cholesterol in lipid rafts  10 mM Sigma-Aldrich 




2.3.5 Transient liposome-based cell transfection 
Approximately 6x105 or 1x105 293T cells were seeded into each well of a 6-well plate 
or a 24-well plate respectively and cultured for 16-24 hr. Cell transfection was carried 
out using the liposome-based GenePORTER 2 Transfection Reagent (Gene Therapy 
Systems, La Jolla, CA). Briefly, 0.5-4 g of plasmid DNA was diluted with an 
appropriate volume of the DNA diluent B buffer as recommended by manufacturer and 
incubated for 5 min at room temperature. An appropriate volume of GenePORTER 2 
reagent in serum-free DMEM was then added to the diluted DNA, incubated for 5-10 
min at room temperature and added directly to the cells. The cells were then incubated 
for 24 hr before use in functional studies. 
 
2.3.6 Dual luciferase assay 
The dual luciferase assay used in this study involves the co-transfection of two 
luciferase reporter plasmids, the p5×NF-B-luc (Stratagene, La Jolla, CA) and pRL-
CMV (Promega, Madison, WI), along with the test plasmids containing the genes of 
interest.  The p5×NF-B-luc cis-reporter plasmid, which contains five tandem repeats of 
the NF-B enhancer element along with the TATA box promoter upstream of the gene 
for firefly (Photinus pyralis) luciferase, serves as the experimental reporter and provides 
an indirect measure of NF-B activation.  The pRL-CMV cis-reporter plasmid contains 
the cytomegalovirus (CMV) promoter upstream of the sea pansy (Renilla reniformis) 
luciferase gene, resulting in constitutive expression of the luciferase in transfected cells. 
This plasmid is the control reporter and provides an internal control that serves as the 
baseline response. Normalising the activity of the experimental reporter to that of the 
internal control minimizes experimental variability caused by differences in cell 
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viability, cell numbers or transfection efficiency, thus allowing for reliable 
interpretation of the experimental data by reducing extraneous influences. 
 
293T cells in a 24-well plate were co-transfected with the two reporter plasmids at 100 
ng/well.  A total quantity of 500 or 1000 ng/well of plasmids, including the reporter 
plasmids, were transfected depending on the various experimental set-ups in the study. 
In experiments with TLR4, 100 ng/well of each of the TLR4, MD2 and CD14 plasmids 
was used. For experiments involving SR-A and TLR2, the amount of plasmid used was 
300 ng/well while those with CR3 required 150 ng/well of each of the M and 
subunit plasmids.  In experiments that entailed the use of dominant negative gene 
constructs, e.g. MyD88 or the Rho-GTPase dominant negative (DN) constructs, 500 
ng/well of each DN plasmid was used along with the receptor plasmid(s) and reporter 
plasmids. As negative controls, cells were transfected with pcDNA3.1 vector in place of 
the receptor plasmid(s) or DN plasmids. All treatment groups in an experiment were 
performed in triplicates. 
 
Luciferase expression was determined 24 hr after stimulation with the Dual Luciferase 
Assay kit (Promega, Madison, WI).  The culture medium in each well was removed and 
stored in -20oC for ELISA analyses.  The cells in the wells were washed once with 
1xPBS and then lysed using 1x PLB (passive lysis buffer). The amount of firefly 
luciferase expressed by cells in a particular well was determined upon addition of the 
firefly luciferease substrate beetle luciferin present in the Luciferase Assay Reagent II 
(LAR II) to the cell lysate. The luminescence emitted in terms of relative light units 
(RLU) was recorded using a single-tube illuminometer TD 20/20 (Turner Designs, 
Sunnyvale, CA). The Renilla luciferase substrate coelenterazine present in the Stop and 
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Glo Reagent was then added to the cell lysate and luminescence emitted by the 
reaction again read to provide an indication of baseline response. The data was 
normalized by calculating the ratio of the firefly luciferase reading to the corresponding 
Renilla luciferase reading and multiplying by 100, to provide NF-B fold activation 
measure.  
 
2.3.7 Treatment of transfected HEK 293T cells with various bacterial and 
molecular stimuli 
 
293T cells were cultured for 24 hr following transfection with various expression 
vectors. In experiments involving bacteria, transfected 293T cells were stimulated with 
the various strains of bacteria at a multiplicity of infection (MOI) of 100 for 1 hr at 
37oC.  The cells are washed three times with warm culture medium and further 
incubated for 24 hr prior to analysis of NF-B activation via the dual luciferase assay 
and of cytokine production by ELISA.  
 
In some experiments, the bacteria (DH5) were opsonized with 10% fresh human 
serum medium (10% human serum in DMEM with 100 units/ml penicillin and 100 
g/ml streptomycin) for 8 min at 37oC.  The transfected 293T cells were initially 
washed and cultured in DMEM containing 10% heat-inactivated BCS, 100 units/ml 
penicillin and 100 g/ml streptomycin prior to stimulation with the opsonized bacteria.  
Following 1 hour incubation with bacteria, the cells were washed and maintained in the 
same medium for 24 hr prior to functional analysis. In experiments that utilize sera 
deficient in specific complement components, e.g. C3-deficient serum, DH5was pre-
incubated in that serum (10%) in place of fresh human serum. Blocking experiments 
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with antibodies specific against a particular complement component, e.g. goat anti-C3 
antibodies, were carried out by pre-incubating fresh human serum-opsonized 
DH5with 100 g/ml of the antibodies for 15 min on ice prior to use in stimulating 
transfected cells. 
 
In experiments involving molecular/PAMP stimulation, the transfected 293T cells were 
incubated with the various stimuli for 1 hr, washed thoroughly and further incubated for 
24 hr.  We also conducted experiments in which the stimuli were incubated with the 
cells for 24 hr.  The functional analysis data (NF-B activation or cytokine production) 
did not differ, trend-wise, between the experimental set-ups. For experiments involving 
pharmaceutical inhibitors, the transfected cells were pre-incubated for 1hr (for most 
inhibitors used) or 24 hr (for Rac inhibitor NSC23766) prior to bacteria stimulation.  
 
2.3.8 Dendritic cell stimulation with various bacterial and molecular stimuli 
Dendritic cells were harvested, washed once with PBS and re-suspended in RPMI 
containing 10% (v/v) heat-inactivated BCS, 100 units/ml penicillin,100 g/ml 
streptomycin and 2 mM L-glutamine. The cells were seeded in 96-well plates at a 
density of 0.5x105 cells/well and stimulated for 24 hr with DH5 (MOI = 20:1). In 
some experiments, DH5 was opsonized with normal (DH5C3+) or C3-deficient 
human sera (DH5C3-) and washed with warm RPMI medium before stimulation of 
DCs.  
 
In antibody-blocking experiments, DCs were pre-blocked with antibodies for Fc 
receptors (FcRs) before bacterial stimulation, i.e. FcR I (clone 10.1), FcRII (clone 
7.3), FcRIII (clone 3G8) (each at 10 g/ml) or isotype mouse IgG1 (clone MOPC 31C, 
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30 g/ml), while in experiments involving pharmaceutical inhibitors, DCs were pre-
treated overnight with the Rac inhibitor NSC23766 (100 M) or Rho GTPase inhibitor 
DTxB (50 ng/ml) before stimulation with DH5. DCs were also stimulated with 
DH5C3+ and DH5C3- in the presence of cytochalasin D (2 M). IL-12p70 and TNF-
 was measured 24 h after stimulation by ELISA.  
 
2.3.9 Enzyme-linked Immunosorbent Assay (ELISA) 
ELISA was performed using either the DuoSet® ELISA Development kit (R&D 
Systems Inc, Minneapolis, MN) for TNF- or BD OptEIA™ ELISA set (BD 
Biosciences, San Diego, CA) for IL-12p70, IL-8 and MCP-1. Briefly, 100l of the 
capture antibodies diluted with PBS (in DuoSet® ELISA) or Coating buffer (0.1M 
sodium carbonate, pH 9.5) (in BD OptEIA™ ELISA) was added to each well of a 96-
well BD FalconTM ELISA plates (BD Biosciences, San Diego, CA) and incubated 
overnight at 4C. The plates were repeatedly washed with Wash buffer (0.05% Tween-
20 in PBS), blocked with Reagent Diluent (PBS with 1% BSA) (in DuoSet® ELISA) or 
Assay Diluent (PBS with 10% Fetal Bovine Serum) (in BD OptEIA™ ELISA) for 2 hr 
at room temperature and again washed thoroughly. Test samples or purified cytokine 
standard diluted in Reagent Diluent/Assay Diluent were then added into each well (100 
l/well) and incubated overnight at 4C. The plates were washed thoroughly following 
overnight incubation. For DuoSet® ELISA, the biotinylated detection antibodies diluted 
in Reagent Diluent were added to each well (100 l/well). After incubation at room 
temperature for 2 hr, the plates were washed and incubated with streptavidin-HRP 
conjugate in Reagent Diluent (100 l/well) for 1hr at room temperature in the dark. For 
BD OptEIA™ ELISA, the biotinylated detection antibodies and streptavidin-HRP 
conjugate were diluted in Assay Diluent, added to each well (100 l/well) and incubated 
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for 2 hr at room temperature in the dark. The substrate solution was prepared by mixing 
equal volume of Substrate reagent A (hydrogen peroxide in a buffered solution) and 
Substrate B (3,3’,5,5’ tetramethylbenzidine in an organic solvent) (BD Biosciences. San 
Diego, CA). 100 l of substrate solution was added to each well and the plate incubated 
in dark for 30 min. The colorimetrical reaction was stopped by adding 50 l of Stop 
Solution (1M phosphoric acid or 2N sulphuric acid). The optical density was 
determined immediately using a microplate reader TECAN SunriseTM (Tecan, 
Männedorf Switzerland) at 450 nm with a wavelength correction at 570 nm. A linear 
standard curve was constructed by plotting the log of the standard cytokine 
concentrations versus the log of the spectrophotomeric O.D. readings and the 
concentration of test samples determined from the curve.  
 
2.3.10 Green fluorescent protein-E. coli DH5 binding assays 
A binding assay was developed to determine C3 deposition on E. coli. Polyclonal goat-
anti-human C3 antibody was coated on a 96-well BD FalconTM ELISA plate at a 
concentration of 500 ng/ml and incubated overnight at 4oC.  Polyclonal goat anti-human 
C1q was also used to determine whether the classical pathway of complement activation 
was involved in E. coli opsonization while polyclonal goat anti-human SR-A serves as a 
negative control. The wells were then washed repeatedly with ELISA Wash buffer, 
blocked with Reagent Diluent (PBS with 1% BSA) for 1 hr at room temperature, 
washed repeatedly again and incubated in serum-free DMEM. Equal numbers of DH5-
GFP (400 X 106 cells/ml) were incubated in 10% fresh, heated or C3-deficient human 
serum for 8 min, washed and added to the antibody-coated wells for 30 mins at 4oC.  
The wells were then washed through and analyzed using an Olympus 1X81 Inverted 
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fluorescence microscope and the Image-Pro MC 5.1 software (Olympus America Inc, 
Center Valley, PA). 
  
Another binding assay was designed to investigate the interaction between SR-A and 
bacteria. Coverslips were coated with sSR-AI, SRCR, BSA, or purified human MBL 
(50 g/ml in PBS) overnight at 4oC in 24-well plates. Recombinant human MBL was 
kindly provided by Dr Alan Ezekowitz (Harvard University, USA). The coverslips were 
washed three times with a TBS buffer (20 mM Tris, pH7.4, 150 mM NaCl, 5mM CaCl2 
and 5mM MgCl2) and blocked for 2 hr with the TBS buffer containing 0.1% (w/v) BSA. 
Washed DH5-GFP was incubated for 30 min with 10% (v/v) fresh or heat-inactivated 
BCS in DMEM and after washing, re-suspended at 4x107/ml in TBS. The bacteria were 
added to coverslips in the 24-well plates at 0.5 ml/well and incubated for 1 hr at 37oC. 
The coverslips were washed 3 times with the TBS buffer, fixed in 4% (w/v) 
formaldehyde, and analyzed using a BX51 Olympus fluorescence microscope (63x 
objective) and the Olympus Micro Image software (Olympus, Tokyo, Japan). 
 
2.3.11 Confocal microscopy.  
This is carried out essentially as previously described (Cao et al., 2006). DCs were 
cultured overnight on glass cover slips and then either left unstimulated or stimulated 
for 1 h with DH5-GFP. The cells were fixed for 15 min in 3.7% (w/v) formaldehyde 
and permeabilized for 5 min in 0.2% (v/v) Triton X-100. After incubation for 30 min 
with rhodamine-phalloidin (5 units/ml), the cells were washed and viewed using a 
LSM510 laser-scanning microscope (Carl Zeiss Inc, Oberkochen, Germany) and the 
Zeiss LSM Image Browser software.  
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2.4 Protein Chemistry 
2.4.1 Antibodies used in this study 
All antibodies used in this study have been listed in Table 2.11, together with 
information of their source, isotype and working concentrations. 
 
Table 2.11 Antibodies used in the present study 
Antibody (anti-) Clone, isotype 
Conjugate and stock 










Goat, antiserum Blocking assay 
100 g/ml 
Sigma-Aldrich,  
St Louis, MO 
Human 
complement C4 
Rabbit, IgG in antiserum Blocking assay 
100 g/ml 
Sigma-Aldrich, 
 St Louis, MO 
Human 
complement C1q 
Goat, antiserum Blocking assay 
100 g/ml 
Sigma-Aldrich,  
St Louis, MO 





Roche Applied Science 
Indianapolis, IN 
β-actin AC-15, mouse IgG Western blot  
(1:5000) 
Sigma-Aldrich,  
St Louis, MO 








Flow cytometry  
10 g/ml 
Dr Alex Law (University 
of Oxford) 
M integrin LMP19c  
Mouse IgG2a 
Flow cytometry  
10 g/ml 
Dr Alex Law (University 
of Oxford) 
X integrin KB43 
Mouse IgG 
Flow cytometry  
10 g/ml 
Dr Alex Law (University 
of Oxford) 












NA Isotype control 
Clone MOPC 31C,  






North Bayport, MN 
NA Isotype control 
Clone RPC 5,  

































2.4.2 Protein concentration determination 
Protein concentration was determined using the Bio-Rad protein assay kit (Bio-Rad, 
Hercules, CA). Briefly, eight serial dilutions of a standard BSA solution were prepared, 
starting with a stock concentration of 0.4 mg/ml. The linear range for BSA in this assay 
is 0.05 mg/ml to 0.5 mg/ml. 10 μl of each of the BSA standard dilutions and protein 
samples (10 μl were added into the wells of a 96-well microtiter plate. The dye reagent 
was diluted (1 part Dye Reagent Concentrate with 4 parts distilled water) and filtered 
through 0.45 m filter. 200 l of the dye was then added to each well and incubated at 
room temperature for 5 min. Absorbance was measured at 595 nm. The standard curve 
was constructed by plotting the known BSA concentrations versus absorbance at 595 
nm and sample concentrations determined from the curve. 
 
2.4.3 Expression of recombinant proteins sSR-AI and sSRCR 
2.4.3.1 Calcium phosphate transfection 
This transfection protocol was employed for the production of recombinant proteins 
used in this study i.e. soluble SR-AI and SRCR domain recombinant proteins. Briefly, 
4x106 293T cells were seeded in a T75 cell culture flask and incubated overnight. The 
cells were then transfected with 50 μg of either SR-AI or SRCR domain expression 
plasmids. 50 μg of DNA plasmid was diluted in 1.26 ml sterile water and 1.4 ml of 2x 
HBS buffer (Appendix). 140 μl of 2.5 M CaCl2 was subsequently added, in a drop-wise 
manner, to the diluted DNA solution, vortexed for 5 sec and then incubated for 30-40 
min at room temperature.  The serum in the cell culture medium was reduced to 5% 
prior to adding the DNA mixture to cells. The cells were incubated for 6-8 hr, the 
culture media replaced with expression culture medium (DMEM supplemented 0.01% 
(w/v) BSA, 2mM sodium butyrate, 100 units/ml penicillin and 100 g/ml streptomycin) 
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and further cultured for 48 hr. The culture media was then harvested for protein 
purification.  
 
2.4.3.2 Purification of recombinant proteins 
The culture media containing the expressed recombinant proteins was harvested after 48 
hr incubation, centrifuged at 3000 rpm for 5 min to remove cell debris and filtered 
through a 0.22 M filter. 350 l of Ni-NTA agarose beads (QIAGEN, Valencia, CA) 
was then added to the filtrate and incubated on a rotator overnight at 4oC.   The nickel-
charged agarose beads will bind to recombinant proteins that express a 6x histidine (6x 
His) tag. The bead-mixture was transferred to a 10 ml Poly-prep chromatography 
column (Bio-Rad, Hercules, CA) and allowed to flow through the resin in the column 
by gravity at 4oC. The column is then washed with 30 ml of wash buffer (Appendix) 
and the expressed recombinant protein eluted with 150 l elution buffer (Appendix) in 
10 fractions. The purified protein was then subjected to analysis by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting. 
 
2.4.4 Preparation of C3 and its degradation fragments 
The purified complement C3 and its degradation fragments, C3b and iC3b, were kindly 
provided by Dr Alister Dodds (University of Oxford, UK). Complement C3 was 
isolated from human plasma and C3b was generated from C3 as previously described 
(Dodds, 1993). iC3b was generated by incubation of human plasma with thiol-
Sepharose followed by elution with L-cysteine as previously reported (Cai and Wright, 
1995). The eluted iC3b was further purified by FPLC using a Mono Q column (HR5/5). 
The purified C3, C3b and iC3b were examined by SDS-PAGE on 10% (w/v) gels with 
Coomassie blue staining (Section 2.4.9). 
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2.4.5 Flow cytometry 
293T cells were seeded at a density of 6x105 cells/well in 6-well plates and transfected 
with the relevant expression vectors or pcDNA3.1A control vector (4 g/well) using 
GenePORTER 2 transfection reagent. The cells were cultured for 36 hours before 
harvesting for analysis by flow cytometry. Flow cytometry was also used to analyze cell 
surface receptors on DCs. The DCs were cultured for 6 days as described in Section 
2.3.2.2. Both DCs and transfected 293T cells were harvested, pelleted by centrifugation 
at 300x g for 5 min and then washed with FACS buffer (Appendix). To detect CR3 and 
CR4 expression on 293T cells, Hank’s balanced salt solution containing 10 mM 
HEPES, 5 mM MgCl2 and 5 mM CaCl2 (Mg/Ca-HBSS) was used instead of FACS 
buffer. The cells were pre-blocked with FACS buffer or Mg/Ca-HBSS containing 20% 
(v/v) goat serum (DakoCytomation, Glostrup, Denmark) at a density of 3x105 cells per 
100 l of buffer on ice for 30 mins and then washed thoroughly with FACS buffer. 
Specific primary murine-derived antibodies or isotype control antibodies were added 
(Section 2.4.1) and the cells incubated on ice for 1 hr. The cells were then wash twice 
with FACS buffer and incubated with the secondary antibody on ice for 30 mins.  
Following antibody incubation, the cells were washed twice with FACS buffer and 
fixed in 1% (v/v) formaldehyde in PBS (pH 7.6). Flow cytometry was carried out using 
FACScalibur (Becton Dickinson Immunocytometry Systems, San Jose, CA). Data was 
analyzed using the WINMDI software version 2.8 (Scripps Institute, La Jolla, CA). 
 
2.4.6 Cell surface biotinylation  
293T cells were seeded in 6-well plates at density of 6x105 cells/well and cultured 
overnight prior to GenePORTER 2-based transfection with 4 μg /well of the receptor or 
vector control plasmids. After further incubation of 24 hr, the cells were washed three 
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times with ice-cold PBS (pH 8.0) and then incubated with a membrane-impermeable 
biotinylation reagent EZ-LinkTM Sulfo-NHS-LC-Biotin (Pierce Biotechnology, 
Rockford, IL) at concentration of 1mg/ml for 30 min at room temperature. The biotin 
reagent was dissolved in PBS (pH 8.0) immediately prior to use. The reaction was 
terminated by adding 50 mM Tris (pH 8.0). The cells were washed three times with ice-
cold PBS (pH 8.0) and then lysed in 100 µl cell lysis buffer (Appendix) on ice for 30 
min.  The cell lysates were centrifuged at 12,000 rpm for 15 min at 4oC and were diluted 
in 0.5 volume of 1:1 slurry immobilized streptavidin-agarose beads (Pierce 
Biotechnology, Rockford, IL).  The cell lysate-beads mixture was then incubated 
overnight at 4°C under constant rotation. The beads were pelleted by centrifugation at 
5,000xg for 1 min and washed three times in the cell lysis buffer without Triton X-100 
(Appendix). Bound proteins were eluted by boiling the beads in SDS-PAGE reducing 
sample loading buffer (Appendix) and then subjected to SDS-PAGE and Western 
blotting. 
 
2.4.7 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Separation of proteins by SDS-PAGE was carried out using the Bio-Rad Mini-
PROTEAN II Cell set. Chemical composition of stacking and separating gels, 
electrophoresis buffer, and sample loading buffer are as described (Sambrook et al, 
1989) and are also presented in the Appendix. Approximately 50 g of each protein 
sample was mixed with 1/5 volume of a 5x SDS-PAGE sample loading buffer with β-
mercaptoethanol (reducing agent). The samples were boiled for 10 min at 100C before 




2.4.8 Western blotting 
Proteins separated on the SDS-PAGE gels were electro-blotted onto nitrocellulose 
membranes (Bio-Rad, Hercules, CA) using the Bio-Rad TransBlot Transfer Cell set 
(Bio-Rad, Hercules, CA). The transfer was conducted in ice-chilled 1 x Western blot 
transfer buffer (Appendix) with 20% methanol at 100V for 2 hr.  The blots were 
blocked for 1 hr in 5% (w/v) non-fat milk dissolved in the TBS-T buffer (Appendix) at 
room temperature and then incubated with appropriate primary antibodies (prepared in 
TBS-T with 5% non-fat milk) overnight at 4C with constant shaking. The blots were 
washed with TBS-T three times (10 min each wash) and then incubated with alkaline 
phosphatase-conjugated (AP) secondary antibodies (prepared in TBS-T with 5% non-fat 
milk) for 1hr at room temperature. After thoroughly washing with TBS-T, the blots 
were developed using the Immun-StarTM Chemiluminescent kit (Bio-Rad, Hercules, 
CA).  
 
2.4.9 Coomassie blue staining  
For coomassie blue staining, gels were stained overnight with staining solution 
containing 0.25% (w/v) coomassie blue R-250, 10% (v/v) acetic acid and 50% (v/v) 
methanol. The gels were then destained using destaining solution containing 5% (v/v) 
acetic and 35% (v/v) methanol. 
 
2.4.10 Solid Phase Protein Binding Assay 
96-well plates were coated with sSR-AI, SRCR, C3, C3b, iC3b or BSA (10 g/ml in 
PBS) overnight at 4oC. The plates were washed in PBS containing 0.1% (v/v) Tween 20 
(PBS-T) and blocked using the same buffer. The plates were then incubated with the 
indicated soluble protein partners (10 or 100 g/ml) overnight at 4oC. Immobilized or 
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bound proteins on the plates were detected, using a goat anti-human C3 antibody (20 
g/ml) (Sigma-Aldrich, St Louis, MO) or a mouse anti-Myc monoclonal antibody (2 
g/ml)(Roche Applied Science, Indianapolis, IN) as specified, by incubation for 2 hr at 
4oC followed by washing with PBS-T, and then by a 2 hr incubation with alkaline 
phosphatase-labeled secondary antibodies in PBS-T. After washing, the plates were 
developed using the substrate p-nitro phenyl phosphate (pNPP) (Sigma-Aldrich, St 
Louis, MO) and read at 405 nm using a Bio-Rad Model 680 microplate reader. 
 
2.5 Statistical Analysis 
Data were expressed as mean values ± SE (standard error). Analysis for statistical 
significance uses the Student’s two-sided unpaired t test. Differences were considered 













Chapter 3. Characterization of SR-AI as a receptor for the 
complement opsonin iC3b. 
 
3.1 Overview 
A significant number of membrane-bound and soluble PRRs have been reported to 
interact with LPS, including TLR4 (Poltorak et al., 1998), CD14 (Blondin et al., 1997; 
Frey et al., 1992; Pugin et al., 1993), CR3 (Wright and Jong, 1986; Wright et al., 1989), 
serum LBP (Schumann et al., 1990), MD2 (Shimazu et al., 1999), the chemokine 
receptor CXCR4 (Triantafilou et al., 2008), CD6 (Sarrias et al., 2007), MARCO 
(Sankala et al., 2002) and SR-A (Hampton et al., 1991). Most of these studies focused 
on interactions between LPS and these proteins. However, little is known about the 
signaling events upon LPS binding to these proteins except for the TLR4-CD14-MD2 
receptor complex, which is known to be the principal signaling receptor for LPS 
(Poltorak et al., 1998).  
 
Although SR-A has been reported as a LPS receptor, how LPS binds to the receptor is 
unclear. To date, evidence provided in support of LPS as an SR-A ligand were derived 
from ligand competition studies and hence considered indirect or implied. Binding of 
LPS to RAW 264.7 mouse macrophages was inhibited by the well known SR-A ligand 
acLDL (Hampton et al., 1991). This inhibition was similarly demonstrated using 
transfected CHO cell that express bovine SR-A (Hampton et al., 1991). 
 
LPS can cause systemic inflammation through TLR4 signaling, a condition known as 
septic shock (Poltorak et al., 1998). How SR-A participates in LPS-induced septic shock 
is inconsistently reported (Hampton et al., 1991; Haworth et al., 1997; Kobayashi et al., 
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2000).  Initial studies reported that LPS induces TNF- from the RAW 264.7 
macrophages but this was not inhibited by acLDL, indicating that SR-A plays an 
insignificant role in LPS-mediated pro-inflammatory cytokine production from 
macrophages (Hampton et al., 1991). However, findings from subsequent studies 
indicated otherwise.  Haworth et al. (1997) reported that SR-A-/- mice are more 
susceptible to endotoxic shock resulting from increased TNF- and IL-6 expression. It 
was proposed that macrophage SR-A clears LPS from blood circulation and thereby 
protects the host from septic shock by reducing pro-inflammatory cytokine production 
(Haworth et al., 1997). Conversely, Kobayashi et al. (2000) reported that SR-A-/- mice 
had lower mortality than wild type littermates after intraperitoneal LPS administration. 
It was observed that, in response to LPS, wild type mice produced higher levels of 
serum IL-1 than SR-A-/- mice indicating more severe sepsis which could account for 
higher mortality rates (Kobayashi et al., 2000). It is unclear as to the reasons behind 
these apparently conflicting results derived from the aforesaid studies. The 
reconciliation of these results would require the understanding of the interaction 
between LPS and SR-A, and also the signaling events initiated via the receptor upon 
LPS stimulation.  
 
Although SR-A and the closely related SR, MARCO, have short cytoplasmic tails 
(Freeman et al., 1990; Krieger and Stern, 2001; Peiser et al., 2002; van der Laan et al., 
1999), they can regulate macrophage production of cytokines, such as LPS/IFN--
induced IL-12 production (Jozefowski et al., 2005; Sutterwala et al., 1997). However, 
little is known about the mechanisms of SR-A and MARCO signaling. The SR-A ligand 
fucoidan activates multiple signaling pathways in macrophages inducing IL-1 
expression (Hsu et al., 2001), but CD14 rather than SR-AI has been suggested to 
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mediate fucoidan stimulation of macrophages (Kim et al., 2003). Nevertheless, the roles 
of SR-A and MARCO in the regulation of LPS/IFN- induction of IL-12 from 
macrophages (Jozefowski et al., 2005; Sutterwala et al., 1997) does imply SR-A and 
MARCO signaling and probable cross-talk with the main LPS signaling receptor TLR4 
(Poltorak et al., 1998). 
 
The ligand promiscuity of SR-A and the considerable overlap in ligand specificities 
with other macrophage receptors hinders investigation of ligand recognition by SR-A 
and its signaling in macrophages (Krieger and Stern, 2001; Peiser et al., 2002). We 
therefore expressed SR-AI in the 293T human embryonic kidney cells (SR-AI-293T), 
which lack most macrophage receptors, to circumvent this multi-ligand/multi-receptor 
complexity and began by comparing SR-AI with TLR4 in their response to LPS. 
 
3.2 TLR4 but not SR-A is able to activate NF-B in response to LPS 
SR-AI-293T cells were co-transfected with two luciferase reporter vectors: a vector that 
expresses firefly luciferase under the NF-B promoter which measures NF-kB 
activation in the cells and another vector that expresses Renilla luciferase under a 
constitutively active CMV promoter as an internal control. As a positive control, cells 
were also transfected to express TLR4/CD14/MD2 (TLR4-293T). The amount of 
expression vector used for transfection was 300ng/well for SR-AI and 100ng/well each 
for TLR4, CD14 and MD2. The cells were stimulated with LPS (500ng/ml) for 24 hr 
before analysis for NF-kB activation. NF-B activation was markedly increased in 
TLR4-293T (p=2x10-7) but not SR-AI-293T cells (Figure 3.1A).  This raises the 
question whether SR-AI is capable of inducing NF-B activation or whether it even 
binds to LPS in view of the fact that there is presently no evidence that suggest SR-AI 
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directly binds to LPS. However, technically, the expression of SR-AI on the transfected 
cells was unclear in these experiments and needed to be verified before such 
conclusions can be derived. 
 
The expression of SR-AI was examined by Western blotting using a polyclonal goat 
anti-human SR-A antibody (Figure 3.1B). Cell lysates from SR-AI-293T and 
pcDNA3.1A vector-transfected 293T (vec-293T) cells were subjected to 12.5% SDS-
PAGE and Western blotting.  A broad band of approximately 75 kDa (arrowed in 
Figure 3.1B), which coincided with the predicted protein mass of SR-AI, was detected 
in SR-AI-293T but not vec-293T cell lysate (Lane 1 and 2 of Figure 3.1B), establishing 
that SR-A is expressed by the transfected cells.  Having confirmed SR-AI expression, 
its cell surface expression was also examined. In this experiment, SR-AI-293T and vec-
293T cells were biotinylated to label proteins present on the cell surface and the cells 
were washed and then lysed.  Biotinylated proteins in the lysate were precipitated using 
streptavidin-agarose beads. Bound proteins were eluted in SDS-PAGE sample buffer by 
boiling and then subjected to SDS-PAGE. Western blotting was carried out using the 
anti-SR-AI antibody.  A broad band of 65-75 kDa corresponding to SR-AI in size was 
detected in biotinylated cell surface proteins of transfected but not vec-293T cells (Lane 
3 and 4 of Figure 3.1B). The gel shows that a significant fraction of SR-AI is surface-
expressed in transfected cells. Therefore, the lack of SR-AI response to LPS by 























3.3 E. coli DH5 induces SR-AI mediated NF-B activation 
The lack of LPS-induced NF-B activation in SR-AI-293T cells could be due to the 
inability of SR-AI to mediate NF-B activation or because LPS may not elicit SR-A 
signaling upon binding to the receptor.  Nonetheless, the ability of SR-A to mediate cell 
signaling, involving the tyrosine kinase Lyn and the MAP kinases, was previously 
reported (Coller and Paulnock, 2001; Miki et al., 1996). To examine whether SR-AI can 
mediate NF-kB activation, we used another known ligand for SR-AI, E. coli DH5. 
Peiser et al. (2000) has established that SR-A binds to DH5. SR-AI-293T cells were 
Figure  3.1.  LPS induces TLR4 but not SR-AI signaling for NF-B activation.  
(A) 293T cells were transfected for 24 hr with pSR-AI (SR-AI-293T) or pcDNA3.1A (vec-293T) or 
triply transfected with pTLR4, pMD2 and pCD14 as indicated. The cells were either stimulated for 
24 hr with LPS (500 ng/ml) or left unstimulated prior to measurement of NF-B-directed firefly 
luciferase expression which is normalized to CMV-directed Renilla luciferase expression taking the 
latter as 100 in each experiment. The experiments are performed in triplicates and results are 
expressed as means ± SD. The results are representative of at least three independent experiments. 
*p<0.001 compared to vector control value.  (B) SR-AI-293T and vec-293T cells were either lysed 
to prepare total lysates or surface-biotinylated followed by lysis and precipitation with streptavidin-
agarose (surface proteins). The lysates and precipitated proteins were subjected to SDS-PAGE on 
12.5% (w/v) gels (100 g/lane for total lysate) followed by Western blotting using a goat anti-
human SR-A antibody.  




stimulated with DH5 at a multiplicity of infection (MOI) of 100 for 1 hr. The cells 
were washed to remove excess bacteria and cultured for 24 hr prior to NF-B 
measurement. Unlike LPS, DH5 induces NF-B activation in both SR-AI-293T 
(p=2.89x10-6) and TLR4-293T (p=2.27x10-6) cells (Figure 3.2).  As a control, DH5 
induced insignificant NF-B activation in vec-293T cells. This is the first report of 
















3.4 LPS does not activate SR-AI-mediated NF-B signaling at high concentrations. 
The ability of DH5a but not LPS (500 ng/ml) to activate SR-AI signaling also raises that 
possibility that DH5a used at 100:1 MOI might provide more than 500 ng/ml LPS to the 
transfected cells.  Approximately 4 X 105 HEK 293T cells are expected in each well by 
Figure 3.2.  SR-AI mediates NF-kB activation by E. coli DH5.  SR-AI-293T and, as controls, vec-
293T and TLR4-293T cells were either left unstimulated or stimulated with E. coli DH5in fresh 
BCS culture media for 1 hr.  The cells were washed and further incubated for 24 hours before NF-B 
activation was determined. The experiment is performed in triplicates and results are expressed as 
means ± SD. The results are representative of at least three independent experiments. *p<0.001 





the time of stimulation and therefore 4x107 DH5 was used in each well to stimulate the 
cells.  Gram-negative bacterium contains approximately 3 mg of LPS per 1012 bacteria 
(Troelstra et al., 1999). The amount of LPS equivalent to 40x106 DH5 is estimated to 
be 120 ng, which is less than the pure LPS used to stimulate the cells (250 ng/well). 
Nevertheless, an attempt was made to stimulate the transfected cells with higher 
concentrations of LPS (1 – 100 g/ml).  As shown in Figure 3.3, a dose of LPS as high 
as 100 g/ml failed to induce NF-B in SR-AI-293T cells (p=0.49).  In contrast, NF-B 
in TLR4-293T cells was induced at all LPS doses (p<1x10-5 for all doses).  As controls, 
DH5 was able to activate NF-B in both SR-AI-293T (p=1.87x10-6) and TLR4-293T 

















Figure 3.3. LPS does not induce SR-AI-mediated NF-kB activation at high concentrations. SR-
AI-293T and TLR4-293T cells were stimulated with different concentrations of LPS, i.e. 1-100 
g/ml, for 24 hr and NF-kB activation was measured using the luciferase assay. As controls, the cells 
were either left unstimulated or stimulated with DH5for 24 hr.  The experiment is performed in 
triplicates and results are expressed as means ± SD. The results are representative of at least three 
independent experiments. *p<0.001 compared to appropriate control values as indicated in the figure.  
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3.5 Neither smooth nor rough LPS activate SR-AI-mediated NF-B signaling. 
LPS is found to exist in two major different forms (Caroff and Karibian, 2003). The 
LPS used in the present study is derived from serotype E. coli 055:B5 which has the 
archetypical LPS structure comprising of a lipid A moiety, an oligosaccharide core and 
a polysaccharide O-chain and is known as smooth LPS (SmLPS). LPS from some 
bacteria are distinct from SmLPS. For example, LPS from Salmonella minnesota lacks 
the polysaccharide O-chain and is known as rough LPS. LPS from S. minnesota strain 
Re595 (ReLPS) was then used to stimulate SR-AI in comparison with SmLPS. As 
observed in Figure 3.4, both ReLPS (p=3.97x10-9) and SmLPS (p=9.94x10-8), at 10 
g/ml, effectively induced NF-B activation in TLR4-293T cells, but neither induced 
significant NF-kB activation in SR-AI-293T cells. It shows that LPS is unable to induce 
SR-A-mediated NF-B activation even though it has been reported as a ligand for SR-A 













Figure 3.4.  Neither smooth nor rough LPS activate SR-AI-mediated NF-kB signaling.  SR-AI-
293T, TLR4-293T and vec-293T cells were stimulated with smooth or rough LPS (10 g/ml) for 24 hr 
or, as a control, left unstimulated. NF-kB activation was measured using the luciferase assay. The 
experiment is performed in triplicates and results are expressed as means ± SD. The results are 




3.6 The SR-A ligands S. aureus and LTA does not induce SR-AI-mediated NF-B 
activation  
SR-A has also been shown to bind Gram-positive bacteria such as S. aureus, and LTA 
derived from these bacteria (Dunne et al., 1994).  SR-A-/- mice were found to be more 
susceptible to S. aureus infection; macrophages in these mice manifest impaired 
phagocytosis and clearance of the bacteria (Thomas et al., 2000). We then examined 
whether S. aureus, and its LTA induce NF-B activation via SR-A.  293T cells were 
transfected with pTLR2 (100 ng/well) as a positive control because TLR2 is activated 
by S. aureus and LTA (Arbibe et al., 2000). Unlike DH5, S. aureus did not cause NF-
B activation in SR-AI-293T cells (Figure 3.5). As a control, S. aureus induced a robust 
NF-kB activation in TLR2-293T cells (p=7.28x10-7).  Compared with S. aureus, LTA 
induced less NF-B activation in TLR2-293T (p=5x10-4) but it failed to induce NF-kB 

















Figure 3.5.  S. aureus and LTA does not activate NF-kB through SR-AI.  SR-AI-293T, TLR2-
293T and vec-293T cells were either left unstimulated or stimulated with S. aureus and, as controls, 
DH5and LTA for 24 hr. NF-B activation in these cells were measured. The experiment is 
performed in triplicates and results are expressed as means ± SD. The results are representative of at 
least three independent experiments. *p<0.001 compared to appropriate control values as indicated in 
the figure.  
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3.7 The potential SR-A ligand B. subtilis induce SR-A mediated NF-B activation 
Since both S. aureus and DH5 have been reported as SR-A ligands, it was unexpected 
that DH5, but not S. aureus, induced SR-A mediated NF-B activation. Another 
Gram-positive bacteria B. subtilis has also been implicated as a ligand for SR-AI. The 
phagocytosis of the endospore-forming B. subtilis was impaired in SR-A-/- macrophages 
(Thomas et al., 2000).  We then asked whether B. subtilis induce NF-B activation in 
SR-AI-293T cells. As shown in Figure 3.6, unlike S. aureus, B. subtilis induced NF-B 
activation in SR-AI-293T (p=1.58x10-5) but not vec-293T cells. B. subtilis also 
activated NF-kB in TLR2-293T cells (p=0.0003) as previously demonstrated (Travassos 












3.8 The potential SR-A ligand M. bovis fails to induce SR-AI mediated NF-B 
activation. 
It was reported that Mycobacterium tuberculosis (M. tuberculosis) utilize SR-A to gain 
entry into human macrophages (Zimmerli et al., 1996), suggesting that it is also ligand 
*
*
Figure 3.6.   B. subtilis induces SR-AI mediated NF-kB activation.  SR-AI-293T, TLR2-293T and 
vec-293T cells were either left unstimulated or stimulated with B. subtilis and, as a control, DH5 for 
24 hr. NF-NF-B activation in these cells were measured. The experiment is performed in triplicates 
and results are expressed as means ± SD. The results are representative of at least three independent 
experiments. *p<0.001 compared to appropriate control values as indicated in the figure. 
 116
for SR-AI. We then asked whether the related mycobacterium M. bovis BCG stimulates 
NF-B activation via SR-AI. As shown in Figure 3.7, M. bovis BCG stimulated NF-B 
activation in TLR2-293T cells (p=1.44x10-7). However, it induced little NF-kB 
activation in SR-AI-293T cells, reminiscent of the data obtained for S. aureus.  It is 
unclear why some potential bacterial ligands for SR-AI elicit NF-B activation via the 
receptor while others do not.  Nevertheless, a plausible explanation is provided in the 












3.9 DH5 induces IL-8 and MCP-1 production through SR-AI stimulation. 
NF-B activation is involved in the expression of many genes including genes that 
encode pro-inflammatory cytokines and chemokines (Liang et al., 2004). NF-kB 
regulates the expression of IL-1 (Hiscott et al., 1993), TNF- (Collart et al., 1990), IL-
6 (Shimizu et al., 1990), IL-8 (Kunsch and Rosen, 1993) and monocyte chemoattractant 
protein-1 (MCP-1) (Ueda et al., 1994a).  HEK 293T cells produce IL-8 and MCP-1 in 
response to TLR ligands which involves NF-B signaling (So et al., 2006). NF-B 
*
*
Figure 3.7.  M. bovis BCG stimulates NF-kB through SR-AI. SR-AI-293T, TLR2-293T and vec-
293T cells were either left unstimulated or stimulated with M. bovis and, as a control, DH5 for 24 
hr. Luciferase activation in these cells were measured. The experiment is performed in triplicates and 
results are expressed as means ± SD. The results are representative of at least three independent 
experiments. *p<0.001 compared to appropriate control value as indicated in the figure. 
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activation in bacteria stimulated SR-AI-293T may also induce IL-8 and MCP-1 
production.   
 
To investigate this, SR-AI-293T and vec-293T cells were stimulated with DH5for 1 
hr, washed and further incubated for 24 hr. The culture media were subjected to ELISA 
for IL-8 and MCP-1. As shown in Figure 3.8A and B, DH5 induced both IL-8 
(p=2.65x10-5) and MCP-1 (p=2.21x10-5) from SR-AI-293T cells showing that SR-AI-
mediated NF-B activation is physiologically relevant, leading to protein expression. In 
contrast, vec-293T cells do not produce significant amounts of either IL-8 or MCP-1 in 












3.10 The SR-A ligand fucoidan does not activate NF-B activation via SR-AI but 
inhibits that induced by DH5
Fucoidan is a polyanionic sulfated polymer of L-fucose obtained from some species of 




Figure 3.8.  DH5 induces IL-8 and MCP-1 production through SR-AI stimulation.  SR-AI-293T 
and vec-293T cells were either left unstimulated or stimulated with DH5 for 1 hr, washed thoroughly 
and further incubated for 24 hr. Cell free supernantants were then assayed by ELISA for (A) IL-8 and 
(B) MCP-1 production. The experiment is performed in triplicates and results are expressed as means 
± SD. The results are representative of at least three independent experiments. *p<0.001 compared to 
appropriate control value as indicated in the figures. 
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competitor of oxLDL or acLDL at a concentration of 25 g/ml in receptor binding 
studies (Brown and Goldstein, 1983; Krieger and Herz, 1994). Fucoidan can also induce 
NF-B activation in murine macrophages, culminating in pro-inflammatory cytokine 
and NO production (Nakamura et al., 2006). We decided to investigate the effects of 
fucoidan in the induction of NF-B in SR-AI-293T cells.  As shown in Figure 3.9, 
fucoidan did not induce the activation of NF-B in SR-AI-293T cells even at a 
concentration of 100 g/ml in the absence of DH5.  However, fucoidan is able to 
significantly inhibit DH5-stimulated NF-B activation in SR-AI-293T cells pre-
incubated with the polysaccharide (p=4.1x10-6)(Figure 3.9).  In contrast, another 
polysaccharide mannan, that is non-anionic in nature, neither induce NF-B activation 
















Figure 3.9. Fucoidan does not activate NF-B via SR-AI but is able to inhibit DH5-induced 
NF-B activation in SR-AI-293 cells.  SR-AI-293T and vec-293T cells were either pre-incubated 
with different concentrations of fucoidan or mannan (25 or 100 g/ml) or not incubated with any 
polysaccharides for 30 min at 37oC and then either left stimulated or stimulated with DH5for 1 hr, 
washed and further incubated for 24 hr. NF-kB activation was measured using the luciferase assay. 
The experiment is performed in triplicates and results are expressed as means ± SD. The results are 
representative of at least three independent experiments. *p<0.001 compared to appropriate control 
values as indicated in the figure.  
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3.11 DH5 only activates SR-AI signaling with fresh BCS 
Experiments were thus far performed using 10% fresh BCS in the 293T cell culture 
media. However, we found that experiments described in Figure 3.2 and others could 
not be repeated using heat-inactivated BCS in later experiments. We then compared the 
ability of DH5 incubated in fresh or heat-inactivated BCS in the same experiment, to 
stimulate SR-AI-293T cells. As shown in Figure 3.10, DH5 activated NF-B in these 
cells in the presence of fresh but not heat-inactivated BCS (p=2.39x10-4). This suggests 
that a heat labile serum factor(s) is involved in SR-A-mediated cellular signaling 













3.12 DH5 activation of SR-AI requires serum opsonin activity 
The involvement of a serum factor in DH5induced, SR-AI-mediated NF-B 
activation was unexpected because SR-AI has been known to be a non-opsonic receptor 
and is able to bind or recognise its ligands directly.  In a previous study, transfected 
*
Figure 3.10.  DH5 only stimulates SR-AI mediated NF-B activation when fresh BCS is present. 
SR-AI-293T and vec-293T cells were either left unstimulated or stimulated with DH5in the presence 
of fresh BCS or heat-inactivated BCS for 1 hr, washed thoroughly and further incubated for 24 hr in the 
same BCS culture media.   NF-B activation was then determined. The experiment is performed in 
triplicates and results are expressed as means ± SD. The results are representative of at least three 
independent experiments. *p<0.001 compared to heat-inactivated BCS value. 
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CHO cells expressing SR-A was shown to bind to E. coli and other Gram-negative 
bacteria, and that the degree of binding did not differ in the presence or absence of 
serum, leading to the conclusion that these bacteria bind to SR-AI in a serum-
independent manner (Peiser et al., 2000). However, heat-inactivated serum was used in 
that study and therefore whether fresh serum would enhance bacteria binding to the 
transfected CHO cells was not assessed.    
 
Although no definitive conclusion can be drawn at this point in time as to the identity of 
the serum factor that is able to initiate DH5induced, SR-AI-mediated signaling, we 
speculate that the serum factor is an opsonin and deposits on DH5 that has been 
incubated in fresh serum. To investigate this, we modified our experimental protocol to 
include a sensitization/opsonization step in which DH5was first pre-incubate in either 
fresh or heated BCS for 30 min at 37oC (sensitization) and then washed thoroughly 
prior to use for stimulating SR-AI-293T cells in the presence of either fresh or heat-
inactivated BCS (activation). As shown in Figure 3.11, the fresh BCS-sensitized DH5 
is potent in inducing NF-B activation (p=3.56x10-5) in SR-AI-293T cells cultured in 
fresh or heat-inactivated BCS. In contrast, sensitization of DH5 with heat-inactivated 
BCS did not cause the bacteria to induce NF-B activation in SR-AI-293T cells unless 
fresh BCS was present in culture media.  In general, when fresh BCS was used during 
DH5 incubation with SR-AI-293T cells, NF-B was activated by DH5 irrespective 
of whether heated or fresh BCS was used in the sensitization step. This finding indicate 
















3.13 DH5 induces CR-3-mediated NF-B activation in the presence of fresh BCS. 
Because the serum factor is heat labile, one plausible candidate group of opsonins 
would be the complement proteins. To pursue the supposition that complements may be 
involved in SR-AI-mediated NF-B activation, it is necessary to show that DH5 is 
opsonised with complements. Complement-opsonized microbes are recognized by 
complement receptors, particularly the integrin CR3, on myeloid cells, resulting in 
enhanced phagocytosis, oxidative burst and pro-inflammatory cytokine production 
(Law, 1988; Reid, 1986). When CR3 subunits, CD11b and CD18, were co-expressed on 
293T cells (CR3-293T cells), these cells also responded to DH5 as ascertained by the 
activation of NF-B (p=3.42x10-5) (Figure 3.12A). The activation of NF-B by CR3 
following bacterial stimulation also required fresh BCS in the culture medium 
(p=6.55x10-5), which in the case of CR3 may be expected because the receptor binds to 
the complement fragment iC3b deposited on the bacterial cell surface. In addition to 
NF-B activation, DH5alsoinduced IL-8 production from both CR3-293T 
*
Figure 3.11.  DH5activation of SR-AI signaling requires serum opsonin activity. DH5 was 
pre-incubated with fresh or heat-inactivated BCS (heated BCS) (10% in DMEM) for 30 min at 37oC 
and washed with serum-free DMEM. SR-AI-293T and vec-293T cells were cultured with or without 
these bacteria in the presence of fresh or heated BCS for 1 hr, washed and further cultured for 24 hr 
prior to NF-B measurement. The experiment is performed in triplicates and results are expressed as 
means ± SD. The results are representative of at least three independent experiments. *p<0.001 
compared to appropriate control values as indicated in the figure. 
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(p=9.35x10-6) and SR-AI-293T (p=4.93x10-6) cells only in the presence of fresh serum 
(Figure 3.12B). 
 
It is important to note that this finding only suggest that complements, in particular 
iC3b, could be deposited on the cell surface of DH5 since CR3 binds the mentioned 
C3 fragment. However, CR3 can also recognise other molecules that may be present on 
the E. coli cell surface such as LPS. Consequently, the observed CR3 mediated NF-B 
activation only suggests, at best, complement activation and deposition on BCS 























Figure 3.12.  DH5a induces 
CR3-mediated NF-kB 
activation in the presence of 
fresh BCS.  (A) CR3-293T 
and vec-293T cells and (B) 
SR-AI-293T, CR3-293T and 
vec-293T were either left 
unstimulated or stimulated 
with DH5in the presence of 
fresh BCS or heat-inactivated 
BCS for 1 hr, washed 
thoroughly and further 
incubated for 24 hr in the 
same BCS culture media.  
NF-B activation was then 
determined in (A).Cell free 
supernantants were assayed 
for IL-8 in (B).  The 
experiment is performed in 
triplicates and results are 
expressed as means ± SD. 
The results are representative 
of at least three independent 
experiments. *p<0.001 
compared to heat-inactivated 
BCS or vector control values.  
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3.14 DH5stimulation of SR-AI requires bacteria opsonization with human 
complement C3. 
3.14.1 DH5 induces SR-AI-mediated NF-B activation in the presence of human 
serum 
To further examine whether SR-AI is activated by surface-deposited complement 
proteins on serum-reacted DH5, human serum was used instead of BCS because of the 
commercial availability of human complement-depleted sera and anti-complement 
antibodies.   
 
As shown in Figure 3.13A, DH5 in human serum can also induce SR-A-mediated NF-
B activation (p=4.92x10-4), although the level of activation was significantly lower 
than that in BCS (p=2.61x10-7). It was noted that there were fewer bacteria in the 
culture wells containing human serum after 1 hr incubation, possibly due to bacterial 
lysis via complement activation.  It is known that serum complement activity and hence 
the extent of bacterial lysis is species-dependent; bovine complements have been 
classified as non-hemolytic for antibody-sensitized human erythrocytes (Triglia and 
Linscott, 1980).  
 
We then conducted a time point sensitization experiment, adapted from that described in 
Figure 3.11, to examine the differential bacteriolytic effects of bovine and human 
serum. DH5 was sensitized with human serum or BCS over a period of time ranging 
from 0-30 mins at 37oC, washed with serum-free DMEM and subsequently used to 
stimulate SR-AI-293T cells in the presence of heat-inactivated BCS. Like BCS, human 
serum also sensitizes DH5 for the induction of SR-AI-mediated NF-B activation 
(Figure 3.13B).  However, there is a difference in kinetics of NF-B activation induced 
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by between DH5 pre-incubated in human serum and BCS. DH5pre-incubated in 
BCS up to 30 min induced a steady increase in NF-B activation whereas human serum 
optimally sensitizes DH5 with a 10 min pre-incubation.  Further incubation with 
human serum resulted in reduced SR-AI stimulation, which probably coincided with the 

























Figure 3.13.  DH5 induces SR-AI-mediated NF-B activation in the presence of human serum.  
(A) SR-AI-293T and vec-293T cells were either left unstimulated or stimulated with DH5 in the 
presence of fresh human serum or BCS for 1 hr, washed and further cultured for 24 hr prior to NF-B 
measurement. (B) DH5 were either left unsensitized or sensitized with 10% (v/v) fresh human serum 
or BCS for 2.5-30 min, washed with serum-free DMEM and used to stimulate SR-AI-293T cells 
cultured in the presence of heated BCS.  After 1 hr stimulation, the cells were washed and further 
cultured for 24 hr prior to NF-B determination.  These experiments are performed in triplicates and 
results are expressed as means ± SD. The results are representative of at least three independent 
experiments. *p<0.001 compared to appropriate control values as indicated in figures. 
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3.14.2 DH5 is opsonized with C3 complements in fresh human serum. 
Similar to BCS (Section 3.13), there is a need to establish that DH5 is opsonized with 
complement components, particularly complement C3, when incubated in human serum 
before we can proceed further to investigate the possibility that SR-AI may interact with 
human complement components.  To achieve this, we took advantage of the commercial 
availability of anti-human C3 antibodies and performed a binding assay that would be 
definitive in establishing the deposition of C3 fragments on the bacterial cell surface 
rather than CR3-293T cells.  In this assay, GFP-DH5sensitized in human serum, or as 
controls, heat-inactivated and C3-depleted human sera are incubated in wells of a 96-
well plate coated with goat anti-human C3 antibody.  The wells are then washed to 
remove unbound bacteria and viewed under an inverted fluorescence microscope.  As 
shown in Figure 3.14A, only DH5 sensitized in fresh human serum but not heat-
inactivated or C3-depleted human sera are able to bind to the anti-C3 antibody coated 
cells, indicating that the bacteria were opsonized with human C3 fragments.    
 
In addition to C3 fragments, we also investigated whether other complement 
components such as C1q is also deposited on DH5. The presence of C1q on the 
bacterial surface may provide some hint as to the complement pathway(s) activated; 
C1q is involved in the classical pathway of complement activation. As shown in Figure 
3.14B, GFP-DH5sensitized in fresh, heat-inactivated or C3 depleted serum did not 
bind to goat-anti human C1q coated wells, suggesting that C1q is not deposited on the 
bacterial surface. As a control, none of the serum sensitized bacteria also bound to goat-






















































Figure 3.14 DH5 is opsonized with C3 
complements in fresh human serum.  (A) 
GFP-DH5 is sensitized in fresh, heat-
inactivated or C3-depleted human serum for 8 
mins at 37oC and washed thoroughly. These 
bacteria were then incubated for 30 min at 
4oC in wells of a 96 well ELISA plate that 
has been coated with goat-anti human C3 
overnight  at 4oC and blocked with 1X PBS + 
1% BSA for 1 hr at room temperature. 
Following incubation, the wells were then 
washed and the bound bacteria viewed using 
an Olympus 1X81 Inverted fluorescence 
microscope.  The experiment was performed 
in triplicates and photographs taken are 
representative of the three wells. (B) GFP-
DH5were sensitized with different human 
sera as in (A) and then incubated in wells 
coated with either goat anti-human C1q or 
goat anti-human SR-A.  The wells were 
washed and the bound bacteria analyzed in a 


























3.14.3 SR-AI is activated by DH5-bound human complement C3 
To examine whether SR-AI is activated by surface-deposited complement proteins on 
human serum-reacted DH5, we pre-incubated DH5 for 8 min in normal or 
commercially available complement-depleted human serum prior to SR-AI-293T cell 
stimulation.  As expected, normal serum enabled DH5 to stimulate NF-B activation 
in SR-AI-293T cells (p=2.03x10-6)(Figure 3.15A), but C3-depleted serum lacked this 
property (p=1.15x10-5). In contrast, C5-depleted (p=0.39) and C7-depleted (p=0.07) 
serum were as potent as normal serum in enabling DH5 stimulation of SR-AI 
signaling. In this experiment, the low response to BCS-sensitized DH5, as compared 
with earlier experiments (e.g. Figure 3.2), could be attributed to the shortened 
sensitization period (8 min).  As shown in Figure 3.13B, it takes approximately 15 min 
for BCS to effect significant sensitization of the bacteria.  In addition to NF-B 
activation, DH5 pre-incubated with C3-depleted serum also failed to induce IL-8 
production from SR-AI-293T cells (p=5.28x10-5) (Figure 3.15B). These results suggest 
a functional role for bacterial cell surface-bound C3 activation products in eliciting SR-
AI signaling. 
 
Involvement of C3 fragments in SR-AI signaling was further evaluated using anti-
complement polyclonal antibodies. DH5 was pre-incubated with human serum for 8 
min, washed and further incubated with 100 g/ml of goat anti-C3 or anti-C1q 
antibodies for 15 min on ice prior to SR-AI-293T cell stimulation. As shown in Figure 
3.16A, the anti-C3 antibodies significantly blocked DH5 stimulation of SR-AI 
mediated NF-B activation (p=1.53x10-5), whereas the anti-C1q antibodies had no 
effect (p=0.16). Similarly, the anti-C3 (p=0.001) but not anti-C1q (p=0.67) antibodies 
also blocked DH5 induction of IL-8 from SR-AI-293T cells (Figure 3.16B). 
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Collectively, these findings indicate that DH5-bound C3 fragment(s) play a dominant 
role in SR-AI mediated bacterial recognition and activation of downstream signaling 





























Figure 3.15.  DH5induced SR-AI-mediated signaling is reduced in the absence of complement 
C3 in serumE coli DH5 were pre-incubated with 10% (v/v) fresh, C3-depleted, C5-depleted, C7-
depleted, or heat-inactivated human sera for 8 min, washed and used to stimulate SR-AI-293T and vec-
293T cells in the presence of heated BCS.  As controls, DH5 were also pre-incubated with fresh BCS 
or heated BCS and used to stimulate the transfected cells.  (A) NF-B activation and (B) IL-8 
production were determined.  These experiments are performed in triplicates and results are expressed 
as means ± SD. The results are representative of at least three independent experiments. *p<0.001 



















3.15 Involvement of the collageneous domain of SR-AI in the signaling response to 
opsonized DH5. 
3.15.1  SR-AI response to opsonized DH5 does not involve the postulated ligand 
binding region of receptor – the lysine cluster at the C-terminal end of the 
collageneous domain. 
To further investigate the possibility that opsonic C3 fragment(s) interact with SR-AI, 
we decided to investigate the domain(s) of SR-AI that is responsible for the association. 
SR-AI and SR-AII have been shown to bind similar polyanionic ligands and this 
Figure 3.16.  SR-AI-mediated 
signaling in response to serum 
opsonized DH5 is reduced by 
polyclonal anti-C3 antibodies.  
DH5 were pre-incubated with 
10% (v/v) human serum for 8 
min, washed , and further 
incubated with either goat anti-C3 
or anti-C1q antibodies.  The 
bacteria were used to stimulate 
SR-AI-293T and vec-293T cells 
in the presence of heated BCS.  
As controls, DH5 were also pre-
incubated with fresh BCS or 
heated BCS and used to stimulate 
the transfected cells.  (A) NF-B 
activation and (B) IL-8 
production were determined.  
These experiments are performed 
in triplicates and results are 
expressed as means ± SD. The 
results are representative of at 
least three independent 
experiments. *p<0.001 compared 
to appropriate control values as 







involves positively-charged lysine residues, the lysine cluster, present at the C-terminal 
segment of the collageneous domain.  In human SR-A, the lysine cluster comprises of 
lysine residues at position 332 (K332), position 335 (K335) and position 338 (K338) 
(Acton et al., 1993; Doi et al., 1993). It has been reported that the C3g fragment, a late 
breakdown product of enzyme-catalyzed C3 degradation, is highly anionic (Lachmann 
et al., 1982).  It is plausible that such a C3 fragment could interact with the lysine 
cluster of the collageneous domain in SR-AI. 
 
By site-directed mutagenesis, we mutated the three lysine residues of the cluster into 
alanine, singly or in combinations, to generate 7 different SR-AI mutants.  These mutant 
receptors, expressed on 293T cells, were assessed whether they activate NF-B in 
response to DH5.  As shown in Figure 3.17, all the mutants appear to be able to 
effectively activate NF-B following DH5stimulation.  This finding suggests that the 
three lysine residues forming the postulated ligand-binding lysine cluster do not play a 











Figure 3.17.  The lysine 
cluster in the collageneous 
domain of SR-AI is not 
involved in activation of 
NF-B in response to 
opsonized DH5pSR-AI 
and the various specified 
lysine cluster mutant vectors 
were transfected in 293T 
cells.  The cells were either 
left unstimulated or 
stimulated with DH5 in the 
presence of BCS for 1 hr, 
washed and further incubated 
for 24 hr prior to NF-B 
determination. These 
experiments are performed in 
triplicates and results are 
expressed as means ± SD. 
The results are representative 
of at least three independent 
experiments. 
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3.15.2 Other basic residues in the proximal region of the collageneous domain are 
also not required for SR-AI signaling induced by opsonized DH5. 
Although Doi et.al (1993) established that the lysine cluster of the collageneous domain 
is critical for acLDL binding and uptake, recent studies reported that the binding of 
acLDL by SR-AI/II could also be influenced by other basic amino acid residues within 
the collageneous domain proximal to the lysine cluster (Andersson and Freeman, 1998).  
Two lysine (K281 and K305) and four arginine (R284, R308, R317 and R325) residues, 
besides the lysine cluster, are present in the collageneous domain of human SR-A.  We 
mutated these basic residues to alanine via site-directed mutagenesis to ascertain their 
involvement in DH5 induced NF-B activation.  In addition to these amino acid 
substitution mutants, a deletion mutant was also generated in which the entire 
collageneous domain of SR-AI was removed (SR-AI-dColl). As shown in Figure 3.18A, 
all the substitution mutants did not significantly reduced NF-B activation.  However, 
deletion of the collageneous domain (SR-AI-dColl) did significantly decrease SR-AI 
signaling activity in response to C3-opsonized DH5(p=2.73x10-6)

The cell surface expression of wild type and all mutant receptors were confirmed by 
surface-biotinylation followed by Western blotting (Figure 3.18B). We could not use 
the polyclonal goat anti human SR-A antibody, described in Figure 3.1, to detect some 
of the mutants because the mutations fall within the epitope recognized by the antibody. 
The antibody recognizes the sequence RPGNSGPKGQKGEKGSGN (amino acid 325-
342 of human SR-AI) which includes the lysine cluster. Consequently, vectors for wild 
type (pSR-AI-MH) and all mutant receptors were constructed to include a C-terminal 
Myc and His tags, which allow detection of expression with a monoclonal anti-Myc 
antibody. These results collectively suggest that, although the collageneous domain is 
 132
involved in the recognition of C3-opsonized DH5the postulated lysine cluster 
























Figure 3.18.  Basic residues proximal to lysine cluster in the collageneous domain of SR-AI are 
not involved in activation of NF-B in response to opsonized DH5(A) pSR-AI and the various 
specified collageneous domain mutant vectors were transfected in 293T cells.  The cells were either 
left unstimulated or stimulated with DH5 in the presence of BCS for 1 hr, washed and further 
incubated for 24 hr prior to NF-B determination. These experiments are performed in triplicates 
and results are expressed as means ± SD. The results are representative of at least three independent 
experiments. *p<0.001 compared to appropriate control values as indicated in figures. (B) SR-AI-
MH-293T cells and various transfected cells expressing specified collageneous domain mutants with 
Myc/His tag were surface-biotinylated, lysed and precipitation with streptavidin-agarose. The 
precipitated proteins were subjected to SDS-PAGE on 12.5% (w/v) gels followed by Western 






3.16 The SRCR domain of SR-AI is required for its recognition of opsonized 
DH5. 
The findings of the present study demonstrate that the lysine cluster, the postulated 
ligand binding site of SR-A, is not involved in NF-B activation and IL-8 production 
induced by C3-opsonized DH5 The association between opsonic C3 fragment(s) and 
SR-AI clearly differ from that of acLDL and possibly does not rely on the positive-
negative charge interactions as previously postulated. It is possible that other domains, 
in addition to the collageneous domain, may be involved in SR-AI signaling.  
 
The class A SR, MARCO, which is structurally similar to SR-A, was reported to bind 
bind FITC-labeled heat-killed E coli and S. aureus through its SRCR rather than 
collageneous domain (Brannstrom et al., 2002; Elomaa et al., 1998). This prompted us 
to evaluate the SR-AI SRCR domain in the recognition of C3-opsonized DH5. We 
generated a SR-AI mutant in which the entire SRCR domain is deleted (SR-AI-dCys). 
As shown in Figure 3.19, NF-B activation is completely abolished in SR-AI-dCys-
293T cells stimulated with DH5(p=1.05x10-5).  SR-AI-dCys should structurally 
resemble the natural SR-A isoform SR-AII, which also lacks the SRCR domain 
(Freeman et al., 1990; Kodama et al., 1990).  However, the SR-AII has a short C-
terminal domain that has little sequence identity between species (Matsumoto et al., 
1990). Human SR-AII has a 17 residue C terminal region, comparatively longer than the 
six-residue C-terminal regions of the bovine or murine receptors (Matsumoto et al., 
1990; Naito et al., 1992).  It is possible, although unlikely, that the 17 residues at the C-
terminal end may account for SR-AII bacterial recognition and downstream signaling. 
As shown in Figure 3.20A, SR-AI-293T cells but not cells that are transfected to 
express SR-AII (SR-AII-293T cells) (p=1.05x10-6) responded to C3-opsonized DH5.  
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In addition to SR-AI-MH, vectors for SR-AII (SR-AII-MH) and SR-AI-dCys (SR-AI-
dCys-MH) with a C-terminal Myc and His tags were also generated to validate cell 
surface expression of these receptors.  The cell surface expression of SR-AI-MH and 
SR-AII-MH were verified by surface biotinylation followed by Western blotting (Figure 
3.20B), and also by flow cytometry (Figure 3.20C). The fusion of the Myc-His tags to 
the C-terminus of SR-AI, SR-AII or SR-AI-dCys does not affect the response of the 
receptors to DH5 (Figure 3.20A).  The findings of the experiment suggest that the 
SRCR domain of SR-AI, like the collageneous domain, is required to facilitate the 


















Figure 3.19. Deletion of the SRCR domain of SR-AI abolish NF-B activation induced by C3-
opsonized DH5SR-AI-293T, SR-AI-dCys-293T and vec-293T cells were either left 
unstimulated or stimulated with DH5in the presence of fresh BCS for 1 hr, washed thoroughly 
and further incubated for 24 hr. NF-B activation was then determined.  The experiment is 
performed in triplicates and results are expressed as means ± SD. The results are representative of 
at least three independent experiments. *p<0.001 compared to appropriate control values as 





























Figure 3.20.  The natural SR-AII isoform does not mediate NF-B activation in response to C3-
opsonized DH5(A) SR-AI-293T, SR-AII-293T, SR-AI-dCys-293T and vec-293T were either left 
unstimulated or stimulated with DH5in the presence of fresh BCS for 1 hr, washed thoroughly and 
further incubated for 24 hr. NF-B activation was then determined.  The experiment is performed in 
triplicates and results are expressed as means ± SD. The results are representative of at least three 
independent experiments. *p<0.001 compared to appropriate control values as indicated in figures. (B)  
SR-AI-MH-293T, SR-AII-MH-293T and vec-293T cells were surface-biotinylated, lysed and 
precipitation with streptavidin-agarose. The precipitated proteins were subjected to SDS-PAGE on 
12.5% (w/v) gels followed by Western blotting using a mouse anti-Myc antibody. (C) SR-AI-MH-293T 
and SR-AII-MH-293T were stained with a mouse anti-Myc antibody at 1g/ml, washed and stained 
with rhodamine-conjugated goat anti-mouse IgG at ratio of 1:50. The cells were then subjected to flow 
cytometric analysis. The isotype control use was mouse IgG1.    
B C
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To further investigate the involvement of the SRCR domain in C3-opsonized DH5 
recognition and signaling, we examine specific amino acid residues in the domain that 
might play a crucial role in these processes.  It is interesting to note that a member of 
the group A SRCR domain superfamily, complement factor I (CFI), interacts with C3 
fragments (Sarrias et al., 2004).  Although there is no evidence to suggest that the 
SRCR domain in CFI is involved in binding to C3 fragments, it is intriguing that the 
SRCR domain of SR-AI appears to interact with C3-opsonized DH5. The bacteria 
binding site of MARCO was mapped to an 11-residue segment on its SRCR domain 
(RGRAEVYYSGT); two arginine residues (Arg432 and Arg434) in this segment 
forming a RXR motif was crucial for bacterial interaction (Brannstrom et al., 2002). By 
comparing this 11-residue segment of human MARCO with the corresponding regions 
in the SRCR sequence of human SR-AI and CFI, two residues (G361 and E364 in 
human SR-AI) were found to be conserved in all three proteins (Figure 3.21A). 
Mutation of G361 into proline residue abolished SR-AI response to C3-opsonized 
DH5(p=2.46x10-6) (Figure 3.21B). Replacing the smaller glycine by a more bulky 
proline would introduce rigid “kinks” in the polypeptide chain because the large, cyclic 
structure of the proline side chain restricts rotation of the polypeptide backbone (limited 
phi and psi torsion angles) while the hydrogen atom forming the side chain of glycine 
allows more rotational flexibility.  NF-B activation was also abolished when 
negatively-charged glutamic acid E364 was mutated into a non-polar alanine 
(p=1.96x10-6). These findings contrast with the unaltered SR-AI response to C3-
opsonized DH5 when the lysine and arginine residues in the collageneous domain 
were mutated.  The surface expressions of the SRCR mutants were confirmed by 





























Figure 3.21. The SRCR domain of SR-AI is required for its recognition of opsonized DH5.  (A) 
Alignment of the SRCR sequences of SR-AI, MARCO and CFI.  The suggested 11-residue ligand 
binding region of MARCO and equivalent sequences in the SRCR domains of SR-AI and CFI are 
highlighted by a red rectangle. The conserved cysteine residues of the domain are highlighted by blue 
rectangles. Note that the fifth cysteine residue in the sequence of CFI is not conserved.  Residues G361 
and E364 (red arrows), which are completely conserved in all three sequences, were mutated into P361 
and A364 in SR-AI respectively.  (B) pSR-AI and the various specified SRCR domain mutant vectors 
were transfected in 293T cells.  The cells were either left unstimulated or stimulated with DH5 in the 
presence of BCS for 1 hr, washed and further incubated for 24 hr prior to NF-B determination. These 
experiments are performed in triplicates and results are expressed as means ± SD. The results are 
representative of at least three independent experiments. *p<0.001 compared to appropriate control 
values as indicated in figures. (C) SR-AI-MH-293T cells and various transfected cells expressing 
specified SRCR domain mutants with Myc/His tag were surface-biotinylated, lysed and precipitation 
with streptavidin-agarose. The precipitated proteins were subjected to SDS-PAGE on 12.5% (w/v) gels 




3.17 Purified SR-AI and SRCR bind serum-opsonized E. coli DH5 
Although SR-AI confers on 293T cells the ability to bind more avidly to serum-
opsonized DH5, whether SR-AI directly binds these opsonized bacteria cannot be 
concluded based on the cell transfection experiments. Hence, the extracellular domain 
of SR-AI as a soluble protein (sSR-AI) was expressed using the psSR-AI-MH vector. 
Purified sSR-AI was immobilized on coverslips to test for binding of serum-opsonized 
DH5-GFP. The SRCR domain was similarly expressed (sSRCR) using the psSRCR-
MH vector and purified sSRCR was immobilized in the same manner. As shown in 
Figure 3.22A, the purified sSR-AI and sSRCR migrated as proteins of approx. 70 and 
20 kDa, respectively. When DH5-GFP was pre-incubated with fresh BCS, the bacteria 
showed prominent binding to immobilized sSR-AI but little binding to BSA-coated 
wells (Figure 3.22B). The sSRCR-coated wells bound fewer bacteria than sSR-AI-
coated wells, but they bound significantly more bacteria than BSA-coated wells. If 
DH5-GFP was pre-incubated with heat-inactivated BCS, wells coated with sSR-AI, 
sSRCR or BSA all showed low background binding (Figure 3.22B). However, these 
bacteria bound prominently to immobilized human mannan-binding lectin (MBL), a 
human serum C-type lectin which is known to bind directly to carbohydrate structures 
on microorganisms without the need of prior serum sensitization (Takahashi et al., 
2006). From these results, it can be concluded that SR-AI directly binds serum-



























3.18 Purified SR-AI binds iC3b but not C3 or C3b 
The observation that DH5 binding to immobilized sSR-AI or sSRCR requires its pre-
incubation with fresh BCS was indicative of SR-AI binding to DH5-bound opsonic C3 
fragments (Figure 3.22B). Activated C3 can deposit on DH5 in the form of C3b which 
is further cleaved into iC3b and C3d (Reid, 1986). To determine which C3 fragments 
Figure 3.22.  DH5binds to purified sSR-AI and SRCR.  (A) Purification of soluble SR-AI (sSR-
AI) and SRCR domain (SRCR).  293T cells were transfected with the psSR-AI-MH or pSRCR-MH 
vector in T75 flasks and were cultured in serum-free DMEM supplemented with BSA (100 g/ml). 
After 48 hr, the conditioned media (60 ml) were filtered and mixed with Ni-NTA-agarose (0.5 ml) and 
bound sSR-AI and SRCR proteins were eluted with imidazole collecting 10 x 150 l fractions. 
Fractions 2-5 from each elution were subjected to SDS-PAGE on 12.5% gels. Proteins were stained 
with Coomassie blue. (B) Coverslips were coated overnight with purified sSR-AI and SRCR or, as 
controls, with BSA or human MBL at 50 g/ml. After washing, the coverslips were incubated in 24-
well plates with DH5-GFP which had been pre-reacted with fresh or heat-inactivated BCS. After 
washing, bound DH5-GFP was fixed with 4% formaldehyde and analyzed using a BX51 Olympus 





SR-AI may bind, C3 was purified from human plasma and cleaved to generate the C3b 
fragment and the iC3b fragment was generated from human serum using thiol-
Sepharose (Figure 3.23A). When sSR-AI was immobilized and then incubated with C3, 
C3b or iC3b, only iC3b showed prominent binding to SR-AI as detected with an anti-C3 
polyclonal antibody (Figure 3.23B). In this experiment, all proteins were used at 10 
g/ml. Little binding to immobilized BSA was observed with C3, C3b or iC3b. These 
results show preferential SR-AI binding of iC3b.  
 
iC3b interaction with sSR-AI was also examined using a reversed binding assay in 
which iC3b was immobilized to incubate with sSR-AI. Bound SR-AI was detected 
using an anti-Myc monoclonal antibody. Binding of sSR-AI to immobilized iC3b was 
not detectable when sSR-AI was used at 10 g/ml (data not shown). However, binding 
was detected when sSR-AI concentration was increased to 100 g/ml (Figure 3.22C). In 
this experiment, binding between SRCR and iC3b was also examined but it was not 
detectable irrespective whether SRCR or iC3b was immobilized and whether SRCR was 
used at 10 or 100 g/ml (Figure 3.23C). This is in contrast to sSRCR binding of serum-
opsonized DH5 (Figure 3.22B). SRCR is expected to be presented as clusters of three 
in native SR-AI and recombinant sSR-AI at the ends of the collagen triple helices. In 
isolation, sSRCR may depolymerize and exhibit lower affinity for ligands. Nonetheless, 
the results collectively suggest SR-AI as an iC3b-specific novel complement receptor 




















































Figure 3.23.  SR-AI selectively binds iC3b.  (A) Purification of C3 and its fragments from human 
plasma.  C3 was purified from human plasma and cleaved into C3b using trypsin. iC3b was generated by 
incubation of human plasma with thiol-Sepharose and purified as previously reported.  Purified C3 and 
its C3b and iC3b fragments were subjected to SDS-PAGE on 10% (w/v) gels and stained with Coomassie 
blue. (B) 96-well plates were coated overnight at 4oC with sSR-AI or BSA at 10 g/ml. The plates were 
washed and blocked with PBS-T and then incubated with the specified binding partner proteins (C3, C3b, 
iC3b or BSA) at 10 g/ml in TBS-T. Bound C3 or its fragments were detected using a goat anti-human 
C3 antibody. As controls, plate-immobilized sSR-AI was directly detected using a mouse anti-Myc 
antibody. (C) C3, C3b and iC3b were coated at 10 g/ml in 96-well plates. sSR-AI or SRCR were 
incubated with the plates at 100 g/ml. At 10 g/ml, neither sSR-AI and SRCR showed detectable 
binding to immobilized iC3b, C3b and C3 (data not shown). As a control, immobilized sSR-AI showed 
prominent binding to soluble iC3b. When SRCR was coated, iC3b binding was not detected. These 






The following conclusions are derived from these results: 
1) LPS and LTA, both proposed SR-A ligands, do not induce SR-AI to activate NF-
B. However, both LPS and LTA are able to elicit NF-B activation via TLR4 
and TLR2 respectively. In contrast, E coli DH5 is able to induce SR-AI-
mediated NF-B activation and chemokine (IL-8 and MCP-1) production. 
 
2) The ability of SR-AI to recognize and effect downstream signaling in response to 
DH5 is dependent on complement C3 fragments that have deposited on the 
bacterial cell surface.  Recombinant soluble SR-AI receptor is able to bind to 
opsonized DH5 and iC3b fragments. 
 
3) Only the SR-A isoform SR-AI, and not SR-AII, is able to induce NF-B 
activation and chemokine production in response to opsonized DH5.  The SRCR 
domain present only in SR-AI, and not the lysine cluster or other basic residues in 
collageneous domain that was postulated to ligand-binding region of the receptor, 
is involved in the recognition of opsonized DH5 and downstream signaling. 
However, it must be noted that the collageneous domain does play a role in this 







Chapter 4 Characterization of the cytoplasmic domain of SR-AI in 
DH5-induced intracellular signaling of receptor. 
4.1 Overview. 
In this study, we have also established that SR-AI can mediate NF-B activation in 
response to iC3b-opsonised DH5Previous studies have also demonstrated that certain 
SR-A ligands such as mal-BSA (Alford et al., 1998; Misra et al., 1996), poly (I) (Campa 
et al., 2005) and fucoidan (Nakamura et al., 2006) can elicit NF-B activation in murine 
peritoneal macrophages or macrophage-like cell lines such as RAW264.7 and J774A.1 
cells, culminating in the induction of inflammatory cytokines like TNF- and IL-1, and 
in nitric oxide (NO) production. Nakamura et.al (2006) reported that fucoidan activated 
inducible nitric oxide synthase (iNOS) and consequently induced NO production in 
RAW 264.7 macrophages via NF-B and p38 MAP kinase-dependent signaling 
pathways. Fucoidan-induced NO production by peritoneal macrophages from SR-A-/- 
mice were observed to be significantly lower than wild type mice (Nakamura et al., 
2006).  Another SR-A ligand, poly (I) was also shown to induce NO and TNF- 
production in RAW 264.7 macrophages via NF-B and AP-1 activation (Campa et al., 
2005).   
 
The above-mentioned findings do suggest that activated SR-A mediates intracellular 
signaling promoting a pro-inflammatory immune response.  However, it appears that 
not all SR-A ligands elicit similar signaling responses upon binding to SR-A. Nakamura 
et.al (2006) reported that some SR-A ligands such as oxLDL, acLDL and dextran 
sulphate did not induce NO production in the RAW 264.7 macrophages. Fucoidan but 
not oxLDL was able to induce IL-1 secretion in murine J774A.1 macrophages (Hsu et 
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al., 2001), while poly (I) but not dextran sulphate induce TNF- and NO production in 
RAW 264.7 macrophages (Campa et al., 2005). In addition, SR-A ligands that do 
transduce intracellular signals also appear to differ in terms of the pro-inflammatory 
genes they induce to express. Misra et.al (1996) reported that mal-BSA stimulation of 
macrophages initiated phosphatidylinositol-4,5-bisphosphate (PIP2) hydrolysis, 
triggered calcium ion (Ca2+) spikes, activated phospholipase A2 and facilitated nuclear 
localization of NF-B en route to the induction of TNF-production. However, mal-
BSA cannot induce NO production on its own (Nakamura et al., 2006), and does so 
synergistically in the presence of IFN-(Alford et al., 1998). In contrast, poly (I) is able 
to independently induce both TNF- and NO production (Campa et al., 2005).   
 
An interesting finding was noted for one SR-A ligand, oxLDL, in terms of NF-B 
activation. OxLDL pretreatment of murine macrophages prior to stimulation with mal-
BSA or LPS (another SR-A ligand) was found to, unexpectedly, suppress rather than 
synergistically promote NF-B activation and TNF- production (Misra et al., 1996; 
Muroya et al., 2003). Intriguingly, oxLDL was shown to suppress mal-BSA induced 
NF-B activation and TNF- production via a pertussis toxin-sensitive signaling 
pathway that also, like mal-BSA, involve PIP2 hydrolysis and Ca2+ spiking (Misra et al., 
1996).  It is difficult to reconcile these findings in that two ligands, mal-BSA and 
oxLDL, engaging the same receptor could elicit opposing outcomes. It was reported that 
long-term incubation of 24 hours with oxLDL suppresses LPS-induced NF-B 
activation and reduced expression of TNF-and IL-1 in murine macrophages 
(Hamilton et al., 1998; Misra et al., 1996), and also in human monocyte-derived 
macrophages (Ohlsson et al., 1996) and THP-1 monocytic cells (Brand et al., 1997). 
However, short-term oxLDL incubation of 1-4 hours conversely activates NF-B and 
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induces IL-8 expression in THP-1 cells (Brand et al., 1997).  This perplexing 
bifunctional effects of oxLDL is not unique amongst SR-A ligands as fucoidan has also 
been reported to increase the basal expression level of iNOS and NO production in 
RAW 264.7 cells but peculiarly inhibit ROS generation in cells stimulated with LPS 
(Yang et al., 2006). 
 
It is currently unclear why some SR-A ligands are able to transduce intracellular signals 
leading to an inflammatory response while others do not. Equally perplexing is why the 
signaling pathway(s) initiated by one ligand could oppose another in relation to 
transcription factor activation and pro-inflammatory cytokine production.  One possible 
reason could be that most if not all of the above-mentioned molecules are not 
exclusively ligands of SR-A. Other receptors besides SR-A, particularly other scavenger 
receptors, that are present on macrophages may also interact with these molecules and 
possibly effect downstream signaling pathways that culminate in NF-B activation.  For 
instance, the interaction of oxLDL with the scavenger receptor LOX-1, that is present 
on monocyte-derived macrophages have been verified (Yoshida et al., 1998), also 
resulted in NF-B activation and enhanced intracellular production of reactive oxygen 
species (ROS) in human endothelial cells (Cominacini et al., 2000; Matsunaga et al., 
2003). Campa et.al (2005) also reported that treatment of poly(I)-stimulated murine 
macrophages with the SR-A antibody 2F8 did not reduce or abolish TNF- and NO 
production by these cells, indicating that other SRs or PRRs may be responsible for cell  
activation.  In this study, we attempt to investigate the signaling pathway(s) mediated by 
SR-AI by exogeneous expression of SR-A in 293T cells. This allows us to investigate 
the signaling properties of the receptor in “isolation”, as was with the case in ligand 
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binding, without interfering “cross-talk” from a myriad of other PRRs present on 
immune cells.  
  
4.2 The cytoplasmic tail of SR-A is not involved in DH5 induced NF-B 
activation.    
In this study, we have demonstrated that SR-AI mediated NF-B activation and 
chemokine production is dependent on the opsonization of DH5 with iC3b 
complement fragments.  We next examine the downstream signaling events initiated by 
interaction between the iC3b-opsonized DH5 and SR-AI. 
 
The cytoplasmic tail of SR-A has been reported to be important in cell adhesion and 
acLDL endocytosis (Kosswig et al., 2003).  Deletion of the first 49 residues of the 
domain in murine SR-A, which correspond to the first 45 residues of human SR-A, 
resulted in failure to endocytose acLDL.  It was postulated that internalization signal 
motifs or phosphorylation sites within that region of the domain are responsible for 
endocytic processes.  We proceeded to examine whether this region is also responsible 
for effecting SR-AI signaling in response to DH5 SR-AI deletion mutant (SR-AI-
d145) which has the proximal 45 residues in the cytoplasmic domain removed was 
expressed in 293T cells.  As shown in Figure 4.1, both SR-AI and SR-AI-d145 are 
able activate NF-B in response to DH5suggesting that that region in the domain is 
not involved in SR-AI mediated NF-B activation.     
 
The cytoplasmic domain of SR-A contains serine and threonine residues that could be 
potentially phosphorylated to initiate the recruitment of SH2 domain-containing 
signaling molecules.  Three of these residues (Ser21, Thr30 and Ser49 in murine SR-A or 
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Ser20, Thr29 and Ser48 in human SR-A) are conserved among species studied.  Ser20 and 
Thr29 do not appear to play a role in SR-A mediated NF-B activation because these 
residues were within the region deleted in SR-AI d145.  We mutated the remaining 
Ser48 (SR-AI-S48A) to alanine to assess whether this residue is involved in SR-AI 
signaling.  In addition, we also generated another mutant which has both residues 1 to 
45 removed and Ser48 substituted to alanine (SR-AI-d145-S48A) to remove all three 
Ser/Thr residues.  As shown in Figure 4.1, both SR-AI-S48A and SR-AI-d145-S48A 
are able to activate NF-B in response to DH5.   
 
The cytoplasmic domain of human SR-A is 52 residues long. We cannot rule out the 
possibility that the remaining 6 residues may play a role in SR-AI mediated NF-B 
activation. In order to assess this possibility, we must remove the cytoplasmic domain 
completely, which was previously reported to significantly reduced receptor expression 
(Kosswig et al., 2003).  It is possible that the reduced receptor expression could result 
from failure of the mutant receptor to orientate correctly during translocation through 
the cell membrane. It has been reported that the distribution of positively charged 
residues may be a major determinant of the transmembrane topology of integral 
membrane protein, known as the “positive-inside” rule (von Heijne, 1989). According 
to the rule, the intracellular stretches of residues that precede the transmembrane 
domain of integral membrane proteins have more positively charged arginine or lysine 
residues compared to those flank the transmembrane domain extracellularly.  There is a 
stretch of 4 lysine residues in the cytoplasmic domain of human SR-A close to the 
transmembrane domain as opposed to only 2 lysine residues in the extracellular spacer 
domain.  By removing the entire cytoplasmic domain, the distribution of charges would 
be altered. We generated a mutant SR-AI construct in which the entire cytoplasmic 
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domain is replaced by a stretch of 3 lysine residues and an alanine spacer (KKKA) that 
preceded the first residue of the transmembrane domain (SR-AI-dCytoKKK).  As 
shown in Figure 4.1, SR-AI-dCytoKKK is able to activate NF-B in response to 
DH5to levels comparable with SR-AI, clearly indicating that the mutant receptor is 
significantly expressed.   
 
The present findings suggest that the cytoplasmic tail of SR-AI does not play a role in 
mediating downstream signaling and NF-B activation although previous studies have 
shown that it is involved in endocytic functions of the receptor. It is clear from the 
present findings that SR-AI must recruit a co-receptor to effect signaling, at least in 















Figure 4.1. Involvement of the cytoplasmic domain of SR-AI in NF-B activation following DH5 
stimulation.  293T cells are transfected with SR-AI or one of the cytoplasmic domain mutants as 
indicated. The plasmid pcDNA3.1 was transfected into 293T cells as a control (vector). The cells were 
either left unstimulated or stimulated with DH5 in fresh BCS culture media for 1 hr, washed 
thoroughly and further incubated for 24 hrs prior to measurement of NF-B.  The experiment is 
performed in triplicates and results are expressed as means ± SD. The results are representative of at 
least three independent experiments. 
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4.3 DH5 induced, SR-AI mediated NF-B activation is not dependent of the 
adaptor molecule MyD88. 
 
To provide some clues as to the nature of the co-receptor, we decided to examine 
potential signaling molecules that may be involved in this novel SR-AI mediated but co-
receptor dependent NF-B activation and chemokine production in response to DH5.   
 
The present study has demonstrated that both SR-AI-293T and TLR4-293T are able to 
activate NF-B in response to DH5. However, the receptors interact with different 
molecules present on the bacteria because only TLR4-293T respond to LPS while SR-
AI binds to iC3b deposited on DH5.  It is therefore unlikely that the co-receptor is 
TLR4, although other TLRs, such as TLR5, cannot be ruled out.  TLR5 has been 
reported to be present on the basal surface of polarized intestinal epithelial cells 
(Gewirtz et al., 2001) and airway epithelial cells (Zhang et al., 2005). It is possible that 
293T cells, of epithelial origin, also express TLR5 or other TLRs. The signaling events 
initiated by activated TLRs have been well-studied and the activation of NF-B 
involves the MyD88-dependent pathway (Krishnan et al., 2007; Watters et al., 2007). 
We ask whether NF-B activation by SR-AI-293T cells in response to DH5also 
involve MyD88.  To answer this question, we express a dominant negative MyD88 
mutant (MyD88 DN) in SR-AI-293T cells.  MyD88 has a modular structure, comprising 
of a C-terminal TIR domain and an N-terminal death domain. The death domain is 
removed in MyD88 DN. Consequently, MyD88 DN cannot associate with IRAKs 
downstream of the signaling pathway although it can interact with receptors via its TIR 
domain. This interaction with receptors prevent native MyD88 from binding to the latter 
and hence the dominant negative effect.  As shown in Figure 4.2, MyD88 DN 
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significantly reduced DH5-induced NF-B activation in TLR4-293T (p=1.61x10-6) but 
not SR-AI-293T cells. This result suggests that MyD88 is not involved in the activation 
of NF-B by SR-AI following bacterial stimulation and possibly rule out TLRs as the 














4.4 SR-A mediated NF-B activation following DH5 stimulation is dependent on 
phosphatidylinositol-3-kinase (PI3K). 
Fucoidan, a SR-A ligand was reported to be able to induce urokinase-type plasminogen 
activator (uPA) expression (Falcone et al., 1991; Hsu et al., 1998) and TNF- 
production (Kim et al., 2003). Both uPA and TNF- gene induction via SR-A was 
reported to proceed via PI3K (Hsu et al., 1998; Kim et al., 2003). We decided to 
examine whether PI3K might also be involved in DH5-induced NF-B activation in 
SR-AI-293T cells.   
*
Figure 4.2. Involvement of adaptor molecule MyD88 in SR-AI mediated NF-B activation 
following DH5 stimulation.  SR-AI-293T (SR-AI) and vec-293T (vector) cells were co-transfected 
with plasmid encoding for dominant negative (DN) MyD88 or, as a control, the pcDNA3.1 plasmid 
(vector). Cells were either left unstimulated or stimulated with DH5in fresh BCS culture media. NF-
B activation was determined. Data are means ± SD of triplicate wells of an experiment that is 
representative of three independent experiments. *P<0.001 compared to control value.  
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To investigate the involvement of PI3K in SR-AI signaling in response to DH5, we 
used to PI3K-specific inhibitors, wortmannin and LY294002.  Wortmannin is a 
furanosteroid metabolite of the fungi Penicillium funiculosum while LY294002 is a 
synthetic analogue of another less-potent PI3K inhibitor the bioflavonoid quercetin. 
Both these inhibitors binds to the ATP-binding site of PI3K, blocking the active site and 
inducing a conformational change in the catalytic domain which lead to enzyme 
inactivation (Walker et al., 2000). As shown in Figure 4.3, both wortmannin (p=0.025) 
and LY294002 (p=9.4x10-4) reduce NF-B activation in SR-AI-293T cells stimulated 
with DH5. It must be noted that LY294002 appears to be more effective in inhibiting 
SR-AI-mediated NF-B activation compared with wortmannin (Figure 4.3).  In 
contrast, the dimethyl sulfoxide (DMSO) control (DMSO was used as solvent for the 
















Figure 4.3. Involvement of 
phosphatidylinositol-3-kinase 
(PI3K) in SR-AI mediated 
NF-B activation following 
DH5 stimulation.  SR-AI-
293T and vec-293T cells were 
pre-incubated with PI3K 
inhibitors Wortmannin (200 
nM) or LY294002 (50 M) for 
1 hr at 37oC. As control, the 
cells were also pre-incubated 
with 0.1% DMSO, which was 
used as a solvent for the 
inhibitors. Cells were then 
either left unstimulated or 
stimulated with DH5in fresh 
BCS culture media for 8 hr at 
37oC. NF-B activation was 
determined. Data are means ± 
SD of triplicate wells of an 
experiment that is 
representative of three 
independent experiments. 
*P<0.05 and **P<0.001 
compared to positive control 
value as indicated in figure. 
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4.5 SR-A mediated NF-B activation in response to DH5 involves the Rho 
GTPase Cdc42. 
It has been previously reported that SR-A plays a role in calcium-independent cell 
adhesion (Fraser et al., 1993).  The binding of SR-A to modified ECM components 
initiated phospholipase A2 (PLA2)-catalyzed release of arachidonic acid (AA), which in 
turn, is metabolized by 12/15 lipoxygenases (LOX) into eicosanoids;  these AA 
metabolites then activate the Rho GTPases Rac and Cdc42, which play crucial roles in 
the regulation of  actin polymerization and focal adhesion formation (Nikolic et al., 
2007b). Rho GTPases have also been reported to activate NF-B (Perona et al., 1997) 
and also PI3K (Deane and Fruman, 2004), both of which are involved in DH5-induced 
SR-AI signaling in this study. We ask whether DH5 induced NF-B activation via SR-
AI involves the RhoGTPases.   
To examine this possibility, we express dominant negative mutants of RhoGTPases, 
RacN17 (Rac DN), Cdc42N17 (Cdc42 DN) and RhoAN19 (RhoA DN), separately in 
SR-AI-293T cells.  The dominant RhoGTPase mutants were generated by substituting 
threonine residue at position 17 to asparagine in Rac and Cdc42, and a serine residue to 
asparagine at position 19 for RhoA (Hall, 1994). As shown in Figure 4.4A, Cdc42 DN 
but not RhoA DN or Rac DN significantly reduced NF-B activation by SR-AI 
following DH5 stimulation (p=1.95x10-5), suggesting the Cdc42 is involved in SR-AI 
mediated NF-B activation. IL-8 production in response to DH5 is also reduced when 
Cdc42 DN was also expressed in SR-AI-293T cells (p=0.0075) but not Rac DN 






























Figure 4.4. Involvement of the Rho family of GTPases in DH5-elicited SR-AI –mediated NF-
B activation. SR-AI-293T (SR-AI) and vec-293T (vector) cells were co-transfected with plasmids 
encoding for dominant negative (DN) Rac, cdc42 or Rho, or the pcDNA3.1 plasmid (vector) as a 
control. Cells were either unstimulated or stimulated with human serum opsonized DH5. NF-B 
activation (A) and IL-8 production (B) were determined. The experiment was carried out in triplicate 
and the results were presented as means ± SD.  The results are representative of at least three 
independent experiments. *P<0.001 compared to control value. 
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4.6 SR-A mediated NF-B activation following DH5 stimulation is reduced by the 
membrane cholesterol sequestering compound -methylcyclodextrin (MCDextrin) 
but not affected by the actin polymerization inhibitor cytochalasin D. 
 
Previous studies have indicated that SR-A mediated cell adhesion is dependent on 
signaling events that facilitate actin polymerization via Rac and Cdc42. The present 
study also suggest that cdc42 may be involved in SR-AI mediated NF-B activation and 
IL-8 production.  Cdc42 could potentially affect SR-AI signaling events in two ways. It 
could be a downstream signaling intermediate of the receptor, acting to activate kinases 
such as PAK1, or SR-AI may need to be associated with the actin cytoskeleton to 
transduce signals as previously reported for integrins (Hotchin and Hall, 1995), and 
Cdc42, which have been established to facilitate actin polymerization (Ma et al., 1998), 
may be required to ensure such an association.  We examine whether an intact actin 
cytoskeleton is necessary for SR-AI signaling by using cytochalasin D (Cyto D), a cell 
permeable and potent inhibitor of actin polymerization.   
 
As shown in Figure 4.5A, a 1 hr pre-incubation of SR-AI-293T cells in 2M Cyto D or 
solvent DMSO control did not affect DH5-induced NF-B activation. Our findings do 
support that reported by Peiser et. al (2000). The authors demonstrated that Cyto D does 
not affect the binding of E coli to CHO cells stably expressing SR-AI or II, suggesting 
that the receptors are not associated with the actin cytoskeleton. 
 
It was reported that the facultative intracellular bacterium, Brucella abortus, infects 
macrophages via SR-A, and that such interactions were mediated by lipid raft 
microdomains on the macrophage plasma membrane (Kim et al., 2004b). SR-AI may be 
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recruited into lipid rafts upon activation.  We examine this possibility by using the 
cholesterol-binding reagent ß-methylcyclodextrin (MCDextrin) to deplete cellular 
cholesterol and disrupt lipid rafts on SR-AI-293T cells. 
 
As shown in Figure 4.5B, a 1 hr pre-incubation of cells with 10mM MCDextrin 
significantly reduced DH5 induced NF-B activation in SR-AI-293T cells (p=0.0001), 
suggesting that cholesterol is needed for SR-AI mediated NF-B activation in response 
to DH5. The requirement for cholesterol does also indicate that SR-AI may associate 




















Figure 4.5.  DH5 induced, 
SR-AI mediated NK-B 
activation is reduced by 
the cholesterol-depleting 
MCDextrin but not the 
actin polymerization 
inhibitor Cyto D.  SR-AI-
293T cells were pre-
incubated with (A) 2 M 
Cytochalasin D (Cyto D) or 
(B) 10 mM -
methylcyclodextrin 
(MCDextrin) for 1 hr. The 
cells were either left 
unstimulated or stimulated 
with DH5 in fresh BCS 
media for 1 hr in the 
presence of the chemical 
reagents, washed thoroughly 
and further incubated for 24 
hours.  The cells were then 
lysed and NF-B activation 
determined.  The experiment 
was carried out in triplicate 
and the results were 
presented as means ± SD.  
The results are 
representative of at least 
three independent 
experiments. *P<0.001 
compared to control value 
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4.7 Conclusion  
 
The following conclusions can be derived from the findings reported in this chapter: 
 
1) The cytoplasmic domain of SR-AI is not involved in NF-B activation and 
chemokine production in response to DH5. This result suggests the existence 
of a co-receptor(s) in SR-AI-mediated signaling. 
 
2) The DH5-induced signaling pathway mediated by the co-receptor(s), in 
conjunction with SR-AI, appears to involve PI3K and the Rho GTPase Cdc42. 
However, the co-receptor is not one of the TLRs because the signaling pathway 
is MyD88-independent; TLR-mediated signaling pathways leading to NF-B 
activation involves MyD88. 
 
3) SR-AI does not appear to be associated with the actin cytoskeleton and appears 










Chapter 5 Opsonization of bacteria with complement C3 induces Rac-





Complement activation causes microbial killing and opsonization with C4b, C3b and 
further proteolytic C3 fragments (Reid, 1986). These opsonic fragments are recognized 
by complement receptors (CRs) for opsonophagocytosis (Law, 1988). CR1 binds to 
C3b/C4b-opsonized microbes whereas CR3 and CR4 mainly recognize iC3b (Carroll, 
2004; Law, 1988). While CR3 is a potent phagocytic receptor for iC3b-opsonised 
targets (Law, 1988; Lu et al., 1997), the functional role of CR4 in opsonophagocytosis 
is less clear (Ross et al., 1992). However, both CR3 and CR4 are known to mediate 
phagocyte adhesion and migration (Springer, 1994).     
 
Besides microbial eradication via opsonophagocytosis, there is strong evidence to 
suggest that activated complement components play major regulatory roles in the 
development of adaptive immunity. For example, iC3b is further cleaved to yield a 
surface-bound C3d fragment which is recognized by CR2 to enhance B cell activation 
(Croix et al., 1996; Fearon and Carter, 1995; Haas et al., 2004). C5 activation yields the 
C5a anaphylatoxin which inhibits lipopolysaccharide (LPS)-induced IL-12 production 
by macrophages (Karp et al., 2000; Wittmann et al., 1999). IL-12 is produced by 
antigen-presenting cells (APCs), such as macrophages and dendritic cells (DCs), to 
induce T helper 1 (Th1) cell-mediated immunity (Trinchieri, 2003). Cross-linking of 
CR3 on macrophages also inhibits IL-12 production (Marth and Kelsall, 1997; 
Sutterwala et al., 1997). Therefore, as an early event of microbial infection, complement 
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reaction can yield a myriad of signals to regulate the development of adaptive 
immunity. 
 
Some mechanisms of complement-mediated regulation of adaptive immune responses 
have been recently elucidated. For example, C5a inhibition of IL-12 production is 
mediated through its G protein-coupled receptor CD88 which involves G(i)-mediated 
PI3K activation and the activation of MAP kinases such as JNK (la Sala et al., 2005). In 
contrast, how iC3b inhibits IL-12 production is not known. In fact, the signaling 
properties of CR3 and CR4 are not consistently reported. Rho GTPases have been 
implicated in CR3 signaling associated with cytoskeletal rearrangements and target 
ingestion (Caron and Hall, 1998; Forsberg et al., 2003), respiratory burst (Dewitt et al., 
2003; Forsberg et al., 2003), and cytokine production (Kim et al., 2004a; Rezzonico et 
al., 2000). However, the exact Rho GTPases involved, i.e. Rho, Rac or cdc42, vary 
depending on the cell type studied in various reports. Using macrophages and 
fibroblasts, CR3 engagement was shown to activate Rho (Caron and Hall, 1998), 
whereas CR3 was reported to elicit Rac and cdc42 activation in neutrophils (Forsberg et 
al., 2003). CR3 stimulation triggered respiratory burst in neutrophils (Dewitt et al., 
2003; Forsberg et al., 2003), but this was not observed in macrophages (Wright and 
Silverstein, 1983; Yamamoto and Johnston, 1984). There are also inconsistencies in 
findings relating to CR3-mediated pro-inflammatory cytokine production.  In 
monocytes, CR3 activation caused IL-1 production according to one study (Rezzonico 
et al., 2000), but not TNF- production according to another study (Fan and Edgington, 
1993). In neutrophils, CR3 engagement caused NF-B activation and elicited the 
production of both IL-1 and TNF- (Kim et al., 2004a). Understanding of the signaling 
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properties of CR3 and CR4 should help elucidate the regulatory roles of opsonic C3 
fragments. 
 
Phagocytes can employ multiple receptors to recognize a single microorganism and the 
range of receptors involved are further expanded with serum opsonization (Gordon, 
2002; Underhill and Ozinsky, 2002). This can cause misinterpretation of results. 
Previous studies have used CR3-specific antibodies or iC3b-opsonized particles to 
investigate CR3 and CR4 signaling on phagocytes. We decided to use serum-opsonized 
DH5 to stimulate CR3 and CR4 after expression of these receptors on transfected 
293T cells and went on to test the findings in DCs. 
 
5.2 Serum-opsonized E. coli DH5stimulates CR3 signaling of NF-B activation.  
As reasoned earlier in last section (Section 5.1), unopsonized DH5 could potentially 
activate a number of PRRs on phagocytes and presumably more receptors when 
opsonized. To study CR3 and CR4 signaling in isolation without possible cross-talk 
from other PRRs, as in the case of SR-A, 293T cells were transfected to express these 
two receptors and then stimulated with serum-opsonized DH5. CR3 was expressed by 
transfection using vectors for its M and 2 subunits (CR3-293T). CR4 was expressed 
using vectors for its X and the same 2 subunits (CR4-293T). The expression of the 
M2 heterodimer or CR3 on 293T cells was verified by flow cytometry using the 
antibody LMP19c for CR3, the KB43 antibody for CR4, and the MHM23 antibody for 
both receptors. Both the LMP19c and MHM23 antibodies produced signals on CR3-
293T cells (Figure 5.1A). As a control, neither antibody yielded specific signals on 
vector-transfected 293T cells (vec-293T) (Figure 5.1A). The KB43 antibody detected 
signals on CR4-293T cells (Figure 5.1A).  These results showed that CR3 and CR4 
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were expressed on the transfected 293T cells and these cells used to investigate CR3 
and CR4 signaling using serum-opsonized DH5 as stimuli. 
 
We have demonstrated earlier that when fresh BCS was used to culture CR3-293T cells, 
the addition of DH5 to the culture induced NF-B activation (Figure 3.11A). This 
finding is consistent with CR3 being shown to mediate NF-B activation in neutrophils 
(Flaherty et al., 1997; Kim et al., 2004a) and monocytic THP-1 cells (Shi et al., 2001), 
and also that, similar to SR-AI, 293T cells can support CR3 signaling as judged by NF-
B activation. NF-B was not activated in CR3-293T cells by DH5 if heat-inactivated 
BCS was used (Figure 3.11A), a validation of the reliability of the assay because CR3 
binds heat-labile, surface-bound iC3b fragments. As expected, DH5 also induced IL-8 
production from CR3-293T cells in the presence of fresh but not heated BCS (Figure 
3.11B). CR3-293T cells cultured in the presence of heat-inactivated BCS are also 
capable of activating NF-B when stimulated by DH5pre-incubated in 10% human 
serum for 8 min at 37oC and thoroughly washed (Figure 5.1B), indicating that CR3-
stimulating factor(s) was deposited on DH5 as expected for activated C3 and C4 
(Carroll, 2004; Law, 1988; Reid, 1986). The divalent cations, Ca2+ and Mg2+, are 
required as co-factors for complement activation (Reid, 1986). When DH5 was pre-
incubated with fresh human serum in the presence of EDTA, which chelates Ca2+ and 
Mg2+, the serum-reacted DH5 failed to elicit CR3-mediated NF-B activation (Figure 
5.1B). In phagocytes, DH5 is expected to activate other receptors besides CR3. 





5.3 Serum-opsonized DH5 does not elicit NF-B activation through CR4.  
We then examined whether DH5 could stimulate CR4 signaling of NF-B activation. 
CR4-293T cells were stimulated with DH5 which were pre-sensitized with human 
sera. As shown in Figure 5.1B, NF-B activation was not observed in CR4-293T cells 
upon DH5 stimulation. CR3 and CR4 share the same 2 integrin subunit. The two  
subunits, i.e. M and X, are also closely related in sequence. Both receptors have been 
reported to bind to iC3b (Micklem and Sim, 1985). The inability of CR4 to cause NF-
B activation in response to DH5 is unknown but does indicate that CR4 is 
functionally distinct from CR3.  
 
It is possible that cellular stimulation does not affect all integrins uniformly, and that 
CR4 is less susceptible to activation than other 2 integrins. Studies have shown that 
although alveolar macrophages and U937 cells co-express CR3 and CR4, stronger 
stimulation was required to activate iC3b binding by CR4 than by CR3 (Myones et al., 
1988; Ross et al., 1992). Furthermore, LFA-1 and CR3 are constitutively active in 293T 
and COS cell transfectants whereas CR4 is not (Bilsland et al., 1994; Diamond et al., 
1993). It was discovered that the PSI domain and cysteine-rich repeats of the 2 subunit 
plays a modulatory role in restraining activation of CR4 by maintaining the heterodimer 
in an inactive conformational state (Zang and Springer, 2001).  As mentioned in Section 
1.6.3, interspecies heterodimers comprising of human X subunit associated with either 
a chicken or mouse 2 subunit on cell transfectants are active in iC3b binding (Bilsland 
et al., 1994), suggesting that the 2 subunit impose an intraspecies-related structural 
restraint on the X subunit conformation. This restraint could be released or loosened by 
an interspecies 2 subunit, resulting in the X subunit adopting an active conformation 
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to bind iC3b.  In addition to the possibility that CR4 maybe inactive on 293T cells, it is 
also plausible that CR4 may respond to DH5 by activating signaling pathways other 
than NF-B. It has been reported that activated CR4 initiate signalling cascade(s) that 
involve tyrosine kinases (p60src) (Zaffran et al., 1998) and MAP kinases (Rezzonico et 
al., 2000), although the receptor is also known to activated NF-B in association with 
CD14 following stimulation with LPS or streptococcal cell wall preparations 
(Medvedev et al., 1998). In view of this uncertainty regarding the role CR4 plays in NF-


















Figure 5.1.  DH5 activates NF-B 
through CR3 but not CR4 on 
transfected 293T cells. (A) Expression 
vectors for M and 2 subunits of CR3 
were transfected into 293T cells (CR3-
293T cells). CR3 expression was 
examined by flow cytometry using the 
MHM23 and LPM19c antibodies. 293T 
cells were also transfected with vectors 
for the X and 2 subunits of CR4 (CR4-
293T cells) and CR4 expression was 
detected using the KB43 antibody. As 
controls, 293T cells were transfected with 
the pcDNA3.1 vector (vec-293T cells). 
Solid histograms represent signals 
obtained with isotype mouse IgG and 
lines represent signals obtained with the 
CR3 and CR4 antibodies. (B) DH5 was 
pre-incubated with fresh human serum or 
BCS in the presence (EDTA) or absence 
(fresh) of 5 mM EDTA for 8 min at 37oC. 
As controls, DH5 were incubated with 
heat-inactivated human serum or BCS. 
The bacteria were then used to stimulate 
CR3-293T, CR4-293T and vec-293T 
cells in the presence of heated BCS. 
These cells were co-transfected with the 
p5xNF-B-Luc and the pRL-CMV 
vectors.  NF-B activation was measured 
as NF-B-directed firefly luciferase 
activity normalized to the CMV-directed 
Renilla luciferase activities taking the 
latter as 100 in each experiment. The 
experiments are performed in triplicates 
and results are expressed as means ± SD. 
The results are representative of at least 
three independent experiments. *p<0.001 
compared to appropriate control values as 






5.4 The cytoplasmic tails of both subunits of CR3 are not involved in DH5 
induced NF-B activation. 
In the present study, we have also established that iC3b-opsonized DH5 can activate 
NF-B in CR3-293T cells.  Integrins are known to trigger intracellular signaling 
cascades by the interaction of cytosolic adaptor proteins with its cytoplasmic tails 
(Hynes, 1992).  Following ligand engagement, integrins initiate “outside-in” signaling 
cascades which affect cell motility, proliferation and survival (Hynes, 1992; Hynes, 
2002). In addition, integrin signaling also modulate gene transcription and one of the 
key transcription factor activated is NF-B (Hynes, 2002). 2 integrins are known to 
activate NF-B (Flaherty et al., 1997; Kim et al., 2004a; Reyes-Reyes et al., 2002) 
although details of signaling pathways have not be fully elucidated. The cytoplasmic 
tails of both the M and 2 subunits of CR3 are comparatively short, similar to that of 
SR-A. Recently, it was demonstrated that the glycoprotein IIb/IIIa (GPIIb/IIIa) 
receptors and 2 integrins co-localized on neutrophils and that these receptors co-
operate in activating NF-B (Salanova et al., 2007). We therefore ask the question 
whether the cytoplasmic tails of CR3 are able to mediate intracellular signaling, or does 
CR3 depend on a signal-transducing co-receptor to effect downstream signaling upon 
receptor activation, as observed for SR-AI. 
 
As shown in Figure 5.2, deletion of the cytoplasmic domains of both the M and 
2subunits (CD11b-dCyto/CD18-dCyto) did not significantly reduce NF-B activation 
in response to iC3b-opsonized DH5 (p=0.06) in comparison with wild-type CR3 
(CD11b/CD18). This result indicates that, like SR-AI, CR3 may also associates with a 






















5.5 CR3 is activated by opsonic C3 deposited on DH5.  
To determine whether complement C3, which is expected to deposit on serum-
sensitized bacteria, is responsible for the observed CR3 activation in CR3-293T cells, 
DH5 was opsonized with human sera deficient for the C3, C5 or C7 component for 
CR3-293T stimulation. As shown in Figure 5.3A, DH5 opsonized with fresh, but not 
heat-inactivated, human sera caused NF-B activation (p=1x10-4). DH5 opsonized 
Figure 5.2. Involvement of the cytoplasmic domains of the  and  subunits of CR3 in NF-B 
activation following DH5 stimulation.  293T cells are transfected with vectors for wild-type M 
(CD11b) and 2 (CD18) subunits of CR3 (CD11b/CD18) or various combinations of wild-type and/or 
cytoplasmic domain-deleted mutant M (CD11b-dCyto) and 2 (CD18-dCyto) subunits as indicated. The 
plasmid pcDNA3.1 was transfected into 293T cells as a control (vector). The cells were either left 
unstimulated or stimulated with DH5 in fresh BCS culture media for 1 hr, washed thoroughly and 
further incubated for 24 hrs prior to measurement of NF-B.  The experiment is performed in triplicates 
and results are expressed as means ± SD. The results are representative of at least three independent 
experiments. 
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with C5- (p=0.15) or C7-(p=0.42) deficient sera were similarly potent in CR3 
stimulation (Figure 5.3 A). In contrast, C3-deficient sera were unable to sensitize DH5 
for CR3 stimulation (p=1x10-4) (Figure 5.3 A). Examining IL-8 production in these 
experiments led to similar conclusions, i.e. serum C3 (p=1.15x10-6) is required to 
opsonize DH5 for CR3 activation in transfected 293 T cells (Figure 5.3B).  
 
These results included CR3 stimulation by components downstream of C3 in the 
complement cascade, i.e. C5 and C7 complements. Using antibodies, we also examined 
whether complement components upstream of C3, such as C1q and C4, might 
contribute to the observed NF-B activation in CR3-293T cells. DH5 was opsonized 
with fresh human serum and, after washing, incubated with polyclonal anti-C3, anti-C4 
or anti-C1q antibodies. As shown in Figure 5.4A, only the anti-C3 antibody 
significantly inhibited DH5-elicited CR3 signaling (p=4.43x10-6), suggesting a 
dominant role for opsonic C3 on DH5 in CR3 activation. Measuring IL-8 production 
led to the same conclusion (p=1.32x10-6) (Figure 5.4B). These results collectively 
suggest that, upon expression on 293T cells, CR3 can be activated by C3-opsonized 
DH5 (DH5C3+). DH5 incubated with C3-deficient sera (DH5C3-), which may be 
opsonized by serum factors other than C3, was unable to activate CR3 signaling. This 
establishes CR3-293T cells as a unique assay for investigating CR3 signaling allowing 






































Figure 5.3.  DH5 requires C3 opsonization to stimulate CR3 signaling for NF-B activation. 
DH5 was incubated with fresh human serum (normal), heat-inactivated serum (heated), or fresh human 
sera with complement deficiency (C3-d, C5-d and C7-d). The bacteria were washed and used to 
stimulate CR3-293T or vec-293T cells in the presence of heat-inactivated BCS. The cells were used to 
measure NF-B activities (A) and the media were used to measure IL-8 production by ELISA (B). The 
experiments are performed in triplicates and results are expressed as means ± SD. The results are 
representative of at least three independent experiments. *p<0.001 compared to appropriate control 



























Figure 5.4.  DH5 stimulation of CR3 signaling is inhibited by anti-C3 antibodies. DH5 was 
incubated with fresh or, as a control, heat-inactivated human serum for 8 min at 37oC. After washing, the 
bacteria were incubated with goat antibodies specific for human C3 (anti-C3), C1q (anti-C1q) or C4 (anti-
C4) for 15 min on ice. As controls, the bacteria were not incubated with these antibodies (-).CR3-293T 
or vec-293T cells were then stimulated with these antibody-treated or untreated bacteria in the presence of 
heat-inactivated BCS. NF-B activation (A) and IL-8 production (B) were determined. The experiments 
are performed in triplicates and results are expressed as means ± SD. The results are representative of at 










5.6 Rac is required for DH5-elicited CR3 signaling of NF-B activation.  
In view of the uncertainty concerning which Rho GTPases are involved in CR3 
signaling mentioned in Section 5.1, we co-expressed dominant negative GTPases (i.e. 
N19Rho, N17Rac and N17cdc42) in CR3-293T cells to assess their roles in CR3 
signaling. Co-expression of N19Rho does not affect DH5C3+-elicited CR3-mediated 
NF-B activation (p=0.22) (Figure 5.5A).  In contrast, both N17cdc42 (p =2.9x10-3) and 
N17Rac (p = 2x10-4) showed partial but significant inhibition (Figure 5.5A). When IL-8 
production was examined, it was observed that N17Rac significantly inhibited IL-8 
production induced by DH5C3+ (p = 3.73x10-4) (Figure 5.5B). Although N17cdc42 
inhibited NF-B activation in CR3-293T cells, it showed no inhibition of DH5C3+-
induced IL-8 induction from these cells (p=0.07) (Figure 5.5B). These results suggest a 
critical role for Rac in CR3 signaling of NF-B activation and IL-8 production and 
insignificant involvement of Rho and probably cdc42 in this arm of CR3 signaling.  
 
To verify our finding that Rac is involved in CR3 signaling, we pre-treated CR3-293T 
cells with the Rac inhibitor NSC23766 for 30 min prior to stimulation with DH5C3+. 
NSC23766 is a cell permeable pyrimidine compound that specifically and reversibly 
inhibits Rac1 GDP/GTP exchange and hence activity of GTPase by interfering with the 
interaction between Rac1 and Rac-specific GEFs Trio and Tiam1. As shown in Figure 
5.6, NSC23766 significantly inhibited DH5C3+-induced NF-B activation in these 
cells (p = 0.001). Collectively, these results suggest a novel pathway of CR3 signaling, 



































Figure 5.5. Roles of the Rho family of GTPases in DH5-elicited CR3 signaling. CR3-293T (CR3) 
and vec-293T cells were co-tranfected with vectors encoding for dominant negative (DN) Rac, cdc42 or 
RhoA or, as controls, the pcDNA3.1 plasmid (vector). Cells were either unstimulated or stimulated with 
DH5C3+. NF-B activation (A) and IL-8 production (B) were determined. The experiments are 
performed in triplicates and results are expressed as means ± SD. The results are representative of at least 
three independent experiments. *p<0.01 and **p<0.001 compared to appropriate control values as 



















5.7 Cytochalasin D inhibits CR3 signaling of NF-B activation and IL-8 
production in CR3-239T cells. 
A principal Rac effector is the cell’s actin cytoskeleton. In phagocytes, Rac-mediated 
cytoskeletal rearrangement and membrane ruffling have been reported to facilitate 
phagocytosis (Caron and Hall, 1998; Forsberg et al., 2003) and macropinocytosis (Cao 
et al., 2006; Garrett et al., 2000; West et al., 2000). Its disruption with cytochalasin D 
was shown to affect NF-B activation in epithelial and myeloid cells (Kustermans et al., 
2005; Nemeth et al., 2004).  It was then examined whether Rac-mediated CR3 signaling 
of NF-B activation involves cytoskeletal rearrangement. CR3-293T cells were 
stimulated with DH5C3+in the presence of 2M cytochalasin D. Compared with its 
solvent DMSO, cytochalasin D caused a 60% inhibition of DH5C3+-induced NF-B 
activation (p=1.67x10-5)(Figure 5.7A). It also inhibited DH5C3+-induced IL-8 
*
Figure 5.6.  The Rac inhibitor NSC23766 partially inhibits CR3-mediated NF-B activation 
following DH5 stimulation.  CR3-293T or vec-293T cells were pre-incubated with 100M Rac 
inhibitor NSC23766 (Rac inh) for 16 hr or left untreated. The cells were then stimulated with serum-
opsonised DH5 or un-stimulated. NF-B activation was determined. The experiments are performed in 
triplicates and results are expressed as means ± SD. The results are representative of at least three 
independent experiments. *p<0.001 compared to appropriate control values as indicated in the figure. 
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production (p =2.84x10-4) (Fig. 5.7B). However, it should be noted that disruption of 
the cell’s cytoskeleton could affect broader cellular activities than that mediated by Rac 
which could indirectly affect NF-B activation. Therefore, the role of the actin 

























Figure 5.7.  Cytochalasin D inhibits DH5-elicited CR3 signaling.  293T cells were transfected with 
the CR3 expression vectors (CR3) or the pcDNA3.1 plasmid (vector) and were either left un-stimulated 
or stimulated with DH5C3+ (DH5). “CytoD”, cytochalasin D was added; “DMSO”, the DMSO 
solvent was added; `-‘, neither cytochalasin D nor DMSO was added. NF-B activation was measured in 
the cells (A) and IL-8 was measured in the media (B).  The experiments are performed in triplicates and 
results are expressed as means ± SD. The results are representative of at least three independent 
experiments. *p<0.001 compared to appropriate control values as indicated in the figure. 
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5.8 Opsonic C3 is a negative regulator of DH5-induced IL-12 production. 
Results obtained with the CR3-293T cells suggested that DH5C3+, prepared in this 
study, was potent in the stimulation of CR3 signaling. We then asked whether this 
naturally deposited C3, amid a myriad of other opsonins or microbial structures on 
DH5C3+, plays a significant role in the regulation of IL-12 production by DCs. IL-12 
production is important to the development of adaptive immunity (Banchereau et al., 
2000; Steinman, 2003; Trinchieri, 2003). The inability of DH5C3- to activate CR3 on 
CR3-293T cells makes it a good reference bacteria as it was only expected to differ 
from DH5C3+ for the lack of surface opsonic C3 and possible some terminal 
complement components, e.g. C9 (Reid, 1986). DH5C3+ is expected to recruit other 
serum opsonins that are recruited by DH5C3-.  
 
CR3 and CR4 were both detected on DCs by flow cytometry (Figure 5.8A). Since the 
MHM23 antibody detects both CR3 and CR4, it produced stronger signals on DCs than 
the other two antibodies. DCs were stimulated with DH5C3+ or, as a control, 
DH5C3-. Heated-inactivated BCS was used in these experiments to avoid further 
complement opsonization of the differentially serum-opsonized DH5. As shown in 
Figure 5.8B, DH5C3+ induced IL-12 production from DCs (413 ± 6.70 pg/ml), but 
DH5C3- induced 1.8 folds more IL-12 than DH5C3+ (1153 ± 56.94 pg/ml). 
Therefore, the lack of C3 deposition, when DH5C3- was used, apparently allowed 
DH5 to induce more IL-12 production, indicating that the deposition of opsonic C3 on 





























Figure 5.8. Opsonic C3 inhibits IL-12 induction by DH5. (A) DCs were incubated with anti-M 
(LMP19c), anti-X (KB43), or anti-CR3/CR4 (MHM23) antibodies (lines) or, as controls, isotype IgG 
(solid histograms). The cells were then incubated with rhodamine conjugated-goat anti-mouse IgG. After 
washing, the cells were analyzed by flow cytometry. B) DCs were either un-stimulated, stimulated with 
DH5C3+ (normal serum) or DH5C3- (C3-d serum). In some experiments, DCs were pre-incubated with 
anti-FcR antibodies (FcR Abs) or isotype control IgG1 before stimulation with DH5C3+ or DH5C3-. 
After 24 h, IL-12 production was determined by ELISA. (C) As in (B) except that IFN- was included to 
co-stimulate DCs. (D) As in (B), except that TNF-, rather than IL-12, was measured. (E) As in (C), 
except that TNF-, rather than IL-12, was measured.  
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Besides complements, DH5 is also expected to recruit other serum opsonins, such as 
antibodies, which may regulate IL-12 production by DCs. However, these other 
opsonins are expected to be recruited by both DH5C3+ and DH5C3-. Therefore, the 
increased IL-12 induction by DH5C3-, as compared with DH5C3+, should be mainly 
due to the lack of opsonic C3 on DH5. Nonetheless, DCs were pre-blocked with 
antibodies for the three known FcRs, i.e. FcRI, FcRII and FcRIII. DH5C3- 
remained 2 folds more potent than DH5C3+ in IL-12 induction from these FcR-
blocked DCs (Figure 5.8B).  
 
Cross-linking of FcRs with activating antibodies has been reported to inhibit LPS-
induced IL-12 production from macrophages (Sutterwala et al., 1997). However, the 
ability of blocking anti-FcR antibodies to inhibit rather than enhanced DH5-elicited 
IL-12 production in this experimental setting, irrespective of C3 opsonization, suggests 
that normal FcR activities enhance IL-12 production (Figure 5.8B). While this appears 
to contradict with the reported inhibitory effects of FcR signaling on IL-12 production 
(Sutterwala et al., 1997), it should be noted that, in this study, whole bacteria rather than 
LPS was used to stimulate DCs. Blocking of FcRs, which is probably not essential to 
LPS recognition by DCs, could inhibit DH5 phagocytosis by DCs. Some Toll-like 
receptors (TLRs) such as TLR9 are intracellularly expressed and are only activated by 
internalized microbial agonists (Wagner, 2004). Blocking of FcRs may affect DH5 
activation of these intracellular TLRs. In any case, opsonic C3 on DH5 clearly 




5.9 IFN- abrogates C3-mediated inhibition of IL-12 production.  
IFN- itself does not induce IL-12 production but it is a potent co-stimulus when the 
cells are also stimulated with microbial structures (Fearon and Carter, 1995; Hayes et 
al., 1998; Ma et al., 1996a). The relationship between C3 inhibition and IFN- 
enhancement of IL-12 production was examined in DCs. As shown in Figure 5.8C, in 
the presence of IFN-, DH5C3+ and DH5C3- became similarly potent in IL-12 
induction. IFN- increased DH5C3+-elicited IL-12 production 4.8 folds from 413 ± 
6.70 pg/ml to 2411 ± 113.84 pg/ml. IL-12 induction by DH5C3- was also enhanced 
1.8 folds by IFN- from 1153 ± 56.94 pg/ml to 3173 ± 175.15 pg/ml. Although 
DH5C3+ remained a poorer IL-12 inducer compared with DH5C3- (p =0.0036) in the 
presence of IFN-, the latter only induced 0.3 folds more IL-12 as contrasted by the 1.8 
fold increase observed in the absence of IFN-. 
 
While DH5C3+ induced significantly lower levels of IL-12 compared to DH5C3- , 
they were both potent in TNF- induction (Figure 5.8D). DH5C3- induced 20% more 
TNF- compared with DH5C3+ which is in contrast with the 1.8 folds more IL-12 
induced by DH5C3- compared with DH5C3+. IFN-, which enhanced IL-12 
induction by DH5C3- 4.8 folds (Figure 5.8C), did not enhance TNF- induction by 
DH5C3- or DH5C3+ (Figure 5.8E). Antibody blocking of FcRs, which partially 
inhibited IL-12 induction by both DH5C3+ and DH5C3-, also inhibited TNF 
production from DCs (Figure 5.8D). It suggests that the inhibitory effects of opsonic C3 




5.10 Inhibition of Rac enhances DH5 induction of IL-12.  
Since Rac mediates CR3 signalling in transfected 293T cells (Figure 5.5) and the Rac 
inhibitor NSC23766 inhibits CR3 signaling (Figure 5.6), we examine whether Rac is 
involved in C3-elicited inhibition of IL-12 production from DCs using this inhibitor. 
While DH5C3+ induced significant IL-12 from DCs (239 ± 75.53 pg/ml), treatment of 
DCs with NSC23766 allowed DH5C3+ to induce 2.5 folds more IL-12 from these cells 
(840 ± 42.24 pg/ml) (p=1.3x10-3) (Figure 5.9). It suggests that, like C3, Rac also 
negatively regulates DH5 induction of IL-12. In fact, Rac inhibition with NSC23766 
caused a similar increase in IL-12 production as the lack of C3 when DH5C3- was 
used, i.e. 2.5 versus 1.8 folds. Like C3, Rac-mediated inhibition of IL-12 production 
was mostly abrogated by IFN- (Figure 5.9). Therefore, C3 and Rac appear to exert a 
similar degree of inhibition on IL-12 production from DCs. Based on these results, it 
remains unclear whether C3 exerts its inhibitory effects through Rac although it requires 
Rac to activate NF-B and induce IL-8 in CR3-293T cells (Figure 5.5). This is the first 










Figure 5.9. Involvement of 
GTPase Rac in DH5-induced IL-
12 production from DCs.  DCs 
were pre-incubated with NSC23766 
(Rac inh) or, as a control, untreated. 
The cells were then either left un-
stimulated or stimulated with 
DH5C3+ in the presence 
(DH5/IFN) or absence (DH5) of 
IFN-. The experiments are 
performed in triplicates and results 
are expressed as means ± SD. The 
results are representative of at least 
three independent experiments. 
*p<0.001 compared to appropriate 






5.11 Cytochalasin D inhibits rather than enhances DH5-induced IL-12 
production from DCs. 
The role of the cytoskeleton in IL-12 induction from DCs was also examined. Although 
both NSC23766 and cytochalasin D inhibited CR3 signaling of NF-B activation in 
CR3-293T cells (Figure 5.6 and 5.7). The two inhibitors exhibited opposite effects on 
IL-12 induction from DCs. While NSC23766 enhanced IL-12 production 2.5 folds 
(Figure 5.9), cytochalasin D inhibited IL-12 production by approximately 70% 
(p=0.0025) (Figure 5.10). Again, disruption of the cell’s cytoskeleton can have broader 
effects on DCs than Rac signaling. For instance, cytochalasin D is expected to inhibit 
DH5 phagocytosis by DCs. The uptake of bacteria would prevent or reduce synergistic 
TLR activation, particularly TLRs localised in intracellular compartments e.g.TLR3, 7, 
8 and 9, which is required for effective IL-12 induction from DCs (Napolitani et al., 
2005). IFN- abrogated the cytochalasin D inhibition of IL-12 production (Figure 5.10). 
The ability of IFN- to override the cytochalasin D-induced cytoskeletal defect to 
enhance IL-12 induction by DH5 suggests that DH5 phagocytosis or TLR synergy 
becomes less critical to IL-12 induction when IFN- is present. It has been shown that, 
in the presence of IFN- or CD40 ligand, stimulation of single TLRs on DCs was 
sufficient to cause IL-12 production (Napolitani et al., 2005). IFN- apparently 






















5.12 DTxB enhances IL-12 production by DH5C3+.  
DTxB is a less specific Rac inhibitor as it also inhibits other Rho GTPases (Boquet, 
1999). Nonetheless, we examine whether it enhances IL-12 production. Like the Rac-
specific inhibitor NSC23766, pre-treatment of DCs with DTxB also enabled DH5C3+ 
to induce 1.8 folds more IL-12 (Figure 5.11). In the same experiment, cytochalasin D 
inhibited DH5C3+-elicited IL-12 production. Co-stimulation with IFN- again 
abrogated the effects of all these inhibitors and potently enhanced IL-12 production 
(Figure 5.11). DTxB and NSC23766 showed similar enhancement of IL-12 induction 
which seemed to suggest that inhibition of other Rho GTPases by DTxB is probably 
insignificant to the regulation of DH5C3+-induced IL-12 production.  
 
*
Figure 5.10.  Involvement of the actin cytoskeleton in DH5-induced IL-12 production from DCs.  
DCs were either unstimulated or stimulated with DH5C3+ in the presence (DH5/IFN) or absence 
(DH5) of IFN-. “+”, cytochalasin D was added. “-“, DMSO was added. DCs were also stimulated with 
IFN- alone (IFN). The experiments are performed in triplicates and results are expressed as means ± 
SD. The results are representative of at least three independent experiments. *p<0.001 compared to 
















5.13 Rac inhibition does not enhance IL-12 induction without opsonic C3 Co-
stimulation.  
Although Rac and C3 similarly inhibited IL-12 production from DCs and Rac was also 
shown to mediate C3-elicited CR3 signaling in CR3-293T cells, it remains unclear 
whether C3 inhibition of IL-12 production from DCs is mediated through Rac. If Rac 
and C3 inhibit IL-12 production through independent signaling pathways, the Rac 
inhibitors are likely to enhance DH5-induced IL-12 production irrespective of C3 
opsonization. If Rac is an intracellular mediator for C3-elicited inhibition, the inhibition 
of Rac is expected to have less or no enhancement on DH5C3--induced IL-12 
production depending whether Rac also mediates inhibition through other DC receptors. 
DCs were pre-treated with NSC23766 or DTxB and then stimulated with DH5C3-. As 
shown in Figure 5.12, DH5C3- in the presence or absence of Rac inhibitors induced 
Figure 5.11.  The general Rho GTPase inhibitor Clostridium difficile Toxin B (DTxB) enhances 
DH5-induced IL-12 production from DCs.  DCs were pre-treated with DTxB and then either left un-
stimulated or stimulated with DH5C3+ in the presence or absence of IFN-. The cells were also 
stimulated with DH5C3+ in the presence or absence of cytochalasin D (CytoD), DMSO or IFN- as 
indicated. After 24 hr, IL-12 production was determined by ELISA. 
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similar levels of IL-12. Therefore, simultaneous abrogation of C3 and Rac inhibition 
does not cause further enhancement of IL-12 production compared with just C3 
abrogation. This was not due to the lack of DC capacity for IL-12 production, as IFN- 
again enhanced IL-12 production irrespective of the inhibitors and/or C3 opsonization. 
It suggests that, in DCs, opsonic C3-mediated inhibition of IL-12 production is probably 
transmitted through a pathway involving Rac, or that C3 and Rac inhibit IL-12 
production through a shared or identical signaling pathway originating from CR(s) on 











5.14 DCs ingestion of DH5 is not significantly affected by Rac inhibition and C3 
deficiency.  
As opsonic C3 on DH5 is expected to mediate DH5 phagocytosis by DCs, DH5C3- 
and DH5C3+ uptake by DCs was also compared. The cells were visualized by staining 
the cytoskeleton with rhodamine-phalloidin and the bacteria used in this experiment 
express a green fluorescence protein. Without DH5 stimulation, DCs exhibited 
extensive membrane ruffling which was consistent with elevated Rac activation in these 
Figure 5.12.  C3 and Rac inhibit IL-12 
production in DCs through a common 
signaling pathway.  DCs were pre-treated 
with DTxB and then either left un-
stimulated or stimulated with DH5C3- in 
the presence or absence of IFN-. The cells 
were also stimulated with DH5C3- in the 
presence or absence of cytochalasin D 
(CytoD), DMSO or IFN- as indicated. The 
Rac inhibitor NSC23766 was included in the 
experiments in parallel with DTxB. After 24 
hr, IL-12 production was determined by 
ELISA. 
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cells (Figure 5.13A) (Cao et al., 2006; Garrett et al., 2000; West et al., 2000). DH5C3+ 
was effectively ingested by DCs (Figure 5.13B). Despite the lack of opsonic C3, 
DH5C3- was also effectively ingested (Figure 5.13C). The latter must be mediated 
through other receptors. DCs exposed to DH5C3- and DH5C3+exhibited similar 
cytoskeletal changes as characterized by elongation and reduced membrane ruffles. In 
the presence of NSC23766, DCs lose membrane ruffling and became rounded up 
(Figure 5.13D). However, this did not prevent DH5C3- or DH5C3+ uptake by DCs 
(Figure 5.13E and F). Therefore, opsonic C3 and Rac probably inhibit IL-12 production 
through mechanisms that do not significantly involve phagocytosis. It may involve 
















Figure 5.13. DH5 uptake by DCs. DCs were seeded on glass coverslips. After the specified treatments, 
the cells were fixed in formaldehyde, permeablized, and stained with Rhodamine-phlloidin. (A) untreated 
DCs. (B) DCs incubated for 30 min with DH5C3+. (C) DCs incubated for 30 min with DH5C3-. D-F) 
DCs treated with the Rac inhibitor NSC23766 overnight before DH5 stimulation. (D) DCs without 
DH5 incubation. (E) DCs incubated with DH5C3+. (F) DCs incubated with DH5C3-. DH5 used in 
this experiment express GFP. The cells were viewed by confocal microscopy.  
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5.15 Conclusion 
The following conclusions can be derived from the findings reported in this chapter: 
 
1) CR3 but not CR4 is able to induce NF-B activation and chemokine production 
following DH5 stimulation. 
 
2) The cytoplasmic domains of both M and 2 subunits are not involved in DH5-
induced NF-B activation and chemokine production. 
 
3) Some of ligand-binding properties of CR3 are verified i.e. CR3 is activated by 
serum complement C3-opsonized DH5and is associated with the actin 
cytoskeleton , which it relies on to effect intracellular “outside-in” signaling. 
 
4) The Rho GTPase Rac is involved in CR3-mediated NF-B activation and 
chemokine production. 
 
5) Opsonic complement C3 negatively regulates DH5-induced IL-12 production 
from human monocyte-derived DCs. 
 
6) The inhibition of IL-12 by opsonic C3 involves the Rho GTPase Rac and is 






Chapter 6 Discussion 
6.1 SR-AI is a novel complement C3-binding receptor 
Tissue macrophages express a myriad of receptors with overlapping specificity for 
infectious and endogenous ligands, and the ability of some of these receptors to also 
recognize opsonized targets adds further complexity to receptor-ligand interactions, 
making it difficult to elucidate the ligand recognition characteristics of a particular 
receptor.  In addition, there is considerable receptor cross-talk with regards to signaling 
events initiated upon ligand binding, confounding attempts to dissect the signaling 
properties of individual receptors present on these cells. Consequently, we expressed 
SR-AI in 293T cells to study its ligand recognition and signaling properties in isolation, 
thus circumventing this receptor complexity on macrophages. With this system, we 
observed SR-AI-mediated NF-B activation and chemokine (IL-8 and MCP-1) 
production in response to DH5 but not LPS. However, the key finding in this study is 
a previously unidentified role of SR-AI as a novel complement receptor for opsonic 
iC3b, in addition to CR3, CR4 and the recently identified Complement Receptor of the 
Immunoglobulin superfamily (CRIg) (Helmy et al., 2006). 
  
The present study is the first to report that SR-AI recognizes complement-opsonized 
bacteria although it was previously reported that SR-A is a receptor for serum-
opsonized Francisella tularensis, a Gram-negative facultative intracellular pathogen 
(Pierini, 2006). The uptake of serum-opsonized F. tularensis by J774A.1 macrophages 
was competitively inhibited by both SR-A ligands (fucoidan and poly I) and the SR-A 
antibody 2F8. Additionally, peritoneal macrophages from SR-A-/- mice ingested few 
serum-opsonized bacteria compared to wild-type controls (Pierini, 2006). The identity 
of the heat-labile serum opsonin for F. tularensis was, however not established. Our 
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finding does infer that complements, particularly C3 fragments, may be the unknown 
serum opsonin(s) responsible for SR-A-mediated binding and uptake of F. tularensis. It 
was previously reported that the phagocytosis of F. tularensis by DCs is mediated 
through CR3 and CR4 (Ben Nasr et al., 2006), leading support that iC3b is deposited on 
the bacteria during serum opsonization. 
 
Although the present consensus remains that SRs bind directly to the ligands, it would 
be interesting to examine whether serum opsonization of bacteria can enhance  receptor 
binding in light of the present findings, particularly SRs belonging to the same class as 
SR-A.  There is presently no evidence to suggest that serum opsonization plays a major 
role in bacterial recognition by MARCO, the SR that is structurally most similar to SR-
A. However, MARCO has been postulated to interact with the complement C4 
fragments C4b and C4d based on a phage display screen with a recombinant soluble 
MARCO (Chen et al., 2006a).  One predominant peptide, VRWGSFAAWL, 
represented a stretch of amino acid sequence of complement C4 following BLAST 
database search but solid phase binding studies failed to corroborate such an interaction 
between MARCO and C4 peptide (Chen et al., 2006a). Nevertheless, both C4 and C3 
contain internal thiolester bonds for surface deposition and are closely related in 
structure and functions (Reid, 1986), and the possibility remains that MARCO may 
binds these opsonic complement fragments.  
 
In addition to C4 fragments, MARCO was also reported to be a receptor for 
uteroglobin-related protein 1 (UGRP1), a soluble 9-13 kDa protein that is exclusively 
expressed by lung epithelial cells (Bin et al., 2003). UGRP1 could serve as an opsonin, 
binding to L. monocytogenes and Pseudomonas aeruginosa, in addition to 
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apolipoprotein A-I (ApoA-I) (Bin et al., 2003). It was demonstrated that UGRP1 bind to 
LPS on Gram-negative P. aeruginosa and subsequently interact with MARCO 
expressed on alveolar macrophages to effect phagocytosis of these UGRP1-opsonized 
bacteria (Bin et al., 2003).  However,  MARCO has been previously reported to directly 
bind LPS (Elomaa et al., 1995; Elomaa et al., 1998; van der Laan et al., 1999).  How 
would one then reconcile the need for URGP1 to facilitate an immune response if 
MARCO alone could effectively contend with the threat? The key word in the sentence 
would be “effectively”.  It is probable that URGP1 has a greater binding affinity for 
LPS compared to MARCO, and could therefore enhance bacterial recognition and 
clearance. In principle, the same could be said about iC3b-opsonised DH5 and 
recognition of the bacteria by SR-A.  Complement-mediated opsonization of bacteria is 
a highly efficient process, and the involvement of complements in SR-A mediated 
bacterial binding could enhance immune responses. We have noted that both SR-AI and 
SR-AII are able to bind, albeit weakly, to DH5 independently of  serum (Figure 3.21) 
as previously reported (Peiser et al., 2000). The relatively weak interactions in serum-
free conditions could be attributed to the fact that the 293T cells in this study are only 
transiently transfected with the SR-A vectors whereas Peiser et.al (2000) used stably 
transfected CHO cells.  Nevertheless, SR-AI, but not SR-AII, showed significantly 
enhanced bacteria binding in the presence of serum (Figure 3.21).   
 
Interestingly, it was recently shown that SR-A is a cellular receptor for the opsonic 
Tamm-Horsfall protein (THpro) (Pfistershammer et al., 2008),  a heavily glycosylated 
94 kDa protein exclusively expressed by renal tubular epithelial cells, initially attached 
to the luminal surface by a GPI-anchor but subsequently cleaved and secreted in the 
urine . This protein has been shown to bind to type I-fimbriated E. coli (Pak et al., 2001) 
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and THpro-deficient mice are impaired in their capability to clear E. coli from the 
urinary bladder (Bates et al., 2004; Mo et al., 2004). The finding that THPpro interacts 
with SR-A suggest that the former may act as an opsonin and facilitate the uptake of E 
coli via SR-A in DCs and macrophages. 
 
6.2 The role of SR-AI as an opsonic PRR in the recognition of complement-
opsonized Gram-positive and Gram-negative bacteria species. 
The ability of SR-AI to recognize C3 fragments implies the receptor could potentially 
interact with a wider range of microbes in the presence of complement. The present 
study demonstrated that SR-AI is activated by E. coli and B. subtilis (Figure 3.6) but not 
S. aureus (Figure 3.5) and M. bovis BCG (Figure 3.7). As a positive control, both 
bacterial species activated TLR2 (Figures 3.5 and 3.7) as previously suggested (Arbibe 
et al., 2000; Heldwein et al., 2003; Tsuji et al., 2000).  It is unclear as to why some 
bacterial species are able to interact with SR-AI and induce receptor signaling while 
others do not.  Both E. coli and B. subtilis have been reported to be sensitive to the 
bactericidal activity of complements, associated with significant C3 deposition on the 
bacterial surface (Virta et al., 1997), possibly in the form of iC3b. In view of the present 
finding that SR-AI binds iC3b, it is possible that some bacterial species may become 
opsonized with other complement fragments other than iC3b. Although it is not known 
whether iC3b is deposited on M. bovis BCG, it was reported that closely related 
Mycobacterium avium is predominantly opsonized with C3b and not iC3b (Schorey et 
al., 1997). If C3b, rather than iC3b, is deposited on M. bovis BCG, it would explain the 
inability of the mycobacterium to stimulate SR-AI signaling in our study. 
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Some bacterial species have evolved strategies to counteract immune responses by 
limiting the extent of complement opsonization. S. aureus and most staphylococcal 
strains are encapsulated with a polysaccharide capsule which were found to deposit only 
20% as much opsonic C3 fragments as un-encapsulated strains (Cunnion et al., 2001), 
enabling the encapsulated strains to evade recognition by complement receptors 
including SR-AI based on present findings.  In addition to the capsule, most 
staphylococcal species also possess virulence factors that are involved in the evasion of 
innate immune responses (Rooijakkers and van Strijp, 2007). Some of these factors, like 
staphylokinase (SAK) and staphylococcal complement inhibitor (SCIN), target the 
complement system by blocking critical steps in the three complement pathways.  SAK 
is a 17 kDa secreted plasminogen (PLG) activator that mediates the formation of 
plasmin (PL) which, in turn, cleaves bacterial surface-bound C3b and iC3b (Rooijakkers 
et al., 2005b). In addition, one-third of  surface-bound C3 degradation fragments were 
reportedly shed from the staphylococcal surface predominantly as iC3b (Cunnion et al., 
2001).  SCIN is a 10kDa secreted protein that potently blocks all three complement 
pathways by stabilizing and inactivating the C3 convertases, C4bC2a and C3bBb, thus 
resulting in reduced C3b/iC3b deposition on the bacteria (Rooijakkers et al., 2007; 
Rooijakkers et al., 2005a). It is thus evident that S. aureus possesses an enormous 
arsenal of complement modulators that target multiple steps of the three complement 
cascades. We postulate that the ability to evade complement activation and C3 fragment 





6.3 The involvement of the SRCR domain of SR-AI in the recognition of C3-
opsonized bacteria.  
The present finding that SR-AI binds C3-opsonized bacteria appears to contradict 
previous studies demonstrating SR-A to be a non-opsonic receptor which bind directly 
to its ligands (Acton et al., 1993; Doi et al., 1993; Dunne et al., 1994; Krieger and Stern, 
2001; Peiser et al., 2000). The polyanionic ligands bind to the positively-charged lysine 
cluster on the collageneous domain of SR-A. By comparison, we have demonstrated 
that the SRCR domain, and not the lysine cluster or basic residues proximal to the 
cluster in the collageneous domain, is involved in C3-opsonized DH5induced NF-B 
activation (Figure 3.16 and 3.17) because SR-AII, which lack the SRCR domain, failed 
to activate NF-B in response toC3-opsonized DH5(Figure 3.19).  At this point, it 
must be emphasized that we do also support a role for the collageneous domain in the 
bacterial recognition and receptor signaling because the removal of the domain resulted 
in a significant reduction of DH5induced NF-B activation (Figure 3.17).  The 
possibility remains that SR-AI does associates with DH5 via electrostatic charge 
interactions between the basic residues in the collageneous domain and polyanionic 
bacterial LPS as previously postulated (Acton et al., 1993; Doi et al., 1993).  In this 
study, we have generated collageneous domain mutants whereby up to three basic 
residues were replaced with alanine at any time in our analysis for bacteria-induced NF-
B activation.  It is plausible that such electrostatic charge interactions require all basic 
residues in the domain to effect binding and downstream receptor signaling. Thus, one 
might to need to substitute all the basic residues of the collageneous domain to 
effectively abolish bacterial binding. Another important point to note is that the 
collageneous domain has only been established to be involved in the binding of 
modified LDLs and not for all SR-A ligands (Platt and Gordon, 2001), and taking into 
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consideration the broad ligand specificity of the receptor, it is highly plausible that other 
domains like the SRCR domain, as suggested in this study, may be involved in 
interacting with the various ligands. 
 
MARCO was also identified as a bacteria-binding receptor (Elomaa et al., 1995) but, 
unlike SR-A, the receptor was found to bind bacteria through its SRCR domain 
(Brannstrom et al., 2002; Sankala et al., 2002). An 11-residue segment in the SRCR 
domain, particularly two arginine residues in the form of a RXR motif, was proposed to 
be involved in bacterial binding athough this was not proven conclusively by 
experiments; some of RXR motif mutants of human MARCO were not expressed on 
cell surface of CHO transfected cells (Brannstrom et al., 2002). By aligning the SRCR 
sequences of SR-AI, MARCO and CFI, we found that a glycine and a glutamic acid 
residue (G361 and E364) within the 11-residue bacteria-binding segment of MARCO 
were conserved in SR-AI and CFI (Figure 3.20A). Mutation of either residue in SR-AI 
abolished receptor signaling (Figure 3.20B), providing further support that SR-AI 
interacts with C3-opsonised DH5 through its SRCR domain.  
 
While we have shown that the SRCR domain in SR-AI enhances bacteria binding 
(Figure 3.21), our study also demonstrated that the domain in isolation i.e. sSRCR 
exhibited low binding to bacteria compared to the full-length receptor, sSR-AI (Figure 
3.22).  In addition, sSR-AI but not its isolated SRCR domain binds to iC3b (Figure 
3.23). Interestingly, such a phenomenon was also reported for MARCO.  A soluble 
recombinant MARCO (sMARCO) bound avidly to FITC-labeled E. coli but the soluble 
recombinant SRCR domain exhibited low, barely detectable bacterial binding activity 
(Sankala et al., 2002). Low affinity of these soluble SRCR domains is likely due to the 
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depolymerization of SRCR trimers into dimers and monoers following removal of the 
collagen and coiled-coil domains (Ojala et al., 2007). In contrast, rotary-shadowed 
images of sMARCO revealed that these molecules formed higher order oligomers 
(Sankala et al., 2002) . Soluble bovine SR-AI and II were also found to form elongated 
trimers that bound crocidolite asbestos (Resnick et al., 1993). In the present study, 
coating the soluble SRCR domain on the solid support (i.e. glass coverslip) may 
aggregate and “oligomerize” the molecules, but the monomeric domains may not be 
structurally orientated in the correct configuration to form functional trimers. 
Hypothetically, such a situation should not occur in sSR-AI or sMARCO because the 
domains postulated to be involved in trimerization, i.e. the coiled-coil domain or 
collageneous domain respectively, are present to facilitate formation of functional 
trimeric receptors. 
 
The Group B SRCR domain-containing PRR, deleted in malignant brain tumours 1 
(DMBT1) (also known as salivary agglutinin/lung gp-340), was reported to bind 
bacteria through its multiple SRCR domains (Bikker et al., 2002). Interestingly, a 
consensus-based synthetic peptide of the SRCR domain of DMBT1, termed SRCRP2, 
was shown to bind avidly to various Gram-positive and Gram-negative bacteria (Bikker 
et al., 2004; Bikker et al., 2002), indicating that an isolated SRCR domain can effect 
ligand binding.  Why would the isolated SRCR domain of one PRR bind avidly to 
bacteria while another does not? Foremostly, the SRCR domains of DMBT1 are 
classified under the Group B SRCR while those of SR-A and MARCO are in Group A. 
In addition, DMBT1, like most Group B SRCR-containing proteins, exists as monomers 
whereas proteins with a single Group A SRCR domain tend to be dimeric (M2-BP, CFI) 
or trimeric (SR-A, MARCO) in nature (Sarrias et al., 2004).  The Group A SRCR 
 191
domains may need to oligmerize in order to effect binding. Nevertheless, bacterial 
binding by DMBT1 has been shown to be attributed to a 11-residue GRVEVLYRGSW 
segment within the SRCR domain (Bikker et al., 2004). This motif resembles those of 
SR-A, MARCO and CFI discussed earlier and, in particular, the glycine and glutamic 
acid residues are conserved in the motif, suggesting that these residues play an 
important functional role in ligand binding.  
 
6.4 Elucidation of SR-A-mediated signaling pathways  
 
As mentioned earlier in Section 4.1, previous studies have indicated that SR-A ligands 
are able to induce NF-B activation in macrophages although these findings are 
inconclusive because these molecules are not exclusively ligands of SR-A.  In the 
present study, the ligand-binding properties and downstream signaling of SR-AI was 
examined “in isolation” from other potential PRRs by exogeneous expression on 293T 
cells. It was demonstrated that SR-AI signaling following stimulation with both Gram 
negative (E. coli) and Gram positive (B. subtilis) bacteria resulted in NF-B activation 
and chemokine production.   
 
Besides NF-B activation, SR-A has also been implicated in the transmission of other 
cell signals that regulate diverse cellular functions (Krieger and Herz, 1994). As with 
studies that examined NF-B activation in SR-A signaling (Section 4.1), endeavors to 
dissect and delineate these other SR-A signaling pathways initiated by putative SR-A 
ligands have met with little success. The binding of oxLDL or fucoidan to SR-A was 
reported to induce TNF-in murine J774A.1 macrophages although only fucoidan 
could induce IL-1 secretion (Hsu et al., 2001), consistent with that reported for THP-1 
cells (Palkama, 1991). Fucoidan-mediated IL-1 induction in the macrophages was 
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effected via the activation of the protein tyrosine kinase (PTK) pp60Src, p21-activated 
kinase (PAK) and the MAP kinases p38 and JNK but not  phospholipase C-1 (PLC-1) 
or protein kinase C (PKC) (Hsu et al., 2001). In contrast, a synergistic effect of PKC 
and cyclic adenosine monophosphate (cAMP)-mediated signaling pathways for SR-
mediated IL-1 production was reported in THP-1 cells (Palkama, 1991). This disparity 
in findings relating to PKC in fucoidan-induced IL-1 production remains unresolved. 
Presently, fucoidan, derived from the brown algae Fucus vesiculosus, is only obtainable 
from one commercial source i.e. the chemical vendor Sigma-Aldrich.  Consequently 
variation in product purity is not an issue and the only discernible difference in the 
experimental protocols employed by the two studies is the cell types used i.e. J774A.1 
murine macrophages as opposed to human THP-1 cells.  It is plausible other receptors 
may interact with fucoidan and the expression of these receptors may vary in different 
cell types. Class B SRs (CD36 and SR-BI) and Class F SRs (FEEL-1 and FEEl-2) have 
been reported to bind fucoidan through competitive inhibition studies (Dinguirard and 
Yoshino, 2006; Husemann et al., 2001a; Tamura et al., 2003). The engagement of these 
or other unknown fucoidan-interacting receptors along with SR-A will result in 
signaling cross-talk and differential activation of signaling intermediates.   
 
The involvement of another kinase, PI3K, besides PKC in SR-A signaling is also 
controversial.  PI3K was found to be a major phosphorylation substrate in fucoidan-
induced TNF- release from both J774A.1 and wild-type murine macrophages (Kim et 
al., 2003). However, TNF- production from RAW264.7 cells induced by other SR-A 
ligands such as LTA and poly (I:C) did not involve PI3K (Coller and Paulnock, 2001). 
To further complicate data interpretation, Hsu et.al (2001) reported that PI3K inhibited 
fucoidan-induced IL-1 production in J774A.1 macrophages.  The present findings 
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suggest the involvement of PI3K in SR-A-mediating signal transduction (Figure 4.3). 
Both of the PI3K-specific inhibitors, wortmannin and LY294002, inhibit NF-B 
activation, although LY294002 appears to be a more potent inhibitor compared to 
wortmannin. The lower potency of wortmannin in inhibiting PI3K activity could be due 
to its relatively short half life of 10 min in tissue culture (Vanhaesebroeck and 
Waterfield, 1999) and as such was reported to be added every 4 hours in some studies 
(Franch et al., 2002).  
 
Hsu et.al (2001) has reported that fucoidan-induced IL-1 production also involves the 
Rho GTPase Rac1 besides kinases. Additionally, SR-A-mediated cell adhesion of 
macrophages to mal-BSA-coated surfaces was shown to be coupled to the activation of 
both Rac and cdc42 via arachidonic acid (AA)-derived eicosanoids generated by 
phosholipase A2 (PLA2) and lipoxygenases (LOX) (Nikolic et al., 2007b). We have 
demonstrated that cdc42 but not Rac or Rho may be involved in DH5-induced NF-B 
activation and IL-8 production.  It is presently unclear as to whether these GTPases 
have distinct roles in SR-A function. The activation of Rho-GTPases, including Rac and 
cdc42, plays a key role in coordinating phagocytosis and cell adhesion (Nobes and Hall, 
1995), two physiological processes associated with SR-A. In these processes, binding of 
microbes or ECM to SR-A promotes Rac and cdc42 activation, which in turn trigger 
additional signaling molecules that facilitate the projection of actin-containing fibers 
and changes in the cytoskeleton that are required for phagocytic cup formation or 
spreading cell morphology typical of adhering cells. In contrast, the role of Rho 
GTPases in NF-B activation or cytokine production is unclear. Recently, it was 
reported that Rac is involved in TNF--induced NF-B and MAP kinase activation 
which culminates in IL6 and IL-8 production (Williams et al., 2008). Whether Rac or 
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Cdc42 are also similarly involved in SR-A-mediated signaling requires further 
verification. 
 
In view of the controversies in data obtained from the use of SR-A ligands to study SR-
A -mediated signaling cascades, various research groups have resorted to the use of 
knock-out mice to circumvent the problems encountered. One particular study utilizing 
SR-A-/- mice published findings which directly called into question the signaling 
capabilities of the receptor. Kim et.al (2003) reported that fucoidan- or LTA-elicited 
tyrosine phosphorylation events, PI3K activation and TNF-production in SR-A-/- 
macrophages did not differ from those of wild-type controls, suggesting that these 
signaling events arise independently of SR-A activity.  In contrast, TNF- release 
triggered by the same SR-A ligands were abrogated in CD14-/- mice, indicating that 
CD14, rather than SR-A, appear to be involved in these inflammatory responses (Kim et 
al., 2003). The validity of fucoidan and LTA as SR-A specific ligands are questionable 
based on the results.  
 
The generation of the SR-A-/- mouse by Suzuki et.al (1997) has advance the 
understanding of the functional roles of the receptor in different biological processes in 
the context of the physiologically relevant in vivo milieu.  However, as with all 
experimental techniques, there are some limitations that may lead to misinterpretations 
of results. Platt and Gordon (2001) have described knockout mice as both “panacea and 
frustration” in the study of SR-A. Unexpected compensatory or redundancy 
mechanisms might be activated when a receptor is missing, and cloud or complicate the 
interpretation of the actual contribution of the receptor in the immune response. There is 
considerable overlap in ligand specificities among the various classes of SRs.  The 
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ablation of SR-A gene in the mouse might trigger the up-regulation in expression and 
activity of another SR to offset the loss of SR-A in a particular biological processes. 
 
6.5 The functional role the cytoplasmic domain of SR-A and CR3 in receptor 
signaling – Possible involvement of a signaling co-receptor(s). 
A novel finding of our study is the lack of involvement of the cytoplasmic domains of 
both SR-AI and CR3 in DH5-induced NF-B activation.  These two receptors have 
relatively short cytoplasmic tails which do not contain any known sequence motifs 
associated with intracellular signaling. In contrast, we have demonstrated indirectly that 
the cytoplasmic domain of TLR 4, i.e. TIR domain, is required for DH5-induced NF-
B activation because co-expression of MyD88 DN abolishes TLR4 signaling (Figure 
4.2). MyD88 DN lacks the death domain required for downstream signaling but retains 
the TIR domain which will interact with that of activated TLR4. Consequently, the 
effect of MyD88 DN would be akin to that predicted as if the cytoplasmic domain of 
TLR4 was removed. These findings clearly indicate that both SR-AI and CR3 must 
associate with co-receptor(s) present on 293T cells to facilitate NF-B activation in 
response to DH5. There are experimental evidence supporting such a co-receptor 
hypothesis for both CR3 and SR-A. In the case of CR3, it was reported that CHO cells 
stably expressing mutated CR3 subunits lacking the cytoplasmic domains exhibited 
impaired phagocytosis of iC3b-coated sheep red blood cells and E. coli but could still 
effect nuclear translocation of NF-B in response to both LPS and E. coli (Ingalls et al., 
1997). This suggests that intracellular signals leading to phagocytic activity via CR3 are 
distinct from those associated with the activation of pro-inflammatory events such as 
NF-B translocation and cytokine production; those of the latter event are proposed to 
be derived from an associated signal transducer (Ingalls et al., 1997).  For SR-A, it was 
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noted that stable transfection of the receptor into 293T but not CHO cells conferred an 
adherent phenotype to the cells grown on tissue culture plastic (TCP) (Hughes et al., 
1995; Robbins and Horlick, 1998) although the receptor in both cell types could still 
mediate acLDL uptake (Hughes et al., 1995). These findings indicate that the adhesive 
property of SR-A-293T cells may not be solely attributed to SR-A and suggest the 
existence of a co-receptor that facilitate the process. Nikolic et.al (2007a) corroborated 
these findings by showing that a murine SR-A mutant with deletion of cytoplasmic 
domain (amino acid 1-49), though defective in receptor internalization (Kosswig et al., 
2003), is still able to facilitate cell adhesion on mal-BSA-coated wells. Overall, these 
studies indicate that SR-A-mediated activation of intracellular signals to facilitate cell 
adhesion upon binding to mal-BSA is independent of those responsible for receptor 
internalization (Nikolic et al., 2007a), and importantly, it appears that the former 
process may involve a co-receptor. In the preceding sub-sections, we will highlight 
membrane receptors that associate with SR-A and CR3, and discuss whether these 
receptors are candidates for the identified co-receptor(s) present on 293T cells which 
associates functionally with the two PRRs. 
 
6.5.1 Recognized co-receptors of SR-A. 
With the exception of methionine at position 1, the first twelve amino acids of the 
murine SR-A differ significantly from the corresponding residues in the SR-A 
sequences of the other three mammalian species analysed; the deviation represents the 
largest single segment of poor homology among the four species (Ashkenas et al., 
1993). If the cytoplasmic tail of SR-A is involved in mediating downstream signals, the 
remaining 38-39 residues in the domain must possess the necessary signaling motifs to 
support the recruitment of signaling intermediates to the activated receptor. In this 
 197
study, we generated a mutant SR-AI receptor in which the entire cytoplasmic domain is 
deleted (SR-AI-dCytoKKK) and demonstrated that the activated receptor is still able to 
transduce intracellular signals (Figure 4.1). Potential phosphorlylation sites, Ser20, Thr29 
and Ser48 in human SR-A, were also either deleted or mutated to alanine, and found not 
to affect receptor signaling (Figure 4.1).  The lack of involvement of the cytoplasmic 
tail of SR-AI clearly indicates that a co-receptor(s) must be present on 293T cells to 
mediate intracellular signaling upon activation of the former receptor. 
 
A signaling co-receptor for SR-A, Mer receptor tyrosine kinase (Mertk), was recently 
identified in the clearance of apoptotic thymocytes by murine macrophages (Todt et al., 
2008). Mertk is 200 kDa transmembrane receptor containing extracellular Ig and 
fibronectin III domains and an intracellular multi-substrate docking site that can bind 
the GEF Vav1 and SH2-containing proteins such as PI3K and the signaling adapter 
Grb2 (Georgescu et al., 1999; Mahajan and Earp, 2003).  The receptor indirectly 
associates with phosphhatidylserine (PS) on apoptotic cells via the serum-derived 
protein growth arrest-specific gene 6 (Gas6) (Nakano et al., 1997).  It was demonstrated 
that Mertk associates with SR-A on murine macrophages during the phagocytosis of 
apoptotic thymocytes, becomes tyrosine-phosphorylated and activates PLCto effect 
downstream signaling; the phosphorylation of Mertk on tissues macrophages of SR-A-/- 
mice was reduced in magnitude and duration relative to wild-type controls (Todt et al., 
2008).  However, Mertk does not appear to be a good candidate for the unidentified co-
receptor of our study.  Mertk expression is restricted to immune cells (Behrens et al., 
2003) and preliminary reports suggest that the receptor may play a role in down-
regulating, rather than promoting, NF-B activation (Camenisch et al., 1999).  
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6.5.2 Recognized co-receptors of CR3. 
The ability for integrins, particularly CR3, to associate with other membrane receptors 
in the formation of distinct functional signaling is well-described (Petty and Todd, 
1996; Porter and Hogg, 1998; Todd and Petty, 1997).  In fact, it has been suggested that 
integrins may not signal through exclusive, integrin-specific pathways but rather appear 
to cooperate with other membrane receptors to influence a variety of signaling pathways 
(Porter and Hogg, 1998).  
 
CR3 has been shown to physically associate with a number of GPI-anchored membrane 
proteins such as FcRIIIb (CD16) (Galon et al., 1996; Poo et al., 1995; Preynat-Seauve 
et al., 2004; Stockl et al., 1995; Zhou et al., 1993), CD14 (Medvedev et al., 1998; 
Troelstra et al., 1999; Zarewych et al., 1996) and the urokinase type plasminogen 
activator receptor (uPAR or CD87) (Bohuslav et al., 1995; Wei et al., 1996; Xue et al., 
1994).  These co-receptors are believed to form cis interactions with the lectin domain 
on the M subunit of CR3 (Zhou et al., 1993). Membrane-associated CD16 was found to 
interact with CR3, promoting antibody-dependent phagocytosis (Krauss et al., 1994), 
iC3b binding (Preynat-Seauve et al., 2004) and the generation of respiratory burst (Zhou 
and Brown, 1994), while soluble CD16 in serum induced CR3/CR4-dependent 
production of IL-6 and IL-8 by monocytes (Galon et al., 1996). Streptococcal cell wall 
preparations were also shown to induce TNF- production via CR3 and CD14 
(Medvedev et al., 1998). CR3-mediated cell adhesion of monocytes to fibrinogen was 
promoted by CR3-uPAR coupling (Sitrin et al., 1996).  However, GPI-anchored 
receptors are devoid of transmembrane and cytoplasmic domains and consequently 
must depend on membrane-spanning partners provide a signaling conduit for 
intracellular signaling. Clearly none of these GPI-anchored receptors can be the 
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unidentified signaling co-receptor for CR3 in our study.  We proposed that activated 
CR3 is probably recruited into a multi-receptor signaling complex, along with GPI-
anchored receptors and receptors that possess cytoplasmic tails bearing signaling 
motif/domains to effect downstream signal transduction. Bohuslav et.al (1995) has 
reported that uPAR, CR3 and LFA-1 are components of large signaling complexes 
formed on the cell surfaces of migrating monocytes, and that signaling via these 
complexes involved protein tyrosine kinases of the Src-family such as p60fyn, p53/56lyn, 
p58/64hck and p59fgr.  
 
CR3 has also been shown to associate with FcRIIA (CD32) (Annenkov et al., 1996; 
Worth et al., 1996) and FcRII (CD23) (Lecoanet-Henchoz et al., 1995). It was 
postulated that these Fc receptors modulate CR3 responses via “inside-out” signaling 
(Ortiz-Stern and Rosales, 2003) that involves PI3K, PAK-1 and PKA (Jones, 2002; 
Jones et al., 1998). A well-characterized signaling motif, the ITAM motif, is present in 
the cytoplasmic tail of CD32 (Van den Herik-Oudijk et al., 1995).  Zhou and Brown 
(1994) have shown that CR3 can co-operate with both CD16 and CD32 in generating a 
respiratory burst in neutrophils. However, it is unlikely that CD32 is the unidentified co-
receptor present on 293T cells because its expression is restricted to leukocytes (Hulett 
and Hogarth, 1994). Moreover, there are reports that suggest that ITAM motifs of FcRs 
associates with protein-tyrosine phosphatase SHP-1 to down-regulate NF-B activation 
(Ganesan et al., 2003; Tridandapani et al., 2002). Interestingly, CD23 was reported to be 
expressed on intestinal epithelial cells in addition to a variety of immune cells that 
includes B cells, eosinophils, macrophages and DCs (Kaiserlian et al., 1993), although 
there is no evidence to support its expression on kidney epithelial cells i.e. 293T cells. 
Nevertheless, it was reported that stimulating CR3- or CR4-expressing cells with 
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soluble CD23 induced NF-B activation and IL-8 production (Rezzonico et al., 2001).  
The possibility therefore remains that CD23 might be the unidentified co-receptor for 
CR3 on 293T cells. 
 
6.6 The suppression of IL-12 by opsonic C3 receptors.    
The role of IL-12 in the induction of an acquired cellular immune response has been 
well documented (Trinchieri and Gerosa, 1996). IL-12 is required for the development 
of a Th1-type immune response (Hsieh et al., 1993; Magram et al., 1996) because this 
cytokine, produced by myeloid cells and neutrophils, is a potent inducer of IFN- from 
T cells and NK cells (Watford et al., 2003). Both in vivo and in vitro experiments have 
demonstrated that IL-12 plays a crucial role in the development of specific immunity 
against a number of intracellular pathogens, including Leishmania major, 
Mycobacterium tuberculosis, Listeria monocytogenes, and Toxoplasma gondii 
(Sutterwala and Mosser, 1999). Animals lacking the IL-12 gene (Mattner et al., 1996) or 
animals treated with antibodies to IL-12 (Scharton-Kersten et al., 1995; Sypek et al., 
1993; Tripp et al., 1994) are invariably more susceptible to infections with these 
intracellular pathogens. 
 
Despite the importance of IL-12 to both innate and acquired immunity, several aspects 
of the regulation of IL-12 biosynthesis remain unknown. Macrophages can be induce to 
express IL-12 by a variety of microbial products including LPS and LTA (Cleveland et 
al., 1996; D'Andrea et al., 1992). Biologically active IL-12 is a 70-kD heterodimer (p70) 
composed of two subunits, p35 and p40 (Gubler et al., 1991; Wolf et al., 1991). IL-12 
p35 is ubiquitously expressed in many cell types while p40 is expressed only by cell 
types that produce biologically active IL-12p70. The induction of IL-12 p40 mRNA is 
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highly regulated both at the transcriptional and translational levels. Transcriptional 
activation of the IL-12 p40 gene by microbial products and IFN- was shown to require 
the recruitment of various members of the CAAT/enhancer-binding protein (C/EBP), 
NF-B, ETS transcription factors (ets-2, PU-1) and interferon regulatory factor 1 (IRF-
1) (Ma et al., 1996b; Murphy et al., 1995; Plevy et al., 1997; Wang et al., 2000).   
Although evidence suggests that induction of IL-12 p35 mRNA is critical for the 
synthesis of bioactive IL-12 p70 (Hayes et al., 1995; Snijders et al., 1996), regulation of 
IL-12 p35 gene transcription remains poorly characterized. Recent studies have, 
however, indicated that the gene is regulated transcriptionally by IRF-1 (Kollet et al., 
2001) and NF-B subunit c-Rel (Grumont et al., 2001).  IL-12 secretion by 
macrophages can be up- or downregulated by other cytokines. Priming phagocytic cells 
with IFN- or GM-CSF, for example, can enhance their ability to produce IL-12 
(Cassatella et al., 1995), whereas IL-4, IL-10, IL-13, and TGF- can suppress IL-12 
production (D'Andrea et al., 1993; D'Andrea et al., 1995). 
 
In addition to cytokines and growth factors, it has also been demonstrated that ligation 
of phagocytic receptors can modulate IL-12 production (Sutterwala and Mosser, 1999). 
Cross-linking of CR3 on monocytes and macrophages using specific antibodies inhibit 
IL-12 production by these cells when stimulated with S. aureus and IFN- (Marth and 
Kelsall, 1997) or LPS (Sutterwala et al., 1997). In the present study, we have also 
demonstrated that IL-12 production in monocyte-derived DCs induced by DH5C3+ 
was significantly lower than that by DH5C3- (Figure 5.8), suggesting that opsonic C3 
fragments binding to complement receptors inhibited IL-12 production. The ability to 
inhibit IL-12 production is not unique to complement receptors, as other phagocytic 
receptors may also contribute to the immunomodulatory process. Sutterwala et.al (1997) 
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has reported that cross-linked FcRII and III, and scavenger receptors were also able to 
reduce IL-12 production. Cross-linking of SR-A with immobilized 2F8 antibody 
(Jozefowski and Kobzik, 2004) or FcRs with IgG-opsonized erythrocytes (Grazia 
Cappiello et al., 2001) were reported to inhibit IL-12 production by macrophages when 
stimulated with LPS and IFN-.  It is interesting that both CR3 and SR-A were found to 
require co-receptors to signal in the present study. Could SR-A and CR3 co-operate 
with the unknown co-receptors to mediate suppression of IL-12 production?  
 
While it has been established that activated CR3 and other phagocytic receptors 
modulates IL-12 production, the mechanism of inhibition i.e. signaling pathways 
involved remains unclear. In the present study, Rac was shown to be a negative 
regulator of IL-12 production. The Rac inhibitor, NSC23766, is able to enhance IL-12 
production induced by DH5C3+ to levels comparable with that induced by DH5C3- 
(Figure 5.9), supporting complement receptors to play a role in the suppression of IL-12 
production by DCs via Rac. We also showed that NF-B activation and IL-8 production 
in CR3-293T cells involved the GTPase Rac but not Rho, providing a plausible hint that 
CR3 may be the receptor responsible on DCs for the Rac-mediated inhibition of IL-12 
production observed in this study. While the activation of Rac by CR3 is consistent with 
Rac or cdc42 being shown to play a role in CR3 signaling in neutrophils (Forsberg et 
al., 2003), it seems to be in conflict with findings that demonstrate Rho but not Rac 
being activated during CR3-mediated macrophage and fibroblast phagocytosis (Caron 
and Hall, 1998; Wiedemann et al., 2006). However, it is important to realize that 
conclusions drawn from these studies relate to two different physiological processes, 
phagocytosis and gene expression (IL-8 production via NF-B), and may simply reflect 
the diverse functional properties of these GTPases. As such, even if Rho is activated in 
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DH5-stimulated CR3-293T cells, it might only be responsible for bacteria uptake and 
may not cause NF-B activation. We have shown that although DH5C3+-induced IL-
12 production in DCs is suppressed by Rac, the GTPase does not influence the 
phagocytosis of DH5C3+ by DCs (Figure 5.13).  Wiedemann et.al (2006) has 
demonstrated that CR3 mediate phagocytosis of iC3b-opsonized particles via Rho; the 
deletion of the cytoplasmic domain of the 2 but not M subunit abolished Rho 
activation and phagocytosis. We, on the other hand, have shown that cytoplasmic tails 
of both subunits are dispensable for NF-B activation (Figure 5.2). This result clearly 
demonstrates that different Rho GTPases may be activated by the same receptor to 
facilitate different physiological processes.  
 
The signaling pathways involved in Rac-mediated NF-B activation are still not 
completely elucidated. It has been reported that Rac, RhoA and cdc42 efficiently induce 
transcriptional activity of NF-B (Perona et al., 1997).  TNF- was reported to induce 
NF-B activation via cdc42 and RhoA (Perona et al., 1997) while IL-1 appears to utilize 
Rac in activating the transcription factor (Montaner et al., 1998). Despite the 
preferential activation of specific RhoGTPases, both cdc42 and Rac were found to 
activate MAPK/ERK kinase kinase 1 (MEKK1) to facilitate downstream signaling 
leading to the activation of NF-B (Montaner et al., 1998). We have shown that the co-
receptor(s) for SR-AI utilized cdc42 while that of CR3 proceeded via Rac to trigger NF-
B activation. Interestingly, it was reported that immobilized fibrinogen-induced 
clustering of CR3 on THP-1 cells initiated a IRAK1/TRAF6/TAK1-dependent but 
MyD88-independent signaling cascade that culminated in NF-B activation (Shi et al., 
2001), suggesting that CR3 “signaling” employs some signaling intermediates from the 
IL-1/TLR signaling pathways. Drawing parallels between the set of results, we can 
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deduce that the co-receptor(s) employed by SR-AI and CR3 might differ; the SR-AI co-
receptor probably belong to the TNF- superfamily while that of CR3 may be from the 
IL-1 receptor superfamily. However, the NF-B activating signaling cascade initiated 
by the CR3 co-receptor differs from that of IL-1R or TLRs because it does not involve 
MyD88 (Shi et al., 2001), and as such, suggest that the co-receptor is neither IL-1R nor 
the TLRs. Nevertheless such deductions are, at the present time, premature. Further 
studies are certainly required to substantiate these inferences.  
 
The present study also provides an opportunity to appreciate the potency of IFN-in co-
stimulating IL-12 induction. IFN- co-stimulation of DCs with DH5 increased IL-12 
production by many folds. It apparently overrides inhibitory effects of opsonic C3, Rac 
and cytochalasin D although IFN- alone does not induce IL-12. In this study, bioactive 
IL-12p70 was measured. LPS alone can induce p40 expression, but IFN- is required for 
LPS to induce p35 expression (Liu et al., 2003). It remains to be investigated whether 
p35 or p40 expression was inhibited by opsonic C3 and Rac. The implications of C3 
inhibition of IL-12 and other cytokine induction are beginning to be addressed from 
various studies. In general, controlled production of inflammatory cytokines is 
beneficial in minor infections. However, during a major infection, significant IFN- 
may be produced which overrides C3 inhibition for escalated inflammation and 
pathogen eradication. In steady states, CR3 is a principal phagocytic receptor for 
apoptotic cells that are opsonized by C3 (Quartier et al., 2005). C3 inhibition of IL-12 
production can contribute to tolerance induction. Indeed, DCs loaded with apoptotic 




6.7 Summary and future studies 
The findings of the present study clearly indicate that the ligand specificity of various 
PRRs overlap significantly and many of these receptors do co-operate in signaling 
complexes to initiate a unique, integrated intracellular signal to effect an appropriate 
immune response, and more importantly, to partake in various innate immunological 
processes such as cell adhesion/migration, inflammation, phagocytosis of microbes and 
tissue homeostasis.  The multi-ligand specificity of PRRs with significant overlap and 
also receptor cross-talk during cooperative signaling of  PRRs in a signalosome 
complex adds a layer of functional complexity that confound interpretations of results 
derived from studies involving ligand-receptor interactions and downstream signal 
transductions in innate immune cells. The HEK 293T-luciferase assay model is useful 
for such studies as the cell line lacks most PRRs and a specific PRR can thus be studied 
in “isolation”.  It must, however, be noted that there are limitations to any experimental 
system/assay. Due to differential expression of genes in different cell types, various 
signaling intermediates in a particular pathway that are present in macrophages, for 
example, may not be available to effect signaling in 293T cells.  In addition, 293T cells 
may express certain signaling proteins, normally not expressed in macrophages, which 
may modulate the particular signaling pathway initiated by the exogeneously expressed 
PRR.  
 
One important conclusion that arises from the present study is the invalidity of grouping 
PRRs into opsonic and non-opsonic receptors. We have shown that SR-AI recognizes 
iC3b and could thus be classified as a novel complement receptor, even though the 
receptor may bind directly to various PAMPs.  Such a concept is not unique. The 
complement receptor CR3 is well-established as an opsonic receptor that binds and 
facilitates the uptake of iC3b-coated targets. However, CR3 can also mediate non-
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opsonic phagocytosis of zymosan particles (Le Cabec et al., 2002). Consequently, do 
we classify CR3 as an opsonic or non-opsonic PRR?  
 
Another key concept strengthen by findings of the present study involves the co-
operation of various PRRs in effecting downstream signaling.  The cytoplasmic tails of 
many phagocytic PRRs are relatively short and are devoid of intrinsic kinase activity or 
signaling motifs. Hence, these receptors must recruit other receptors (co-receptors) that 
may aid in the transmission of downstream signals.  This study has established that both 
SR-AI and CR3 require such “assistance” in signaling transmission.  Future studies will 
focus on identifying the co-receptor(s) present on 293T cells that co-operate with SR-AI 
and CR3 to effect NF-B activation and chemokine production. 
 
Rac activation via CR3 has been shown to play an important role in modulating IL-12 
production. We have shown that NF-B, along with Rac, is involved in IL-8 production. 
Is NF-B involved in IL-12 suppression?  The expression of both p35 and p40 subunits 
of IL-12 are positively regulated by NF-B. If activated CR3 induces NF-B and the 
latter induce IL-12 production, then why would DH5-induced CR3-mediated signaling 
suppress IL-12 production? Could CR3 elicit the activation of NF-B dimers that could 
inhibit p35 or p40 transcription? Future work will focus on identifying signaling 
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LB-broth (Luria-Bertani medium) 
 
Bacto-tryptone  1.0% 
Yeast extract  0.5% 
NaCl   0.5% 
Adjust pH to 7.5 with 5 M NaOH prior to autoclaving. 
Media was sterilized by autoclaving at 15 LB/in2 for 15 min. 
Thermolabile antibiotics were filter-sterilized through 0.2 m filters and added to the autoclaved LB-
broth. Final concentrations for ampicillin was 100 g/ml.   
  
LB agar plates 
 
LB-broth was prepared as above with 15 g/L of Bacto-agar added. Media was sterilized by autoclaving. 
 
50 x TAE buffer (for DNA gel electrophoresis) 
 
Tris base  2 M 
Acetic acid  1 M 
EDTA   0.1 M 
pH 7.8 
 
10 x DNA loading buffer 
 
Ficoll400  20% (w/v) 
EDTA(pH 8.0) 0.1 M 




The stock solution was made at 10 mg/ml and stored in a light-tight bottle. Final working concentration 
was 0.5 μg/ml. 
 
10X TNE buffer 
 
Tris base  100mM 
Sodium chloride  2 M 





1 x Phosphate buffered saline (PBS) 
 
KH2PO4   1.76 mM 
Na2HPO4   10.4 mM 
NaCl    137 mM 
KCl    2.7 mM 
 
FACS Wash buffer 
 
1 x PBS 
BCS    2% (v/v) 







Cell lysis buffer  
 
Tris-HCl, pH 7.5-8.0  50 mM 
NaCl    300 mM 
EDTA    2mM 
EGTA    2mM 
KCl    20mM 
Triton-X 100   1% (v/v) 
Leupeptin   100 g/ml 
Aprotinin   100 g/ml 
PMSF    2 mM 
 
PMSF = phenylmethylsulphonyl fluoride 
 
2x HBS buffer 
 
NaCl    280 mM 
KCl    10 mM 
Na2HPO4.2H2O  1.5 mM 
KCl    2.7 mM 
D-glucose (anhydrous) 12mM 




Tris-HCl, pH 8.0 20 mM 
NaCl   500 mM 





Tris-HCl, pH 8.0 20 mM 
NaCl   500 mM 
Imidazole  250 mM 
 
 
SDS-PAGE gel electrophoresis and Western Blotting 
 
Stacking gel preparation (for 1 mini SDS-PAGE gel)  
 
dH2O       3.05 ml 
0.5 M Tris-HCL, pH 6.8     1.25 ml 
10% (w/v) SDS      50 l 
30% Acrylamide/Bisacrylamide solution 29:1 (3.3%C)  0.65 ml 
10% APS       25 l 
TEMED       5 l 
 
 
Separating gel preparation (for 1 mini SDS-PAGE gel)-12.5% gel  
 
dH2O       3.17 ml 
1.5 M Tris-HCL, pH 8.8     2.5 ml 
10% (w/v) SDS      100 l 
30% Acrylamide/Bisacrylamide solution 29:1 (3.3%C)  4.16 ml 
10% APS       50 l 





10 x SDS-PAGE electrophoresis buffer 
 
Tris base  250 mM 
Glycine   2.5 M 
SDS   1% (w/v)   
Adjust the pH to 8.3. 
 
 
5 x Reducing sample loading buffer 
 
Tris-HCL, pH 6.8 250 mM 
Glycerol   50% (v/v) 
SDS   10% (w/v) 
Bromophenol Blue 1% (w/v) 
Dithiothreitol (DTT) 0.5 M 
 
 
10 x Western blot transfer buffer  
 
Tris base 250 mM 






Tris-HCL, pH 7.5 50 mM 
NaCl   150 mM 





Non-fat milk  5% 
(prepared in TBS-T buffer) 
  
